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One in 50 babies would have been born with severe birth defects without the use of 
prenatal diagnosis. Current methods to obtain fetal cells for prenatal diagnosis involve 
invasive procedures such as amniocentesis and chorionic villus sampling, which all 
carry potential risks of miscarriage. Non-invasive prenatal diagnosis (NIPD) has been 
pursued during the past two decades to overcome the problems associated with 
invasive prenatal diagnosis. Nucleated fetal cells and cell-free fetal DNA/mRNA 
circulating in the maternal blood are promising fetal materials being studied for NIPD. 
Nucleated fetal cells are better targets because they contain the complete genetic 
information of the fetus and pure fetal DNA can be obtained from these cells. They 
are suitable to be used for a wide range of diagnostic tests.  
Human fetal primitive erythroblast (hEryP) is considered as an ideal candidate for 
first trimester NIPD due to their early presence in the maternal circulation and distinct 
embryonic haemoglobin marker. However, the enrichment and culture of hEryPs from 
maternal blood are the major challenges that limit their routine clinical applications. 
What’s more, little is known about the biology of these cells as they are only 
produced during early embryogenesis and have short life span.  
My thesis addresses the issue of scarcity of hEryPs in the maternal blood by studying 
their biological properties, developing isolation and culture techniques, and evaluating 
the nuclear reprogramming efficiency in these cells. hEryPs originate from primitive 
erythropoiesis in the extra-embryonic yolk sac. The screening for embryonic, 
mesenchymal and haematopoietic stem cell markers suggested that hEryPs did not 
possess any stemness properties. However, they were strongly positive for CD36, 
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CD47, CD59, CD71 and GPA, confirming their erythroid origin. hEryPs underwent 
maturation in the fetal circulation as gestational age increased. Cell cycle analysis and 
BrdU assay demonstrated very limited proliferative activity in these cells, probably 
due to their condensed nuclei. Interestingly, unlike the definitive erythroblasts, 
hEryPs did not enucleate in vitro. TUNEL and Annexin V staining both showed that 
hEryPs did not undergo apoptosis in the fetal blood by the first trimester.  
A manual isolation technique was developed for isolating pure hEryPs from enriched 
maternal blood. The viability of the isolated cells was maintained by a novel 
microdroplet culture system under optimized conditions. During the optimization, it 
was found that hEryPs survived longer under normoxic condition (20% O2) than 
hypoxic condition (2% O2). Efficiency of nuclear reprogramming methods on hEryPs 
was evaluated with the aim to increase the proliferation of these cells. The chromatin 
structure of hEryPs could be remodelled with epigenetic factors to a less condensed 
state. However, the efficiency with lentiviral transductions was very low. The non-
viral reprogramming using hESC extracts was also not able to stimulate proliferation 
in these differentiated cells. The poor reprogramming efficiency in the hEryPs was 
most likely due to the low transcriptional and translational activities in their 
condensed nuclei. 
In conclusion, I have provided additional knowledge on the biological properties of 
hEryPs. I also developed a manual isolation method and a microdroplet culture 
system for hEryPs from maternal blood. These techniques will be useful for NIPD. 
The nuclear reprogramming efficiency was very low in the hEryPs with lentiviral 
transductions or hESC extract treatment. However, their chromatin structure could be 
remodelled with epigenetic factors making their genome more accessible.   
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Chapter 1: Introduction 
1.1 Background 
Since the first chromosomal analysis on amniotic fluid cells performed half a century 
ago (Steele and Breg, 1966), prenatal diagnosis today has become a routine tool for 
detecting birth defects in the fetus. Common birth defects include chromosomal 
abnormalities (e.g. Trisomy 21, Monosomy X), structural malformation (e.g. neural 
tube defects) and genetic diseases (e.g. thalassemia, cystic fibrosis).  Current prenatal 
diagnosis in the clinical practice involves mainly invasive procedures such as 
amniocentesis, chorionic villus sampling and fetal blood sampling. However, there 
are potential risks of miscarriage and other complications associated with these 
invasive tests, which also cause anxiety and stress on the parents.  
To overcome these problems, non-invasive prenatal diagnosis (NIPD) has been 
pursued for more than two decades. Cell free fetal DNA (cffDNA), mRNA (cffmRNA) 
and nucleated fetal cells present in the maternal blood were identified as good sources 
of fetal genetic materials for diagnosing chromosomal and genetic disorders non-
invasively. The use of cffDNA for detecting fetal aneuploidies in high risk 
pregnancies has achieved optimistic results in the past few years, as evidenced by 
many large-scale trials conducted in the clinical settings (Chen et al., 2011a; Bianchi 
et al., 2012; Palomaki et al., 2012).  Some monogenic diseases have also been 
detected using cffDNA, but to a limited number (Bustamante-Aragones et al., 2012). 
Compared with cffDNA, the utilization of fetal nucleated cells in the maternal 
circulation is a more promising strategy because the fetal cell nucleus contains 
complete fetal genetic information which can be virtually used for diagnosis of any 
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kind of genome-related abnormalities. Unfortunately, the occurrence of fetal 
nucleated cells is usually rare in the maternal blood, which is about 1 to 2 cells per ml 
of maternal blood (Bianchi et al., 1997; Krabchi et al., 2001). The enrichment of these 
scarce fetal cells and their in vitro culture to obtain adequate materials for prenatal 
diagnosis thus poses a big challenge.  
Among the several fetal cell types found in the maternal blood including trophoblasts, 
leukocytes, fetal erythroblasts and progenitor/stem cells, fetal erythroblasts (FEs) are 
considered as good candidate cells for NIPD due to their short life span and distinct 
haemoglobin marker for identification. Various enrichment techniques have been 
developed to isolate FEs from maternal blood, but most of them were not able to 
achieve high cell recovery and purity due to the rare number of them. Culture of the 
enriched cells from maternal blood has also been attempted by many groups in order 
to expand the number of FEs or their progenitors within the mixed cell population (Lo 
et al., 1994; Valerio et al., 1996; Bohmer et al., 2002). However, in some studies, the 
substantial contamination by maternal cells led to no detection of fetal cell signal in 
the cultured cells (Chen et al., 1998; Huber et al., 2000; Zimmermann et al., 2002).   
There are two types of FEs present in the maternal blood, namely, fetal primitive 
erythroblasts (hEryPs) and fetal definitive erythroblasts (hEryDs). hEryPs are large 
nucleated red cells produced by primitive erythropoiesis in the yolk sac around 5 
weeks of gestation (Bloom and Bartelmez, 1940). They are only abundant in the first 
trimester fetal blood and carry the embryonic haemoglobins (Choolani et al., 2003). 
hEryDs are produced by definitive erythropoiesis in the fetal liver and bone marrow 
which occurs later than primitive erythropoiesis. They resemble the definitive 
erythroblasts produced in the adult bone marrow. Compared with hEryDs, hEryPs 
have the advantages that they can be detected earlier in the maternal circulation and 
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their morphology is distinguishable from the maternal erythroblasts. Hence, hEryPs 
are ideal target cells for first trimester NIPD. However, thus far most of the 
enrichment and culture studies on FEs have been on hEryDs or a mixture of the two 
types because the maternal blood samples collected were beyond the first trimester.  
Enrichment and culture of only hEryPs from first trimester maternal blood has not 
been reported.  
Furthermore, very few studies have been carried out to understand the properties of 
hEryPs, probably due to the limited access to these cells. Some anatomical studies on 
human erythropoiesis in the yolk sac were performed many decades ago (Bloom and 
Bartelmez, 1940; Fukuda, 1973), but most of the recent research on mammalian 
primitive erythropoiesis is based on murine models (Palis et al., 2010). It is unknown 
whether hEryPs share the same characteristics as mouse primitive erythroblasts 
(mEryPs) such as enucleation (extrusion of nucleus from cytoplasm to form 
anucleated erythrocyte). Due to the transient presence of human primitive 
erythropoiesis in the yolk sac, our understanding of this process is far less than 
definitive erythropoiesis in the bone marrow, although both of them play critical roles 
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1.2 Research aims and hypotheses 
Limitations in the existing knowledge of hEryPs and their small numbers in the 
maternal blood hamper the progress of using them routinely for NIPD. My thesis aims 
to gain a better understanding of the properties of this cell type and provide solutions 
for their use in NIPD.  
The three experimental aims are:  
(1) to study the biological properties of hEryPs with regards to their morphology, 
characteristic markers, maturation, proliferation, enucleation and degeneration 
(Chapter 3);  
(2)  to develop a technique of isolating pure hEryPs from maternal blood, and a 
culture system for maintenance of the isolated cells (Chapter 4);  
(3)  to evaluate the reprogramming efficiency in hEryPs with viral and non-viral 
nuclear reprogramming methods (Chapter 5).  
The hypotheses involved are: 
(1)  hEryPs do not enucleate in vitro. 
(2)  Pure hEryPs can be isolated from maternal blood and cultured for an extended 
period of time.  
(3)  hEryPs can be coaxed to undergo nuclear reprogramming. 
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Chapter 2: Literature Review 
2.1 Prenatal screening  
Prenatal screening involves non-invasive tests that are able to estimate the risk of 
having a fetus with certain birth defects with good sensitivity. It is an efficient and 
harmless way to detect abnormal pregnancies among the large population. 
Ultrasonography and maternal serum screening are the two routinely used tests in the 
clinical settings.  
Ultrasonography helps to visualize the embryo or fetus in the mother’s uterus with 
ultrasound-based imaging technique. It provides information on the fetal health and 
growth status. In many countries, ultrasound scans at different gestational stages are 
recommended for pregnant women for monitoring the fetal development throughout 
the whole pregnancy and for detecting major fetal abnormalities preferably in the first 
and second trimesters. Structural malformations can normally be detected by 
ultrasound scan of fetal head, limbs and vital organs. Some major developmental 
defects such as Down syndrome (Trisomy 21) can be detected by measuring the 
thickness of the nuchal fold and its translucency, called ‘Nuchal translucency (NT) 
scan’. The NT scan is usually performed between 11 weeks and 13 weeks plus 6 days 
of gestation. In addition to this, a scan of the nasal bone in the same gestational period 
is also useful in detecting Down syndrome, as many studies showed that high 
percentage of fetuses with Trisomy 21 did not have nasal bone (Sonek et al., 2006).  
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Although ultrasonography is a very useful method in monitoring fetal growth and 
detecting the phenotypes of developmental abnormalities, its false-positive rates are 
high. For example, in the NT scan, about 5% of cases with positive results do not 
actually carry a fetus with Down syndrome (Muller et al., 2003). Many other fetal 
defects are caused by abnormal genetic make-up and do not present clearly on the 
phenotype, so they cannot be detected via ultrasound scan.  
Maternal serum screening is a blood test which helps determine the risk of certain 
chromosomal abnormalities such as Down syndrome, Edwards syndrome (Trisomy 18) 
and neural tube defects. It is usually carried out in the first and second trimester of 
pregnancy by measuring serum levels of a combination of alpha-fetoprotein (AFP), 
unconjugated estriol, human chorionic gonadotropin (hCG) and inhibin A. As the risk 
of fetal aneuploidies increases with maternal age, some other factors including 
maternal age and ethnicity are also considered while estimating the risk. A positive 
result of this test indicates a high risk of having the abnormality. However, there is a 5% 
false positive rate set for this screening test. It is because when it was first developed 
in the 1970s, about 5% of the pregnant women were above 35 years old and 35 years 
was used as a cut-off point for the high-risk group. The detection rate of Down 
syndrome with second trimester maternal serum screening on the four serum proteins 
combined with maternal age is 75% (Haddow et al., 1998). For screening in the first 
trimester, use of NT scan in combination with maternal age and two serum markers 
namely, pregnancy-associated plasma protein A (PAPP-A) and the free β subunit of 
human chorionic gonadotropin (f β hCG) can further improve the detection rate and 
reduce the false positive rate (Wald et al., 2003; Malone et al., 2005). Depends on the 
combination of markers used, the detection rate varies from 65% to 95% (Nicolaides, 
2011). Nevertheless, the result of screening test is not a definitive one. The suspected 
                                                                                          Chapter 2: Literature Review 
7 
 
condition needs to be further confirmed by performing a diagnostic test such as 
amniocentesis or chorionic villus sampling according to the gestational age.  
New prenatal screening tests are being developed with the aim of higher detection rate, 
and earlier detection, but the confirmation of the abnormality from a positive 
screening result still relies on diagnostic tests which can provide definitive answers.  
 
2.2 Prenatal diagnosis 
Unlike a screening test, a diagnostic test gives definitive result on the disease. For 
prenatal diagnosis of chromosomal and genetic disorders, invasive tests including 
amniocentesis, chorionic villus sampling and fetal blood sampling remain the gold 
standards. After performing the screening tests, these tests are usually offered to high-
risk pregnant women. However, all these procedures carry potential risks of 
miscarriage. To overcome the problems associated with invasive tests, non-invasive 
prenatal diagnosis (NIPD) has evolved rapidly for the past two decades with 
breakthroughs that brought forward new technologies to clinical applications.  
2.2.1 Current invasive methods  
Amniocentesis. Chromosome analysis on aspirated amniotic fluid in the mid trimester 
of pregnancy was first carried out more than four decades ago (Kubli and Hindemann, 
1966). Today, amniocentesis is the conventionally used prenatal diagnostic method 
performed at 15-18 weeks of pregnancy posing low risk to the fetus. The procedure 
withdraws about 10-20 ml of fluid from the amniotic sac with the aid of ultrasound 
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guidance. Cells present in the amniotic fluid are then separated and cultured in vitro to 
amplify their numbers for later diagnosis. Amniotic fluid cells are heterogeneous 
because of their different origins from the fetus, including the inner lining of amniotic 
membrane, skin, respiratory, digestive and urogenital tract.  
Amniocentesis has been routinely used for detecting chromosomal anomalies such as 
Down, Edwards and Patau syndromes, neural tube defects and other genetic disorders. 
The final result for chromosome analysis, called karyotype, is usually made available 
10 to 14 days after the procedure and this is due to the long cell culture period. Today, 
more advanced techniques have emerged such as quantitative fluorescent polymerase 
chain reaction (QF-PCR) and fluorescence in situ hybridization (FISH) which shorten 
the diagnosis process. Results are available within two days by directly testing the 
cells from amniotic fluid without culturing them (Lapaire et al., 2007a; Ho and 
Choolani, 2010; Ho et al., 2012). The accuracy of amniocentesis for detecting 
chromosomal abnormalities is almost 100% because of the full karyotype result. 
However, as mentioned, invasive test always carries a risk of miscarriage. The rate of 
amniocentesis-related miscarriages has been reported to be about 1% (Tabor et al., 
2009). Amniocentesis performed earlier than 14 weeks of gestation was shown to 
result in 2% higher rate of fetal loss and fetal injury (Winsor et al., 1999).  
Chorionic villus sampling (CVS) as a tool for prenatal diagnosis was first developed 
in 1984 (Kuliev et al., 1993). In this procedure, samples of chorionic villi from the 
placenta are aspirated transcervically or transabdominally and the fetal cells found in 
the biopsy are used for diagnosis. The advantage of CVS over amniocentesis is that it 
can be performed at an earlier stage of pregnancy which is usually between 10-13 
weeks of gestation. It can provide early diagnosis of chromosomal and genetic 
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anomalies, thus relieving much anxiety to the parents and giving more time for 
decision-making. Cells from the chorionic villi can either be expanded in culture to 
get a karyotype result or be used directly by extracting the fetal DNA which can be 
then analysed by polymerase chain reaction (PCR). A limitation of this test is that in a 
small percentage of pregnancies, the genetic make-up of the placental cells does not 
represent that of the fetus due to a condition called ‘confined placental mosaicism’ 
(Kalousek and Dill, 1983). In such case, a further diagnostic test needs to be 
performed. Similar to amniocentesis, CVS also carries risk of miscarriage in the 
region of about 0.5 - 1% (Tabor and Alfirevic, 2010).  
Fetal blood sampling is a procedure to draw a small amount of fetal blood from the 
umbilical cord vein (Cordocentesis) or intrahepatic vein. It is usually performed in 
late gestation after 18 weeks when diagnostic information cannot be obtained through 
amniocentesis and CVS. Hence, it is not a common diagnostic test. DNA can be 
extracted from fetal whole blood for molecular analysis by PCR, while fetal white 
blood cells (WBCs) in the blood can be cultured for karyotyping. This invasive 
method has an even higher miscarriage rate of 2-3% (Buscaglia et al., 1996; Antsaklis 
et al., 1998) compared with the other two methods. The risk further increases if the 
procedure is done before 18 weeks of gestation (Orlandi et al., 1990) or in growth 
restricted or hydropic fetuses (Maxwell et al., 1991). 
2.2.2 Non-invasive prenatal diagnosis (NIPD) 
Non-invasive prenatal diagnosis (NIPD) is highly desirable because it does not carry 
miscarriage risk and complications brought on by invasive prenatal tests. NIPD has 
been pursued for more than two decades for both fetal chromosomal anomalies and 
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single gene disorders. The discoveries of the presence of fetal cells (Walknowska et 
al., 1969), fetal DNA and mRNA (Lo et al., 1997; Poon et al., 2000) in the maternal 
circulation laid the foundation for development of non-invasive prenatal tests using 
maternal blood.  Both fetal cells and cell-free fetal nucleic acids carry valuable fetal 
genetic information which can be analysed with various molecular techniques. Many 
studies have been performed to explore these new sources of fetal genetic materials 
and test their application in the clinical settings.  
2.2.2.1 Fetal-maternal trafficking 
The constant bi-directional trafficking of nutrients, gas, molecules and cells between 
the mother and the fetus at the placental site results in crossing of some of the fetal 
materials such as fragmented DNA and intact cells into the maternal circulation. 
Hence, these materials can be captured from the maternal blood and utilized for NIPD. 
The fetal-maternal interface is maximized in area by the numerous placental chorionic 
villi which are in direct contact with the maternal decidua and maternal spiral arteries 
(Whitley and Cartwright, 2009). The intervillous space is filled with maternal blood to 
allow immediate exchange with the fetal blood. It is not clear how the fetal DNA and 
cells cross the placental barrier, but it seems that the rate of crossover is associated 
with the condition of the placenta and the development of the fetus (Bianchi et al., 
1997; Holzgreve et al., 1998; Al-Mufti et al., 2000; Zhong et al., 2000b; Parano et al., 
2001). The migration of fetal cells into the maternal circulation is considered as a 
form of microchimerism, named ‘fetal microchimerism’. The allogeneic fetal cells 
may end up being trapped or homed in certain maternal tissues (O'Donoghue et al., 
2004; Saadai and Mackenzie, 2012). Some of these cells can persist in the mother’s 
body for decades (Bianchi et al., 1996). From the diagnostic perspective, the details 
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for each of the fetal materials present in the maternal blood are described in the 
following sections. 
2.2.2.2 Cell-free fetal DNA and mRNA in maternal blood 
Cell-free fetal DNA. In 1997, Lo et al. first reported the consistent detection of fetus-
derived Y sequences in the maternal plasma and serum samples of pregnant women 
bearing male fetuses, which suggested that cell-free fetal DNA (cffDNA) circulate in 
the maternal blood during pregnancy. Since then, there has been tremendous interest 
towards the development of NIPD using cffDNA in the maternal blood. It was later 
found that cffDNA could be detected as early as 7 weeks of gestation and its 
concentration increases as the pregnancy progresses (Lo et al., 1998b).  Another 
important feature of cffDNA is the rapid clearance from the maternal circulation after 
delivery, which gives it high specificity for testing only the current pregnancy (Lo et 
al., 1999c).  The origin of cffDNA in the maternal blood has been speculated to be 
mostly from trophoblasts that are undergoing apoptosis or necrosis in the placenta 
(Bianchi, 2004; Flori et al., 2004; Bischoff et al., 2005; Tjoa et al., 2006; Faas et al., 
2012a). A strong piece of evidence to support this is that in anembryonic pregnancies, 
the cffDNA concentrations in the maternal plasma were comparable to those in the 
normal cases, and positive male signal could be found in the plasma after QF-PCR, 
which corresponded to the chorionic tissue results (Alberry et al., 2007). Interestingly, 
the concentration of cffDNA was found to be elevated in cases with fetal 
abnormalities (Lo et al., 1999a; Bauer et al., 2006) and preeclampsia (Holzgreve et al., 
1998; Lo et al., 1999b; Zhong et al., 2001), compared with normal pregnancies.  
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Cell-free fetal DNA was initially shown to have high sensitivity for determining fetal 
sex in the first trimester (Pertl et al., 2000; Costa et al., 2001; Sekizawa et al., 2001; 
Honda et al., 2002; Guibert et al., 2003; Mortarino et al., 2011) and fetal rhesus D 
(RhD) blood type (Lo et al., 1998a; Zhong et al., 2000a; Legler et al., 2002; Cardo et 
al., 2010). Many single gene disorders were also successfully detected using cffDNA 
in small scale studies, including achondroplasia (ACH) (Saito et al., 2000; Chitty et 
al., 2011), myotonic dystrophy (Amicucci et al., 2000), Huntington’s disease 
(Gonzalez-Gonzalez et al., 2003a; Gonzalez-Gonzalez et al., 2003b; Gonzalez-
Gonzalez et al., 2008), alpha-thalassaemia (Tungwiwat et al., 2006), beta-
thalassaemia (Chiu et al., 2002b; Vrettou et al., 2003; Tungwiwat et al., 2007; 
Phylipsen et al., 2012), sickle-cell disease (Phylipsen et al., 2012), cystic fibrosis  
(Gonzalez-Gonzalez et al., 2002; Nasis et al., 2004; Bustamante-Aragones et al., 
2008), congenital adrenal hyperplasia (Chiu et al., 2002a), and haemophilia (Tsui et 
al., 2011). However, most of the detected single gene disorders are paternally 
inherited as the paternal mutated allele present in the cffDNA can be easily 
distinguished from the maternal genomic background (Bustamante-Aragones et al., 
2012).  For maternal dominant single gene disorders or diseases from parents carrying 
the same mutation, more techniques and/or analytic methods need to be developed for 
their diagnosis using cffDNA (Lun et al., 2008; Chiu and Lo, 2011).  
A recent breakthrough in the NIPD field is the use of cffDNA for detection of fetal 
aneuploidies, namely trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) 
and trisomy 13 (Patau syndrome). As early as 2008, two groups have demonstrated 
the possibility of using cffDNA to test fetal aneuploidies with massively parallel 
genomic sequencing (MPS) method (Chiu et al., 2008; Fan et al., 2008). It was 
suggested later that the whole genetic profile of the fetus could be revealed by 
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sequencing cffDNA in the maternal blood (Lo et al., 2010). The same group 
conducted a larger scale study on maternal plasma samples using multiplexed DNA 
sequencing analysis and showed that it was able to rule out fetal trisomy 21 among 
high risk pregnancies, thus avoiding the invasive diagnostic procedures (Chiu et al., 
2011).  In 2011 and 2012, many large scale clinical studies were conducted world-
wide to validate the method of cffDNA sequencing for detecting fetal aneuploidies. 
All of them demonstrated high sensitivity, high specificity and low false-positive rates 
using this method (Chen et al., 2011a; Ehrich et al., 2011; Palomaki et al., 2011; 
Sehnert et al., 2011; Ashoor et al., 2012; Bianchi et al., 2012; Lau et al., 2012; 
Palomaki et al., 2012; Sparks et al., 2012). Despite the highly promising results from 
these studies, this non-invasive test for fetal aneuploidies is still considered as a 
screening test and is only recommended after the routine first-trimester or second-
trimester screening procedures. In addition, most of the clinical trials were only 
performed on high risk pregnancies. Low risk population has not been included. This 
cffDNA test is commercially available in some countries, but further studies in the 
clinical settings are still necessary before it can be routinely employed as a primary 
screening or as a diagnostic test in the large and diverse populations all over the world.  
Cell-free fetal mRNA. Three years after the discovery of cffDNA, cell-free fetal 
mRNA (cffmRNA) was also observed in the maternal plasma (Poon et al., 2000). 
Placenta-specific mRNA has been readily detected in the maternal plasma (Ng et al., 
2003; Heung et al., 2009), implying its potential use in NIPD. Similar to cffDNA, the 
cffmRNA can be detected early in the first trimester and quickly cleared from the 
maternal circulation after delivery (Chiu et al., 2006). Chromosome 21-specific 
mRNA was found in the maternal plasma (Oudejans et al., 2003), which could enable 
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detection of trisomy 21. Using a RNA-SNP allelic ratio strategy, some recent studies 
demonstrated the possibility of using placental cffmRNA for testing fetal aneuploidies, 
although the accuracy was not as high as using cffDNA (Lo et al., 2007; Go et al., 
2008; Tsui et al., 2009; Tsui et al., 2010). Compared with cffDNA, cffmRNA in the 
maternal circulation is detected at higher levels, which is a great advantage as they 
can be discriminated from the maternal genetic materials easily. However, the 
relevant techniques are yet to be fully developed and optimized for clinical 
applications.   
2.2.2.3 Nucleated fetal cells in maternal blood  
The presence of fetal cells in the maternal circulation was first documented in 1893 
when multinucleated syncytial trophoblasts were found in the lung tissue of pregnant 
women who died from eclampsia (Schmorl, 1893), original paper in German, 
translated to English by (Lapaire et al., 2007b). This important observation raised the 
possibility of using fetal cells circulating in the maternal blood for prenatal diagnosis.  
Intact nucleated fetal cell contains complete fetal genetic information in the cell 
nucleus and cytoplasm, which can be used for detecting both fetal chromosomal and 
genetic disorders.  
A variety of fetal cell types has been identified in the maternal blood, namely 
trophoblasts, leukocytes, erythroblasts or nucleated red blood cells, CD34+ progenitor 
cells and mesenchymal stem cells (Table 2-1). Each of them carries distinct features 
in terms of cellular properties, surface antigens, frequency and persistence in the 
maternal circulation.  
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Table 2-1 Discoveries of fetal cells in the maternal blood 
Year Author Fetal cell type Method 
1893 Schmorl Syncytial trophoblast Autopsies 
1969 Walknowska et al. Lymphocyte Cytogenetics 
1990 Bianchi et al. Erythroblast Flow cytometry, PCR 
1992 Wessman et al. Granulocyte FISH 
1996 Bianchi et al.  CD34+CD38+ progenitor cell Flow cytometry, PCR 
1997 Little et al.  CD34+ progenitor cell Flow cytometry, FISH 
2003 O’Donoghue et al. Mesenchymal stem cell Magnetic cell sorting, FISH 
 
Trophoblasts originate from the placenta, so they are all fetal in origin. They could 
serve as good target cells for NIPD because it is not necessary for these cells to cross 
the placental barrier to reach the maternal blood. They were reported to actively 
migrate to the maternal tissues and arteries during the first trimester of pregnancy 
(Pijnenborg et al., 1981; Zhou et al., 1997).  Two types of trophoblasts are released 
into the maternal circulation, namely syncytiotrophoblast which is multinucleated and 
cytotrophoblast which is single nucleated.  The syncytiotrophoblasts are rapidly 
cleared by the pulmonary circulation (Attwood and Park, 1961), while the 
mononuclear cytotrophoblasts persist in the maternal circulation. However, some 
have suggested that trophoblast deportation to the maternal blood is not a common 
phenomenon in all pregnancies (Wagner, 1968; Sargent et al., 1994; Schueler et al., 
2001). It may be more evident in abnormal pregnancies. The absence of trophoblast in 
some cases could also be explained by their small numbers in the maternal blood and 
lack of specific markers for their enrichment. Some later studies showed the presence 
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of trophoblasts in the maternal blood after using specific antibodies. Mueller et al. 
(1990) were able to isolate trophoblasts from maternal peripheral blood with screened 
murine monoclonal antibodies and amplify the Y-chromosome-specific DNA 
sequence using PCR from the isolated cells, with an accuracy of up to 92%. In 
another study, multinucleated cells with identical morphology to syncytiotrophoblasts 
were identified in 12 of 14 maternal blood samples (Hawes et al., 1994). van Wijk et 
al. achieved a 91.7% success rate in determining the fetal gender by nested X/Y PCR 
from the isolated trophoblasts in 33 out of the 36 maternal blood samples (1996).  
Later on, they were also able to detect Trisomy 21 using the trophoblasts selected by 
HLA-G (human leukocyte antigen G) antibody (van Wijk et al., 2001). In contrast, 
some other groups reported the failure or inconsistency in the enrichment of 
trophoblasts from maternal blood (Hviid et al., 1999; Schueler et al., 2001). In 
addition to non-availability of highly specific antibodies, placental mosaicism in some 
pregnancies may pose a major challenge in making the correct diagnosis (Henderson 
et al., 1996; Goldberg and Wohlferd, 1997; Holgado et al., 2011).  In these special 
cases, about 1% of trophoblasts have different karyotype from the actual karyotype of 
the fetus, so there is a risk of misinterpretation of the results.  Due to these limitations, 
further studies are necessary before the use of trophoblast as a target cell type for 
NIPD.   
Fetal leukocytes, particularly lymphocytes, present in the maternal blood were useful 
in fetal sex determination as early as 1970’s (Walknowska et al., 1969; Schroder and 
De la Chapelle, 1972; Grosset et al., 1974; Herzenberg et al., 1979) because of their 
ability to proliferate in the presence of mitogens in vitro. Since maternal lymphocytes 
and fetal lymphocytes express the same CD antigens, fetal lymphocytes in the 
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maternal blood were enriched based on the HLA class of antigens if the maternal and 
paternal HLA types were not shared. However, this required additional paternity 
information, which was not always available. Another major drawback of using fetal 
leukocytes is that many studies have demonstrated the persistence of these cells in the 
maternal blood post-delivery for a very long period of time (Schroder and De la 
Chapelle, 1972; Ciaranfi et al., 1977; Hsieh et al., 1993; Bianchi et al., 1996). This 
could lead to misdiagnosis of the current pregnancy. Thus, using fetal leukocytes for 
NIPD is not ideal.  
Fetal progenitor and stem cells such as CD34+ cells and mesenchymal stem cells 
seem promising as their number can be expanded in vitro after enrichment from 
maternal blood. Many researchers have cultured fetal progenitor cells from the 
maternal blood with the hope of increasing their numbers (Huang et al., 2011). 
However, due to the contamination of maternal cells in the culture, selective 
amplification of fetal over maternal cells was not successful in some studies (Lo et al., 
1994; Bohmer et al., 2001; Campagnoli et al., 2002).  Similar problems occurred 
when culturing fetal CD34+ stem cells from the maternal blood (Jansen et al., 2000; 
Manotaya et al., 2002). CD34+ cells have also been reported to persist post-delivery 
in maternal blood as long as 27 years (Bianchi et al., 1996). They were even 
suggested to colonize a variety of maternal organs (Mikhail et al., 2008).  Fetal 
mesenchymal stem cells found in the maternal blood have also been isolated and 
cultured (O'Donoghue et al., 2003). However, they were too rare to be amplified in 
vitro. Hence, this group of fetal cells may not be ideal for NIPD due to the suboptimal 
existing culture methods and their postpartum persistence in the maternal circulation 
and organs.  
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Fetal erythroblasts (FEs) or fetal nucleated red blood cells (FNRBCs) are nucleated 
red cells produced from fetal erythropoiesis including both primitive and definitive 
types. Compared with the other fetal cell types, FEs have several advantages in terms 
of their use for NIPD: 1) they can be detected from the first trimester of pregnancy. 
Particularly the fetal primitive erythroblasts are the prominent cell population in the 
first trimester fetal blood (Thomas and Yoffey, 1962; Choolani et al., 2001); 2) they 
have short life spans with half-life of 25 – 35 days (Pearson, 1967). Thus they are 
suitable for diagnosing the current pregnancy; 3) specific antibodies can be developed 
for their enrichment from the maternal blood (detailed in section 2.3.1); 4) they 
contain embryonic or fetal haemoglobins in the cytoplasm which distinguish them 
from maternal cells (Choolani et al., 2001).  
However, like other fetal cell types, FEs are scarce in the maternal blood. There is 
about one FE per 105 to 109 of mononuclear cells (Price et al., 1991). The enrichment 
process has to be highly specific and efficient in order to separate such small number 
of cells from the massive number of maternal cells. To overcome the limited cell 
numbers, some cultural studies have also been performed on fetal erythroid cells from 
maternal blood with the aim of expanding their numbers for diagnosis (detailed in 
section 2.3.2).  The cell enrichment and in vitro culture are the two major challenges 
faced in the development of using FEs from the maternal blood for NIPD.   
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2.3 Current state of using fetal erythroblasts (FEs) for 
NIPD 
Among the various types of fetal cells found in the maternal blood, fetal erythroblast 
(FE) is considered as the most suitable target cell for NIPD. Before the use of cffDNA 
became widely accepted for prenatal testing, enrichment and culture of FEs from the 
maternal blood had been extensively studied for diagnostic purposes. The commonly 
used cell separation techniques, culture protocols, and the available downstream 
molecular tests for the isolated FEs are summarized here.  
2.3.1 Enrichment of FEs from maternal blood 
Common methods used for FE enrichment from maternal blood include density 
gradient centrifugation, fluorescence-activated cell sorting (FACS), magnetic 
activated cell sorting (MACS), lectin-based methods, charged flow separation, 
filtration, selective erythrocyte lysis and micromanipulation.  
Density gradient centrifugation is often used as the first enrichment step to separate 
the mononuclear cells from red blood cells. In the procedure, maternal blood is 
layered on top of the density gradient which could be steps or continuous and 
centrifuged at appropriate speed for the sample of interest. The principle behind is that 
cells will travel in the gradient during the centrifugation and remain at a layer which 
has the same density as their buoyant density (Wood, 1991). For cells having buoyant 
density heavier than the highest gradient, they will be settled at the bottom of the 
centrifuge tube. Percoll and Ficoll are the most frequently used density gradient for 
FE separation from maternal blood. Gradients with various densities have been 
attempted to capture these cells in a single step but overall the recovery rates were 
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very low (Troeger et al., 1999; Samura et al., 2000; Smits et al., 2000; Prieto et al., 
2001; Voullaire et al., 2001; Kwon et al., 2007). This could be due to the varying 
densities of FEs of different types and differentiation stages (Smits et al., 2000). 
Although the one step centrifugation can reduce processing time, labour and cost; in 
order to achieve a higher recovery and purity of FEs after the enrichment, an 
antibody-based separation following the gradient centrifugation is still preferred.  
FACS and MACS are the two most popular cell separation techniques based on 
antigen-antibody recognition. FACS utilizes a light source, usually a laser, to detect 
cells that are fluorescently labelled by a specific antibody and separate them from 
non-labelled cells. The optical-based design of the FACS instrument makes this 
technique highly sensitive in sorting the differentially-stained cells, thus it can yield 
higher purity of the target cells. Another advantage of using FACS is that it allows 
multi-parameter analysis, meaning that more than one antigen or cell parameter such 
as size can be analysed simultaneously. As early as 1979, Herzenberg et al. had used 
FACS to enrich fetal cells from maternal blood with antibody against paternal HLA 
antigen.  Following the success of this, many studies were carried out to enrich FEs 
with FACS from maternal blood (Bianchi et al., 1990; Price et al., 1991; Wachtel et 
al., 1991; DeMaria et al., 1996; Lewis et al., 1996; Bischoff et al., 1998). The most 
commonly tested antigens were CD71, CD36 and Glycophorin A (GPA) (Bianchi et 
al., 1990; Price et al., 1991; Bianchi et al., 1993; Bischoff et al., 1998), which are 
specific surface antigens of erythroid cells. Intracellular markers such as fetal 
haemoglobin and nuclear stain were also used in some studies (DeMaria et al., 1996; 
Bianchi et al., 2002). However, there are a few limitations hampering the use of 
FACS as a routine enrichment method in the clinical settings. The recovery and purity 
of FEs after FACS sorting were still not high enough for full detection of fetal cells in 
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large sample scale (Bianchi et al., 2002). The operation of FACS facility is relatively 
expensive and requires trained personnel.  
Compared with FACS, MACS has been proven to be a more rigorous and cheaper 
separation method for FEs from maternal blood. It also relies on antibody-antigen 
interaction, but in this case, the labelled cells are attracted to a magnetic field and 
being selected or depleted from the mixed population. The same range of surface 
antibodies used in FACS could be applied in MACS. Purity of FEs was improved by 
using MACS depletion of CD45 positive white blood cells prior to selection of CD71 
positive cells (Busch et al., 1994). In one study, the enrichment of FEs was 
reproducible in more than 600 cases using a triple density gradient followed by CD71 
MACS (Ganshirt et al., 1998). From the data of a large-scale multicentric study, 
known as NIFTY, MACS was shown to produce better recovery of FEs from maternal 
blood compared with FACS (Bianchi et al., 2002). The disadvantage of using MACS 
is that only one antigen can be targeted each time. If multiple antibodies are required 
to sort the fetal cells, the whole enrichment process will take a long time.  
Other than surface antigens, saccharides that are highly expressed on the FE surface 
such as galactose were also exploited for cell enrichment. Galactose-specific lectin, 
soybean agglutinin, has been used to isolate FEs from cord blood and maternal blood 
with galactose-coated slides (Kitagawa et al., 2002; Ikeya et al., 2005; Sekizawa et al., 
2007). In one study comparing MACS with lectin-based method, the latter was found 
to recover eight fold higher number of erythroblasts per ml of maternal blood, but the 
cell purity was significantly lower than that of MACS (Babochkina et al., 2005b). In 
addition, it is a time-consuming process to locate the potential FEs from mass number 
of maternal cells after the lectin selection. 
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Charge flow separation has been demonstrated by one group to be highly efficient in 
recovering FEs from maternal blood (Wachtel et al., 1996; Wachtel et al., 1998). In 
the first attempt, they were able to obtain more than 2000 FEs from 20 ml of blood.  
Two years later, they reported the average separation of 345 erythroblasts per ml of 
maternal blood. 30% of these separated cells were confirmed to be fetal in origin. 
However, this method was not repeated by others later on, probably due to the 
complexity of the instrument used and the additional density gradient step required 
prior to the flow separation.   
Filtration-based cell separation is a straightforward way of enriching the target cells 
according to their sizes. It does not involve the use of any antibody, thus suitable for 
cells that lack specific surface markers. Microfluidic devices have been invented for 
the separation of FEs from cord blood or model mixtures (Mohamed et al., 2007; Lee 
et al., 2010). Cell size, shape, deformability are the three main factors considered for 
designing these devices. Depending on the contaminating cell population present in 
the sample, different sizes of microchannels could be designed either to filter the FEs 
from the bigger sized white blood cells, or to remove the smaller sized adult RBCs 
from the FEs. The limitations of this method are the slow flow rate, cell adhesion to 
the channel walls and cell clogging problem (Kavanagh et al., 2010).  
Selective cell lysis was suggested to be useful in removing adult RBCs in the maternal 
blood, because FEs are less susceptible to ammonium chloride than adult RBCs 
(Boyer et al., 1976; Alter et al., 1979). However, loss of cell morphology and cell 
clumping were observed after the lysis (Voullaire et al., 2001; Choolani et al., 2003), 
which rendered its limited role in FE enrichment.  
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Micromanipulation at single cell level to isolate FEs has been reported in several 
studies, including the use of classic micromanipulator or laser-microdissection 
machine (Takabayashi et al., 1995; Sekizawa et al., 1996; Sekizawa et al., 1998; 
Nagy et al., 2005; Kolialexi et al., 2007). The micromanipulation step usually follows 
prior cell enrichment with other methods. It could be carried out on live cells without 
confirmation of fetal origin, or on fixed and stained cells which are already confirmed 
to be fetal. Although the accuracy of getting fetal cells is high with this method, it 
requires expensive instruments and expertise for operating the procedure. If possible, 
an automated process would be preferred to save time and effort.  
In summary, for most fetal cell enrichment methods, target cell recovery and purity 
are the two major concerns. This is primarily because fetal cells are rare in the 
maternal circulation. For the isolation of FEs from maternal blood, enrichment 
protocols that can produce high recovery and purity are still under development. More 
specific antigens need to be discovered for antibody-based approaches and new 
micro-devices can be fabricated for a better cell separation.  
2.3.2 In vitro culture of FEs from maternal blood 
To solve the problem of having too few fetal cells from maternal blood, in vitro cell 
culture and expansion after enrichment was attempted by many groups to provide 
adequate fetal cell numbers for NIPD (Table 2-2) (Huang et al., 2011). Fetal erythroid 
progenitor or precursor cells, hematopoietic stem cells, mesenchymal stem cells and 
endothelial precursor cells were chosen for such expansion culture because they had 
the potential to proliferate in vitro.  
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Table 2-2  In vivo culture of fetal cells from maternal blood for NIPD 
 
* indicates Trisomy case(s) 
Lo et al. first showed the detection of Y-probe positive cells by FISH after culturing 
the maternal blood cells for 7 days in erythropoietin-enriched medium (Lo et al., 
1994). They suggested that fetal erythroid progenitor cells present in the maternal 
blood could be amplified after culture due to a preferential growth advantage over 
adult cells. The same concept was adopted by others later on. Erythropoietin 
responsive CFU-E and BFU-E cells sorted from second trimester maternal blood 
formed colonies in semi-solid culture medium, and about 18% of the colonies were 
proven to be fetal in origin (Valerio et al., 1996).  These progenitor cells could also be 
expanded in colonies with a fetal purity of 16 to 25% in cases of aneuploid 
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pregnancies (Valerio et al., 1997). In a larger scale study conducted by another group, 
however, the production of fetal cell colonies after culture was not successful (Chen et 
al., 1998). All of the colonies obtained turned out to be of maternal origin. The 
inconsistency in detecting fetal erythroid cells from the culture was also reported in 
Han et al.’s work, where they could detect male DNA in the cultured cells by PCR, 
but could not find XY karyotype in metaphase analysis (Han et al., 1999; Han et al., 
2001). Contradictory results have been shown in two independent studies using 
similar culture conditions and PCR analysis of SRY on comparable maternal blood 
sample sizes (Tutschek et al., 2000; Zimmermann et al., 2002). The earlier study was 
able to detect male DNA from the cultured cells, but not subsequent study. In another 
study where quantitative FISH analysis was used to detect male erythroid cells after 
suspension culture, no Y chromosome signal could be found (Huber et al., 2000).  
Preliminary study before the NIFTY trial found that post termination blood samples 
yielded fetal cells with high purity; however, none of the maternal blood samples 
from normal or abnormal pregnancies seemed to have fetal cells after PCR, FISH 
analysis and flow-sorting of fetal haemoglobin positive cells (Bohmer et al., 2002).  
To summarize, despite the various conditions or protocols that have been developed 
for culturing fetal erythroid cells from maternal blood, the results were not consistent 
among the different groups probably due to the scarcity of these cells. Therefore, a 
highly efficient enrichment method is still critical before the downstream procedures 
can be carried out.    
It is worth noting that most of the previous FE culture studies were performed on 
second trimester onwards maternal blood samples, and only the presence of fetal 
haemoglobins was investigated. Little work has been done on the in vitro culture of 
first trimester erythroblasts, which primarily belong to the primitive type and carry 
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embryonic haemoglobins (Choolani et al., 2001; Choolani et al., 2003). A recent 
study demonstrated the possibility of culturing epsilon globin (embryonic 
haemoglobin) positive FEs from maternal blood, although it was very hard to detect 
and expand them in vitro (Zheng et al., 2012). More investigations on this cell type 
are required in order to use first trimester maternal blood for NIPD.   
2.3.3 Diagnostic tests for fetal cells from maternal blood 
Once the enrichment of fetal cells from maternal circulation reached consistency, 
many molecular tests could potentially be applied to these cells to detect fetal 
chromosomal and genetic anomalies. The currently available tests for both invasive 
and non-invasive prenatal diagnosis include PCR (polymerase chain reaction), 
karyotyping, FISH (fluorescent in situ hybridization), array CGH (comparative 
genome hybridization), SNP (single nucleotide polymorphism) array and DNA 
sequencing. In view of the rare number of fetal cells that can be recovered from 
maternal blood, karyotyping may not be feasible to perform. The other methods are 
reviewed as follows.  
PCR  
PCR is considered as the gold standard approach of retrieving genetic information 
from DNA and RNA. Nowadays, the simple PCR technology has been developed into 
numbers of more complicated variations for different purposes. For NIPD, real-time 
PCR, multiplex- PCR, QF-PCR (quantitative fluorescent-PCR) and RT-PCR (reverse 
transcription-PCR) are most commonly used. Each method is capable of detecting 
specific targets. Real-time quantitative PCR was often used for fetal sex prediction 
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(Honda et al., 2002; Guibert et al., 2003; Mortarino et al., 2011), RhD genotyping 
(Legler et al., 2002; Cardo et al., 2010) or monogenic disorder detection (Tungwiwat 
et al., 2006; Chitty et al., 2011), as it amplifies one signature sequence of the target 
gene each time. Multiplex-PCR was a good option when more than one target genes 
need to be amplified (Zhong et al., 2000a; Tounta et al., 2011; Kolialexi et al., 2012). 
QF-PCR has been considered as a sensitive and rapid method in detecting 
aneuploidies from amniocentesis and CVS samples (Rahil et al., 2002; Ogilvie et al., 
2005; Mann et al., 2012). For NIPD, it has also been used for testing monogenic 
disorders from maternal plasma (Gonzalez-Gonzalez et al., 2003a; Ho et al., 2010; 
Lim et al., 2011). RT-PCR was exclusively designed for RNA analysis. It first 
converts RNA to single stranded cDNA (complimentary DNA), which will be then 
amplified like normal DNA sequence with specific primers and probes. A few studies 
have used RT-PCR to detect fetal aneuploidies from maternal plasma cell-free fetal 
mRNA (Go et al., 2008; Tsui et al., 2009; Tsui et al., 2010).  Most of the PCR-based 
techniques used in NIPD were analysing the cell-free fetal DNA or mRNA from 
maternal plasma, DNA extracted from the fetal cells in the maternal blood should be 
explored in the same way in the future.  
FISH 
FISH is particularly useful for detecting fetal aneuploidies including autosomal 
trisomies and sex chromosome numerical disorders, as shown by the routine tests 
carried out on fetal cells obtained from amniocentesis and CVS (Tepperberg et al., 
2001; Witters et al., 2002; Ho et al., 2012). It has also been applied to fetal cells 
isolated from maternal blood for verifying fetal origin and known chromosomal 
disorders (Lo et al., 1994; Little et al., 1997; Valerio et al., 1997; Bischoff et al., 1998; 
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Valerio et al., 2000; Bianchi et al., 2002; Sekizawa et al., 2007; Calabrese et al., 
2012).  The advantages of using FISH for prenatal diagnosis are its high sensitivity, 
accuracy, relatively low cost and short processing time. However, to use it as a 
regular diagnostic test for fetal cells from maternal blood, more optimization needs to 
be done as the fetal cell number is usually small and purity is low due to maternal cell 
contamination. A scanning method might be useful to detect the rare signals from the 
fetal cells (Johnson et al., 2007; Seppo et al., 2008; Emad et al., 2012).  
Array CGH 
Array CGH is a recently developed technique that can detect genomic copy number 
variation (CNV) at a resolution level of 5 to 10 kilobases of DNA sequences (Ren et 
al., 2005). Compared with the conventional cytogenetic analysis or karyotyping, it has 
a few advantages including submicroscopic resolution, no requirement for cell culture, 
automation and faster turnaround time. The high resolution of this technique allows it 
to detect deletions and duplications in any site of the human chromosomes, and 
importantly, all at one time. In the clinical settings, array CGH has been applied in 
PGD (Preimplantation Genetic Diagnosis) and invasive prenatal diagnosis. One 
validation study showed that array CGH was able to identify all PGD embryos with 
reciprocal and Robertsonian translocations which were also confirmed by FISH 
analysis (Colls et al., 2012). The simultaneous detection of all chromosomes in array 
CGH also overcomes the limited coverage by FISH. In the context of invasive 
prenatal diagnosis, two large-scale studies have been performed to assess the 
feasibility of offering array CGH as a routine test and the results were promising 
(Fiorentino et al., 2011; Lee et al., 2012). Both common and submicroscopic 
chromosomal abnormalities were detected by array CGH, and most of them were in 
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concordance with karyotyping results while some were not detectable in karyotyping.  
In the near future, array CGH may also be applied to NIPD using fetal cells from 
maternal blood.  
SNP array 
SNP array, with a similar basic principle as array CGH, can also be used to detect 
genomic or chromosomal imbalance for prenatal diagnosis (Srebniak et al., 2011; 
Faas et al., 2012b; Srebniak et al., 2012). The advantage of SNP array over array 
CGH is that it can identify uniparental disomy, a form of loss of heterozygosity in 
which two copies of one parent’s allele are inherited, but the copy from the other 
parent is missing. The role of this array-based method in NIPD needs to be evaluated 
further.  
DNA sequencing 
In the past decade, DNA sequencing technology has become a popular tool for 
prenatal testing of aneuploidies (trisomy 21, 18 and 13) using cffDNA from maternal 
blood (Lo et al., 2010; Chiu et al., 2011; Ehrich et al., 2011; Ashoor et al., 2012; 
Bianchi et al., 2012; Lau et al., 2012; Palomaki et al., 2012; Sparks et al., 2012). The 
sequencing method used was called massively parallel sequencing (MPS) or next 
generation sequencing (NGS). Based on the results from many large-scale trials in the 
clinical settings, this approach demonstrated high sensitivity, high specificity and low 
false-positive rate for detecting fetal aneuploidies in high-risk population. The 
limitation lies in the high cost due to the expensive instruments and labour-intensive 
process. This sequencing method could also be applied to fetal cells isolated from 
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maternal blood, which contain intact whole fetal genome, rather than DNA fragments, 
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2.4 Human primitive erythroblasts (hEryPs)  
Human fetal primitive erythroblast (hEryP) has been considered as a promising 
candidate for early NIPD because it appears within the first trimester of gestation, has 
a short life span and has unique embryonic haemoglobin markers (Choolani et al., 
2003). However, this cell type is not well-studied in the humans, probably due to the 
limited access to embryonic and extra-embryonic tissues. The following sections 
review the current understanding of human erythropoiesis, particularly primitive 
erythropoiesis and the biological properties of erythroblasts.  
2.4.1 Primitive erythropoiesis vs. Definitive erythropoiesis 
Two distinct types of erythropoiesis exist in the human development. They are 
primitive erythropoiesis in the yolk sac during embryogenesis and definitive 
erythropoiesis mainly in the bone marrow, which begins from fetal stage and 
continues to postnatal life. While definitive erythropoiesis is well studied in the adult, 
primitive erythropoiesis is less understood due to its transient presence in the early 
embryo.  
It was recognized more than hundred years ago that primitive erythroid cells emerged 
in the yolk sac blood islands in mammalian embryos (Maximov, 1909). Primitive 
erythropoiesis is the first developmental process producing erythrocytes or red blood 
cells to supply oxygen for the growing embryo before liver and bone marrow become 
functionally ready for definitive erythropoiesis. Bloom and Bartelmez  (1940) 
reported that haemopoiesis first appeared in the mesoderm layer of human yolk sac by 
producing blood sinuses containing progenitor cells around  4 weeks of gestation. As 
the gestation advances, some of the progenitor cells differentiated into primitive 
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erythroid cells. After 5 weeks of gestation, primitive erythroblasts were already 
visible in the blood vessels of the chorionic villi. An electron microscopy study 
showed that hEryPs were the only circulating red cells present within the fetus and its 
yolk sac until 6 weeks of gestation (Pereda and Niimi, 2008).  For the origin of those 
blood islands, some evidences from the murine model suggested that they share the 
same precursor as the endothelial cells, called ‘haemangioblast’, in the yolk sac 
mesoderm layer (Choi et al., 1998; Ema et al., 2006; Lugus et al., 2009).  The 
primitive erythropoiesis is only prominent during the first trimester, as shown by the 
decreasing frequency of hEryPs circulating in the fetal blood as gestation progresses 
(Choolani et al., 2001; Choolani et al., 2003). By 6 weeks of gestation, the fetal liver 
takes over the role of producing erythrocytes via definitive erythropoiesis. After 20 
weeks of gestation, the bone marrow which is the final destination for haematopoiesis, 
becomes the major site for producing definitive erythroblasts (Tavassoli, 1991).  
Morphology-wise, primitive erythroblasts are larger in size and have smaller nuclear 
to cytoplasmic ratio compared with definitive erythroblasts. They share some 
common properties in their maturation process such as haemoglobin accumulation in 
the cytoplasm (De la Chapelle et al., 1969), decrease in cell size (Henery and 
Kaufman, 1992), progressive nucleus condensation (Sasaki and Kendall, 1985) and 
loss of intermediate filaments with the nucleus being free to move about in the 
cytoplasm (Sangiorgi et al., 1990). However, the differentiation pathway of primitive 
erythropoiesis is not identical to the definitive one. Definitive erythropoiesis is well 
studied and a schematic diagram of its differentiation pathway is presented in Figure 
2-1. The earliest stage in the definitive erythropoiesis can be traced to progenitor cells 
with the ability to form colonies (BFU-E and CFU-E). However, the earliest stage in 
the human primitive erythropoiesis has been traced only to the basophilic erythroblast 
                                                                                          Chapter 2: Literature Review 
33 
 
stage (Bloom and Bartelmez, 1940; Pereda and Niimi, 2008). Earlier stages such as 
CFU-E and proerythroblast have not been reported and characterized in the human 
embryo. In the mouse primitive erythropoiesis, however, cells capable of forming 
colonies and producing embryonic haemoglobins have been found (Wong et al., 1986; 
Palis et al., 1999; Ferkowicz et al., 2003). Another distinct feature of primitive 
erythroblasts is that they start circulating in the fetal blood in a nucleated state, while 
definitive erythroblasts enucleate before they enter the circulation.  
Figure 2-1 Human definitive erythropoiesis  
 
The terminal products of primitive and definitive erythropoiesis (nucleated 
erythroblast in the primitive and anucleated erythrocyte in the definitive) both contain 
large amount of haemoglobins for oxygen binding and transport throughout the whole 
body. Haemoglobin is a well-preserved iron-contained protein in the erythrocytes of 
vertebrates. In the humans, it contains four subunits of which two are called alpha 
chains and the other two called non-alpha chains. These subunits are encoded by the 
alpha and beta gene clusters located on chromosomes 16 and 11 respectively. At 
different developmental stages and in different erythropoietic organs, different types 
of globin chains are expressed in the cells through controlled expression of certain 
globin genes on the gene clusters. Generally, fetal primitive erythroblast contains zeta 
globin (alpha-chain) and epsilon globin (non-alpha chain), and some other 
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combinations including alpha and epsilon, and zeta and gamma. Fetal definitive 
erythrocyte contains alpha globin and gamma globin, while adult erythrocyte 
(definitive) contains alpha globin and beta globin. Hence, based on the different 
globin expression patterns, the types of erythrocytes or erythroblasts could be 
identified in most normal cases.   
2.4.2 Erythroid cell differentiation and proliferation 
In the fetal and adult bone marrow, multipotent hematopoietic stem cells (HSC) give 
rise to all the blood lineages by first differentiating into lymphoid and myeloid 
progenitors. The myeloid progenitors further differentiate to a range of lineages 
including erythroid cells. The downstream progenitors are also capable of self-
renewal as the upstream stem cells, but in a more restricted way as they continue to 
differentiate. The earliest committed progenitors identified for definitive 
erythropoiesis are the burst-forming unit- erythroid (BFU-E) which proliferate and 
further differentiate to rapidly dividing colony-forming unit-erythroid (CFU-E) 
(Elliott et al., 2008). CFU-E undergo a few rounds of divisions and differentiate into a 
cascade of erythroid precursors which further undergo three to four cell divisions as 
they progress from proerythroblast to basophilic, polychromatic and orthochromatic 
erythroblast stages. Orthochromatic erythroblasts finally extrude their nucleus 
(enucleation) to form reticulocytes which enter the blood stream and soon become 
erythrocytes.  
Interestingly, definitive erythroid cells at different stages respond to different growth 
factors as they proliferate and differentiate. Erythropoietin (Epo) has long been the 
principle factor in regulating definitive erythropoiesis in the bone marrow. BFU-E 
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respond to a group of cytokines including Epo, stem cell factor (SCF), insulin-like 
growth factor I (IGF-I), glucocorticoids, interleukin-3 (IL-3) and interleukin-6 (IL-6) 
(Hattangadi et al., 2011). CFU-E is highly dependent on Epo for commitment to the 
subsequent differentiation (Wu et al., 1995). However, the later stages of 
erythroblasts seem to not require Epo, as Epo receptors are lost as they undergo 
terminal proliferation and differentiation (Wickrema et al., 1992; Zhang et al., 2003). 
In addition, definitive erythroid proliferation and differentiation are also tightly 
controlled by gene regulations some of which are as a result of stimulation by growth 
factors. Some major transcription regulators of definitive erythropoiesis include 
GATA-1, SCL, Klf1, LDB1, Gfi-1b and LMO2 (Hattangadi et al., 2011).  
Mechanisms that govern the primitive erythropoiesis are still poorly understood. With 
gene-knockout murine models, GATA-1(Fujiwara et al., 1996), GATA-2(Tsai et al., 
1994), Klf1, Klf2 and Myc (Pang et al., 2012) were identified to play important roles 
in controlling primitive erythroid cell development. In terms of growth factor 
requirement, it is controversial whether primitive erythropoiesis requires Epo. Most 
evidences indicated that primitive erythroblasts do not require Epo for their 
proliferation and maturation (Cole and Paul, 1966; Rich and Kubanek, 1980; Lee et 
al., 2001), although haem synthesis could be stimulated when they were cultured with 
Epo (Bateman and Cole, 1971).  
As mentioned, primitive erythroblasts circulate in the fetal blood as nucleated cells. 
They complete their differentiation from basophilic primitive erythroblast, to 
polychromatic primitive erythroblast and lastly to orthochromatic primitive 
erythroblast in the circulation. The first two stages were found to have proliferative 
activity in the human embryo (Bloom and Bartelmez, 1940). Mitotic primitive 
erythroblasts have also been found in the blood of mouse embryo (De la Chapelle et 
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al., 1969; Bethlenfalvay and Block, 1970; Sangiorgi et al., 1990; Fraser et al., 2007). 
A recent study reported that the definitive erythroid precursors derived from early 
mouse embryos (yolk sac and fetal liver) had extensive proliferation potential in vitro, 
but the primitive erythroid precursors were not found to be proliferative (England et 
al., 2011). The authors suggested that primitive erythroblasts may not be as active as 
definitive erythroblasts in proliferation when cultured in vitro due to lack of responses 
to the added growth factors.  
2.4.3 Erythroblast enucleation 
Mammalian adult RBCs are unique among the vertebrates in that they are anucleated, 
unlike those of birds, amphibians and reptiles which are nucleated for the entire life. 
In the terminal stage of mammalian definitive erythropoiesis, the orthochromatic 
erythroblasts extrude their nucleus from the cytoplasm, the phenomenon of which is 
called ‘enucleation’, to form reticulocytes (anucleated) which subsequently become 
RBCs.  
Before enucleation occurs, a series of morphological, structural and molecular 
changes are already present in the maturing erythroblasts. Nucleus condensation is the 
most notable feature which has been suggested to result from epigenetic changes on 
the histone tails that induce heterochromatin (tightly packed chromatin) formation 
(Popova et al., 2009; Ji et al., 2010). Histone deacetylation carried out by histone 
deacetylases (HDACs) is responsible for this condensation process. The use of HDAC 
inhibitors such as Tricostatin A, sodium butyrate and valproic acid were able to delay 
or prevent definitive erythroblast from enucleation in vitro. In addition, histone 
methylation level was also increased in the terminally differentiated erythroblasts. 
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Apoptotic signalling pathways involving caspases have also been suspected to play 
roles in the erythroblast maturation (Testa, 2004), because higher levels of caspases 
were observed in the immature erythroblasts than the terminal ones (Gregoli and 
Bondurant, 1999; Zermati et al., 2001). However, more recent work failed to show 
any evidence of caspase-mediated cleavage of target proteins in the later stages of 
erythroblasts (Krauss et al., 2005).  These apoptotic proteins may be involved in other 
non-apoptotic pathways to promote erythroblast enucleation (Carlile et al., 2004). 
Loss of intermediate filaments, components of the cytoskeleton, is another important 
feature before enucleation happens. In the early erythroblast precursors, the 
intermediate filaments vimentin connect the plasma membrane to the nuclear 
membrane to maintain the nucleus position. As the maturation advances, this 
cytoskeletal framework is destroyed due to repressed vimentin expressions (Dellagi et 
al., 1983; Ngai et al., 1984). As a result, the pyknotic nucleus starts to move freely 
within the cytoplasm and can be extruded easily during enucleation.  
The process of enucleation is considered as a form of cytokinesis because it produces 
two daughter parts, the reticulocyte, containing the majority of cytoplasm and the 
pyrenocyte, a naked nucleus surrounded by a narrow rim of cytoplasm (Simpson and 
Kling, 1967; Skutelsky and Danon, 1967). Beginning from the displacement of the 
nucleus from the centre to the side of the cytoplasm,  to the formation of contractile 
actin ring between the cytoplasm and the extruding nucleus, the cytoskeleton and 
plasma membrane undergo extensive changes (Geiduschek and Singer, 1979; Koury 
et al., 1989; Wickrema et al., 1994; Lee et al., 2004). However, the mechanism of 
these changes is poorly understood. It has been suggested that Rac GTPases and 
mDia2 play essential roles in the erythroblast enucleation as disrupted enucleation 
was observed after inhibition of Rac GTPases (Ji et al., 2008). 
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The role of macrophages in the enucleation of definitive erythroblast is debatable. The 
presence of erythroblast island in the bone marrow was first noticed decades ago 
where central macrophages were surrounded by a ring of erythroblasts (Bessis, 1958). 
It was speculated that the macrophages functioned as nursing cells by providing iron 
to haem synthesis in the erythroblasts (Bessis and Breton-Gorius, 1962) and also 
engulfed the extruded nucleus from terminally differentiated erythroblasts. Emp 
(erythroblast macrophage protein) is the first recognized molecule present on both 
erythroblast and macrophage membrane and it mediates erythroblast-macrophage 
interaction (Hanspal et al., 1998). In the Emp null mouse embryo, erythroblasts failed 
to enucleate in the fetal liver and erythroblast islands were not observed (Soni et al., 
2006). It indicated the critical role of Emp in the erythroblast maturation and 
enucleation. The high levels of phosphatidylserine exposed on the external membrane 
of extruded nucleus also serves as an ‘eat-me’ signal to the macrophages for 
phagocytosis (Yoshida et al., 2005). Interestingly, mature RBCs escape from 
clearance by splenic macrophages by expressing CD47 on the surface (Oldenborg et 
al., 2000). Despite the many evidences showing the association of differentiating 
erythroblasts with macrophages, it is still unclear whether macrophages are necessary 
for erythroblast enucleation. In a few in vitro studies, spontaneous enucleation of 
definitive erythroblasts from mouse and human without the presence of macrophages 
have been reported (Koury et al., 1989; Zhang et al., 2003; Miharada et al., 2006; 
Hebiguchi et al., 2008). 
Even though the enucleation of definitive erythroblasts has been extensively studied, 
the enucleation of primitive erythroblasts from yolk sac has been puzzling. For a long 
time, the dogma existed that mammalian primitive erythroblasts shared many features 
with their non-mammalian counterparts such as being nucleated throughout the whole 
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life span. In the past ten years, there were more studies investigating primitive 
erythropoiesis using murine model. In the mouse embryo, there were evidences that 
primitive erythroblasts underwent enucleation in the fetal liver by interacting with 
macrophages (Kingsley et al., 2004; Fraser et al., 2007; Isern et al., 2008; McGrath et 
al., 2008). In the human, however, due to ethical sensitivities and practical reasons, 
not many studies on primitive erythropoiesis have been carried out. However, a recent 
study suggested that the human placenta was the anatomical site for hEryP 
enucleation and that enucleation probably required interaction with macrophages in 
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2.5 Nuclear reprogramming of cells 
Nuclear reprogramming of somatic cells has been a popular subject in the biomedical 
research field for decades, because with this technique, the differentiated somatic cells 
can be brought back to a primitive stem cell-like stage with potentials to differentiate 
into other cell types. In other words, the cell fate can be changed to another after 
nuclear reprogramming. It is a useful technique for both therapeutic applications and 
basic scientific research. The mechanisms of nuclear reprogramming and the three 
main reprogramming approaches are reviewed here.   
2.5.1 Cell plasticity 
In the 1960’s, Gurdon demonstrated that by transplanting the nuclei of intestinal 
epithelial cell from feeding tadpoles (frogs) to the eggs, normal male and female frogs 
could be produced (Gurdon, 1962; Gurdon and Uehlinger, 1966). This ‘milestone’ 
experiment revealed the plasticity within the nucleus of a differentiated cell which 
could be fully reversed to the state of totipotency or pluripotency. This is because 
during the cell differentiation, its genomic content does not change, but the gene 
expression profile changes to meet the requirements for that particular cell type or 
tissue. Under conditions that are capable of altering the expression profile, the cell 
fate can be switched to another cell type. The technique used in the experiment, later 
named ‘somatic cell nuclear transfer (SCNT)’ became an essential tool for cloning 
animals such as ‘Dolly the sheep’ (Wilmut et al., 1997). Embryonic stem cells (ESC) 
of monkey have also been generated from the nuclei of adult monkey cells using this 
technique (Byrne et al., 2007). The efficiency of reprogramming via SCNT is about 
30% from embryo nuclei, but only 1-2% from adult nuclei (Gurdon, 2006; Tecirlioglu 
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et al., 2006). It was suggested that the chance of successful nuclear reprogramming is 
smaller when the donor cell is more differentiated (Gurdon, 1962; Yang et al., 2007).  
The mechanisms of somatic cell nuclei being reprogrammed by eggs have been 
investigated using oocytes, the immediate progenitors of eggs.  Studies showed that 
oocytes contain molecular components that can decondense the chromatin of the 
transferred nucleus such as nucleoplasmin (Philpott et al., 1991; Tamada et al., 2006) 
and can remove DNA methylation and histone modifications (Barreto et al., 2007). 
Additionally, exchange of chromatin proteins between the oocyte and the nucleus was 
also involved to complete the reprogramming (Saeki et al., 2005). 
Based on the same concept, cell fusion with another cell type and cell culture with the 
extracts of a different cell were later developed for reprogramming of differentiated 
cells. Pluripotent tetraploid hybrid cells have been obtained after fusing somatic cells 
with ESC in the mouse and human respectively (Cowan et al., 2005; Ambrosi et al., 
2007). Similarly, after co-culture with the cell-free extracts from ESC, 
dedifferentiated cells expressing ESC genes or even holding multipotency could be 
produced (Bru et al., 2008; Rajasingh et al., 2008). The latest breakthrough in the 
stem cell field is the generation of induced pluripotent stem cells (iPSCs) from 
somatic cells by ectopic expressions of pluripotency genes including Oct4, Sox2, 
Nanog and c-Myc (Takahashi et al., 2007). It further advanced the nuclear 
reprogramming technology. The success of all the reprogramming approaches 
strongly indicates that the differentiated somatic cells are plastic.  
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2.5.2 Reprogramming approaches 
SCNT (Somatic cell nuclear transfer) 
SCNT was the first reprogramming method developed and also the most efficient one 
in regards to generating the entire organism and pluripotent stem cells. To date, a 
wide range of species have been cloned using SCNT. Embryonic stem cell lines have 
also been established from blastocysts formed via SCNT, including those of non-
human primates.  Due to ethical concerns, SCNT is prohibited to be used on the 
human cells for cloning purposes.  
Cell fusion and cell extracts 
In cell fusion, two or more types of cells are fused together to form one single cell. 
The nuclei from the respective cells may fuse to form a ‘hybrid’ cell, or remain 
separate to form a ‘heterokaryon’ cell. Fusions of cells from the same species or 
between different species have been performed decades ago for the study of gene 
regulations during the reprogramming process (Davidson et al., 1966; Harris et al., 
1966; Blau et al., 1983; Baron and Maniatis, 1986). Especially in the heterokaryons, 
the gene expressions of one nucleus may modify or dominate the expressions of the 
other nucleus, thus lead to dramatic changes in the cellular properties. The 
disadvantage of using cell fusion to generate pluripotent cells may be that the hybrid 
cells obtained are tetraploid, not a normal karyotype. Interestingly, cytoplast (cell with 
nucleus removed) of hESCs has been used to fuse with human somatic cells to 
generate diploid hybrid cells with stem cell properties (Strelchenko et al., 2006). 
Landsverk et al. first demonstrated that cell-free extract could be used to reprogram 
the nuclei of differentiated cells (2002). After incubation with extracts of mouse ESC, 
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human 293T cells (kidney epithelial cells) exhibited high expressions of pluripotent 
genes such as Oct4 and Sox2 (Taranger et al., 2005; Bru et al., 2008). The 
reprogrammed cells even acquired differentiation potentials to other lineages 
(Taranger et al., 2005). The limitations of this method are the complicated protocol 
which needs optimization for each of the steps and the relatively low reprogramming 
efficiency.  
iPSCs (induced pluripotent stem cells)  
The generation of iPSCs from the differentiated cells with the introduction of only 
four transcription-factor-encoding genes (KOSM factors: Oct4, Sox2, Klf4, c-Myc) 
opened a new era for nuclear reprogramming  (Takahashi et al., 2007). The four 
factors used by Yamanaka’s group were considered crucial, but some of them were 
later found to be replaceable. Another group showed that by using Nanog and Lin28 
in replacement of Klf4 and c-Myc, similar iPSCs could be generated from somatic 
cells (Yu et al., 2007). c-Myc has also been suggested to be not necessary for iPSC 
generation (Nakagawa et al., 2008). Nevertheless, all these genes used play essential 
roles in maintaining the pluripotency and indefinite self-renewal potential of ESC. In 
the differentiated cells, the expression of these genes may have been shut down or 
expressed at very low levels to avoid unnecessary cell potencies. Hence, after 
introducing the actively transcribed genes back into the cell, they will be expressed to 
form active transcription factors that can act on the cell genome and activate other 
gene expressions. As a result, the expression profile of the cell transforms to an 
embryonic state or embryonic-like state. Phenotypically, the iPSCs behave like ESC. 
They grow in colonies with similar morphology to the ESC colonies. They divide 
actively and express all the characteristic markers of ESC. Importantly, they can form 
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teratoma which contains tissues from the three germ layers (endoderm, mesoderm, 
ectoderm) after injecting into immunodeficient mice. This is a gold standard test for 
pluripotency. 
Retroviral or lentiviral vectors carrying the reprogramming factors were used initially 
to generate iPSCs because of their high gene delivery efficiency. However, vector 
integration into the host cell genome may lead to insertional mutagenesis which poses 
a risk for clinical application (Yamanaka, 2012). To solve this problem, vector 
integration-free methods were rapidly developed for iPSC generation, including use 
of adenovirus (Stadtfeld et al., 2008), Sendai virus (Fusaki et al., 2009), plasmids 
(Okita et al., 2008; Okita et al., 2010), mRNA (Warren et al., 2010; Yakubov et al., 
2010) and proteins (Kim et al., 2009; Zhou et al., 2009). Interestingly, many small 
molecules have been shown to be able to enhance the efficiency of iPSC generation 
significantly (Lin et al., 2009; Chen et al., 2011b). Some of the small molecules can 
even replace one or more of the reprogramming factors. Neonatal human 
keratinocytes were reprogrammed to iPSCs with only Oct4 and a cocktail of chemical 
compounds (Zhu et al., 2010). Another recent study even reported the reprogramming 
of mouse skeletal myoblasts to pluripotency using only valproic acid and without use 
of any transgenes (Pasha et al., 2012).  
The efficiency of iPSC generation is generally low. Virus-mediated reprogramming 
methods have higher efficiency than non-viral methods, but the efficiency is only up 
to 1% (Yamanaka, 2012). Non-viral approaches are safer but overall have very low 
efficiency ranging from 0.001% to 0.01% (Kiskinis and Eggan, 2010). The efficiency 
of reprogramming also depends on the target cell type. Less differentiated cells such 
as progenitor cells and stem cells can be reprogrammed at a much higher efficiency 
compared with terminally differentiated cell types such as adult skin fibroblasts and 
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lymphocytes from peripheral blood (Loh et al., 2009). This is probably due to the fact 
that in a fully differentiated cell, more epigenetic patterns formed during the 
differentiation need to be altered before the cell can turn back to a non-differentiated 
state.  
Despite the few obstacles faced in the development of iPSC technology, it still holds 
great potential for clinical applications such as cell-based therapy. Attempts using 
iPSCs for medical treatment have been shown in the mouse and human, such as 
Parkinson’s disease (Kriks et al., 2011), platelet deficiency (Takayama et al., 2010) 
and spinal cord injury (Tsuji et al., 2010; Nori et al., 2011). In addition, patient-
specific iPSC lines are useful for studying disease mechanisms and screening drug 
candidates. 
2.5.3 Generation of hiPSCs from human blood 
The spectrum of human somatic cell types that can be used to produce hiPSCs is 
being expanded. In the recent years, human blood (e.g. peripheral blood, cord blood, 
menstrual blood) has become a popular cell source for hiPSC generation because 
blood is readily available, blood collection is less invasive than tissue biopsies and 
blood can be frozen for future use. Cells from adult peripheral blood such as CD34+ 
cells (Loh et al., 2009), T lymphocytes (Brown et al., 2010; Staerk et al., 2010; Seki 
et al., 2012), endothelial progenitors (Chang et al., 2012) and erythroid cells (Sommer 
et al., 2012) have been reprogrammed to hiPSC with viral or non-viral methods. As 
little as 1 ml of whole blood was sufficient to generate hiPSCs from T cells within one 
month of the blood sampling (Seki et al., 2012). Cord blood has also been used to 
generate hiPSCs successfully from mononuclear cells including CD34+ cells (Meng 
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et al., 2012; Okita et al., 2012) and erythroid cells (Dowey et al., 2012). Interestingly, 
stromal cells derived from menstrual blood were recently shown to be able to form 
hiPSCs after lentiviral transductions (Li et al., 2012). Hence, the human blood holds 
great potentials for generating hiPSCs which can be applied for regenerative medicine 
and disease modelling studies.  
As fetal cells are present in the maternal blood during pregnancy, the maternal blood 
may serve as a valuable source for generating hiPSCs from the fetal cells within the 
blood for the unborn child (Huang et al., 2011). Fetal cells may have a higher 
reprogramming efficiency than the adult cells due to less mutations accumulated in 
the nucleus and higher endogenous expressions of the hiPSC reprogramming factors.  
Fetal hiPSCs have been generated from amniotic fluid and chorionic villous cells (Ye 
et al., 2009).These fetal hiPSCs could potentially be used for fetal cell-based therapy 
during perinatal life.  Thus far no study has been reported on generating fetal hiPSC 
from maternal blood, probably due to the scarce numbers of them present in the 
maternal circulation.  If the fetal cells could be isolated and expanded in vitro to a 
larger number, it is possible that they can be used to generate fetal hiPSC for clinical 
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Chapter 3: Biology of hEryPs 
3.1 Introduction 
The co-existence of two distinct types of erythropoiesis viz. primitive erythropoiesis 
and definitive erythropoiesis in the mammalian embryos was discovered more than a 
hundred years ago (Maximov, 1909). In the following decades, however, not many 
studies were reported on mammalian primitive erythropoiesis, especially in humans, 
probably due to limited access to embryonic tissues. In the few studies published 
during that time, the anatomy of human primitive erythroblasts (hEryPs) was 
described with light and electron microscopy of the yolk sac and the origin of these 
cells were debated on whether they came from the mesoderm or endoderm layer of 
the yolk sac wall (Bloom and Bartelmez, 1940; Fukuda, 1973; Fukuda, 1974; 
Takashina, 1987). In the past decade, the phenomenon of ‘primitive erythropoiesis’ 
gained attentions again probably because it is possible now to investigate its 
physiological roles with more advanced technologies.  
Murine models are commonly used to investigate mammalian developmental 
processes because they are evolutionally close to the humans and are readily accessed. 
A few research groups have performed extensive studies on the course of mouse 
primitive erythropoiesis by characterizing the mouse primitive erythroblasts (mEryPs) 
in the areas of surface antigens, proliferative ability, capability to enucleate and 
important regulatory pathways that control mEryP differentiation or maturation 
(Kingsley et al., 2004; Fraser et al., 2007; McGrath et al., 2008; England et al., 2011; 
Isern et al., 2011). The information gathered from these mouse studies largely 
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increased our understanding of primitive erythropoiesis in the mammals. However, 
there is still a lack of knowledge in the human counterpart, which may not present 
exactly the same properties as in the mouse.  Moreover, as mentioned earlier, hEryP 
has been identified as a good candidate cell type for performing non-invasive prenatal 
diagnosis (NIPD), but not much information regarding this cell type can be obtained 
in the literature. Hence, an in-depth study of the biological properties of hEryPs is 
timely not only for a better understanding of primitive erythropoiesis in the humans 
but also for the development of NIPD. 
In this chapter, the biological properties and in vitro behaviour of hEryPs isolated 
from first trimester human placental tissues were investigated. The thorough 
investigation includes the basic characterization of cell size, nuclear to cytoplasmic 
ratio, morphology and characteristic antigens, followed by examination of different 
cellular activities including maturation, proliferation, enucleation and degeneration of 
hEryPs. This chapter will provide additional knowledge on the cell type and also build 
the foundation for the following chapters which are to culture and reprogram hEryPs 
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3.2 Materials and Methods 
3.2.1 Collection of human tissue and blood samples 
Collection of human tissue and blood samples was approved by Domain Specific 
Review Board, Singapore and Institutional Research Board of National University of 
Singapore in compliance with guidelines regarding the use of human sample for 
research purposes. All research participants gave written informed consent for the 
collection of samples and their use for research purposes. All samples were collected 
in the National University Hospital.  
First trimester placental tissues at 6 to 11 weeks of gestation were collected 
immediately after elective surgical termination of pregnancy (TOP). Gestational age 
was determined by ultrasound scan. The tissues were kept in saline in sterile 
containers.  
Peripheral blood samples (10 - 20 ml per sample) were collected via venepuncture 
from patients undergoing TOP and volunteers with on-going pregnancy. Blood 
samples were drawn into EDTA-coated vacutainer tubes (Becton, Dickinson and 
Company, USA).   
Cord blood samples were collected immediately after the patient delivery from the 
vein of umbilical cord. Blood was drawn into a cord blood collection bag.    
All samples were processed within 4 hours after the collection from the hospital.   
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3.2.2 Cell lines 
Use of commercial human cell lines was approved by Institutional Research Board of 
National University of Singapore. Commercial cell lines included human embryonic 
stem cell line hES4 (ES Cell International, Singapore), human new-born foreskin 
fibroblast CCD1112sk (ATCC, USA). In-house produced cell lines included mouse 
embryonic fibroblast (MEF), human fetal mesenchymal stem cell (FMSC) from fetal 
liver and human macrophages differentiated from monocytes obtained from 
peripheral blood mononuclear cells.  
3.2.3 Reagents, culture media, antibodies and kits 
Chemical reagents:  
Paraformaldehyde, Triton X-100, Tween-20, BrdU (Bromodeoxyuridine),  Sodium 
Chloride, EDTA (Ethylenediaminetetraacetic acid), 10% Formalin (Sigma Aldrich, 
USA); Methanol, Acetone (Quality Reagent Chemical, New Zealand); Propidium 
Iodide, 4’,6-diamidino-2-phenylindole (DAPI), SYTO red nuclear dye 59, Phalloidin-
Alexa Fluor 488 (Invitrogen, USA); Percoll (Pharmacia, Sweden); Ficoll-Paque 
Premium (GE Healthcare, USA); 10x PBS (Vivantis, USA); Eosin, Thiazine, Aerofix 
Addictive for Methanol (Wescor, USA); Nuclear Fast Red, Vectashield mounting 
medium (Vector Laboratories, USA); DEPC (Diethylpyrocarbonate) water (Ambion, 
USA); mitomycin C (NUH Pharmacy, Singapore). 
Biological reagents:  
Fetal bovine serum (FBS) (Biochrome AG, Germany); Knockout serum replacement 
(KOSR), bovine serum albumin (BSA), β-mercaptoethanol, antibiotic-antimycotics 
                                                                         Chapter 3: Biology of hEryPs – M & M 
51 
 
(AA), penicillin/streptomycin (PS), normal goat serum, Insulin-Transferrin-Selenium-
G (ITS), L-Glutamine, Non-essential amino acids (NEAA), TrypLETM Express, 
Collagenase IV (Invitrogen Gibco, USA); Gelatin (ACROS Organics, USA); basic 
fibroblast growth factor (bFGF) (Merck Millipore, USA); Titanium Taq DNA 
polymerase (Clontech, USA); DNase I (Promega, USA); 10x Trypsin (PAA, Austria); 
RNase A, human iron-saturated transferrin, Erythropoietin (Sigma Aldrich, USA); 
MACS buffer, MACS BSA stock solution (Miltenyi Biotec, Germany); Maxima 
SYBR Green qPCR Master mix (Fermentas, USA). 
Culture media: 
Dulbecco’s Modified Eagle Medium with High Glucose (DMEM High Glucose), 
Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12), Iscove’s 
modified Dulbecco’s medium (IMDM), Roswell Park Memorial Institute 1640 
medium ( RPMI 1640). All are from Invitrogen Gibco, USA.  
Antibodies: 
Primary antibodies against human antigens (host in mouse unless stated): Sox2, Tra-
1-60, Tra-1-81, SSEA3 (rat), SSEA4 (Merck Millipore, USA); Oct4 (Santa Cruz 
Biotechnology, USA); Nanog (rabbit) (Abcam, UK); CD29, CD34, CD35, CD36, 
CD44, CD45, CD47, CD59, CD71, CD73, CD90, CD105, CD117, Glycophorin A 
(CD235a), Proliferating cell nuclear antigen (PCNA) (Biolegend, USA); epsilon 
haemoglobin (Fitzgerald, USA). 
Primary antibodies against other antigens: Anti-BrdU (mouse) (Merck Millipore, 
USA) 
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Secondary antibodies (host in goat): Anti-mouse IgG (H+L) Alexa Fluor 488, Anti-
mouse IgM Alexa Fluor 568, Anti-mouse IgG3 Alexa Fluor 488, Anti-rabbit IgG 
(H+L) Alexa Fluor 568 (Merck Millipore, USA); Anti-rat IgM FITC (eBioscience, 
USA); Anti-mouse IgG (H+L) biotinylated (Vector Laboratories, USA)  
Antibodies conjugated with magnetic beads (for MACS): CD71 microbeads and GPA 
microbeads (Miltenyi Biotech, Germany) 
Commercial kits: 
Alkaline phosphatase detection kit (Merck Millipore, USA); TRAPeze RT 
Telomerase detection kit (Merck Millipore, USA); Vector Blue Alkaline Phosphatase 
Substrate kit (Vector Laboratories, USA); DeadEnd Fluorometric TUNEL system 
(Promega, USA); Annexin V staining kit (BioVision, USA); RNeasy Plus Mini kit 
(Qiagen, USA); Maxima first strand cDNA synthesis kit (Fermentas, USA).  
3.2.4 Isolation of primitive erythroblasts (hEryPs) from placental 
tissues 
Human primitive erythroblasts (hEryPs) were isolated from chorionic villi found in 
the placental tissues. First, placental tissues were washed with 1x PBS in 100 mm 
tissue culture dish (BD Biosciences, USA) to remove as much blood clots as possible. 
Chorionic villi were separated from the basal membrane using two watch maker 
forceps. They were minced and digested in 30 - 45 ml of 1x Trypsin in a 50 ml Falcon 
polypropylene tube (BD Biosciences, USA) for 30 min at 37oC in a water bath 
(Model 1136, VWR Scientific, USA) with constant shaking, after which, 5 ml of fetal 
bovine serum was added to stop the enzyme activity. The digested cell suspension 
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was passed through a 40 µm cell strainer (BD Falcon, USA) to remove undigested 
tissues and then spun down for 5 mins at 3000 rpm using centrifuge (Sorvall Legend 
RT+ Centrifuge, Thermo Scientific, USA). Cell pellet was resuspended in 5 ml of 1x 
PBS and slowly layered onto 5 ml of Percoll density gradient with a density of 1.083 
mg/ml in a 15 ml Falcon polypropylene tube. Cells were spun for 20 mins at 3000 
rpm without brakes. After the density gradient centrifugation (DGC), the red pellet 
found at the bottom of the tube contained hEryPs and RBCs while the interface layer 
contained mainly trophoblasts (Figure 3-1). Additionally, a red thin layer containing 
primarily polychromatic hEryPs was formed at the interface below the trophoblast 
layer for tissue samples of 7 to 8 gestational weeks. Each layer of cells was aspirated 
separately using a clean sterile glass Pasteur pipette (LabIVF, Singapore), dispensed 
into a 15 ml Falcon tube and washed with 1x PBS twice. Cells in the red pellet were 
resuspended with 500 µl of 1x PBS, transferred to a 15 ml Falcon tube and also 
washed with 1x PBS twice. Cell numbers were counted using a haemocytometer 
(Neubauer improved bright-line, Marienfeld, Germany) after suspended in 1x PBS. 
For each sample processed, two cytospun slides were made as confirmatory slides 
from trophoblast cells and cells in the red pellet (suspended in 1x PBS) respectively.  
Figure 3-1 Isolation of hEryPs from chorionic villi  
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3.2.5 Isolation of definitive erythroblasts (hEryDs) from cord blood 
Cord blood was diluted with rinsing buffer (1x PBS + 2 mM EDTA, pH 7.2) at 1 to 4 
dilutions. 35 ml of diluted blood was added to 15 ml of Ficoll-Paque (density: 1.077 
g/ml) slowly in a 50 ml Falcon tube and centrifuged at 400 g for 35 mins without 
brakes. Interphase layer which contains the mononuclear cells (MNCs) was collected 
using a 10 ml serological pipette (BD Biosciences, USA) without disturbing the red 
pellet at the bottom. The MNCs were washed with equal volume of rinsing buffer 2 to 
3 times at 400 g for 10 mins. To enrich the definitive erythroblasts (hEryDs) which 
are CD71+ from the population of MNCs, CD71-MACS was carried out. Cytospun 
slides were made after the MACS and Wright stained to confirm the cell identity.  
3.2.6 Cell enrichment by magnetic-activated cell sorting (MACS) 
Cells were resuspended in 80 µl of MACS buffer containing 1% BSA and added with 
20 µl of anti-CD71 or anti-GPA MACS microbeads per 107 total cells. They were 
incubated at 4oC for 15 mins and then diluted with 1 ml of MACS buffer per 107 total 
cells and centrifuged at 3000 rpm for 5 mins. Cells were then resuspended in 1 ml of 
MACS buffer up to 108 cells. Mini MACS separator and MS column (Miltenyi Biotec, 
Germany) were used for positive selection of CD71+ or GPA+ cells. Cell sorting was 
performed according to manufacturer’s instructions. Cells obtained from the positive 
fraction were washed twice with MACS buffer and number was counted with 
haemocytometer.  hEryPs enriched after CD71-MACS were used for DNA or RNA 
extraction. hEryDs enriched after CD71-MACS were used as positive control for cell 
enucleation study.  
                                                                         Chapter 3: Biology of hEryPs – M & M 
55 
 
3.2.7 Cell culture 
hEryPs and the cells obtained from cord blood and peripheral maternal blood samples 
were cultured in home-made media with the composition of IMDM basal medium, 30% 
FBS, 1% BSA, 10-4 mol/l β-mercaptoethanol, 100 µg/ml iron-saturated transferrin and 
1% AA. Human embryonic stem cells (hESCs) were cultured on top of mitomycin C-
treated mouse embryonic fibroblast (MEF) layer in the home-made media of 
DMEM/F-12 basal medium, 20% KOSR, 2 mM L-glutamine, 1% AA, 1x NEAA, 1x 
ITS,  10-4 mol/l  β-mercaptoethanol and 16 ng/ml bFGF. Human new-born foreskin 
fibroblast cell line CCD1112sk was cultured in IMDM basal media supplemented 
with 10% FBS and 1% AA. Macrophages were cultured in RPMI1640 medium 
supplemented with 10% FBS and 1% AA. Fetal mesenchymal stem cells (FMSCs) 
were cultured in DMEM high glucose basal medium supplemented with 10% FBS 
and 1% AA. MEFs were cultured in DMEM high glucose basal medium 
supplemented with 10% FBS, 2 mM L-glutamine and 1% PS.  
The cells (CCD1112sk, FMSCs and MEFs) were passaged using TrypLETM Express 
to detach the adherent cells for 5 mins of incubation and equal volume of culture 
media was added to stop the enzyme reaction. Cells were centrifuged at 1000 rpm for 
5 mins, and resuspended in fresh media. Bulk passaging of hESCs was done using 1 
mg/ml collagenase IV dissolved in DMEM/F-12. MEF feeder layer was seeded on 0.1% 
gelatin-coated 60 mm tissue culture dishes (BD Biosciences, USA) one day before the 
hESC passaging. Culture vessels of all cell types except hESCs include multi-well 
plates (6-well, 12-well, 24-well) (NUNC, USA), tissue culture dishes (35 mm, 60 mm, 
organ culture dish) (BD Biosciences, USA) and cell culture flasks (T-25, T-75, T-125) 
(NUNC, USA), depending on the experimental design. All cells were cultured at 37oC, 
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with 5% CO2 in humidified incubators (Function Line, Heraeus Instruments, 
Germany).  
3.2.8 Preparation of cytospun slides 
Cytospinning of cells was performed using a cytospin centrifuge (Shandon Cytospin 4, 
Thermo Scientific, USA). A maximum number of 5 x104 cells suspended in no more 
than 300 µl of PBS or medium were loaded into a cytospin chamber and cytospun 
onto a microscope glass slide at 500 rpm for 5 mins. Cytospun slides were air dried 
before cells were fixed for Wright’s staining or immunocytochemistry.  
3.2.9 Wright’s staining 
Cytospun slides were fixed with 100% methanol for 2 mins and stained with Eosin for 
1 min and Thiazine for 1 min in coplin jars. After rinsing with water, slides were air 
dried and stored at room temperature before viewing under up-right microscope 
(Olympus BX51, USA).  
3.2.10  Measurement of nuclear and cytoplasmic size 
Nuclear and cytoplasmic diameters of hEryPs were measured using NIS Elements 
software after taking pictures under inverted microscope (Nikon Eclipse Ti-400, 
Japan). For each biological sample, 100 hEryPs were randomly chosen from the 
pictures and measured.  
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3.2.11  RNA extraction and cDNA synthesis 
RNA of hEryPs, hESCs, FMSCs and CCD1112sk were extracted using Qiagen 
RNeasy Plus Mini kit according to manufacturer’s protocol and stored at -80oC until 
use. RNA concentration was measured using Nanodrop (Thermo Scientific, USA). 
cDNA was synthesized using Fermentas Maxima first strand cDNA synthesis kit 
according to manufacturer’s protocol and stored at -20oC until real-time PCR.  
3.2.12  Real-time RT PCR 
Real-time RT PCR was carried out using Fermentas Maxima SYBR Green qPCR 
master mix by 7500 Fast Real-time PCR system (Applied Biosystems, USA) with 
primers shown in Table 3-1. Relative quantitation of gene expressions (Oct4, Sox2, 
Nanog, c-Myc, Klf4, Lin28) in hEryPs, FMSCs and CCD1112sk was performed using 
hESCs as the calibrator. β-actin was the house-keeping gene. Primer final 
concentration in each reaction well was 0.9 µM. 10 ng of cDNA was used for each 
reaction well of 96 well PCR plate. Each sample had triplicates. PCR run mode was 
fast 7500. PCR setting was: 95oC for 10 mins, 1 cycle; 95oC for 15 secs, 60oC for 30 
secs, 72oC for 30 secs, 40 cycles. cDNA from three biological samples of hEryPs 
were evaluated. Relative quantity (RQ) of cDNA was calculated as below:  
∆Ct = Ct (gene of interest) – Ct (β-actin) 
∆∆Ct = ∆Ct (cell of interest) - ∆Ct (hESC) 
RQ = 2 - ∆∆Ct 
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Table 3-1 Real-time RT PCR primers  
Gene   Forward (5’ to 3’) Reverse (5’ to 3’) 
Oct4 AGCGAACCAGTATCGAGAAC TTACAGAACCACACTCGGAC 
Sox2 AGCTACAGCATGATGCAGGA GGTCATGGAGTTGTACTGCA 
Nanog TGAACCTCAGCTACAAACAG TGGTGGTAGGAAGAGTAAAG 
c-Myc ACTCTGAGGAGGAACAAGAA TGGAGACGTGGCACCTCTT 
Klf4 TCTCAAGGCACACCTGCGAA TAGTGCCTGGTCAGTTCATC 
Lin28 ACCAGCAGTTTGCAGGTGGCT CCGAACCCCATGCGCACGTT 
β-actin GATGCAGAAGGAGATCACTGC CACCTTCACCGTTCCAGTTT 
3.2.13  Measurement of telomerase activity  
TRAPeze RT telomerase detection kit was used to measure the telomerase levels in 
the hEryPs, hESCs and CCD1112sk. Manufacturer’s instructions were followed. 
Briefly, cells (hESCs, hEryPs) were lysed with CHAPS lysis buffer and centrifuged at 
12,000 g for 20 mins at 4oC in a microcentrifuge (Eppendorf 5417R, Germany). 
Supernatant was collected for the measurement together with positive control cell 
extract and heat-inactivated extract (incubation on heat block (Stuart SBH130D, 
Bibby Scientific, UK) at 85oC for 10 mins). Absolute quantitation of telomerase 
expression was performed using 7500 Fast Real-time PCR system. TSR8 quantitation 
controls at different dilutions were used to generate a standard curve. 2 µl of extract 
was used for each reaction well. PCR setting was: 30oC for 30 mins, 1 cycle; 95oC for 
2 mins, 1 cycle; 94oC for 15 secs, 59oC for 1 min, 45oC for 30 secs, 45 cycles. Data 
were analysed according to the standard curve generated by TSR8 controls. Three 
biological samples of hEryPs were measured.  
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3.2.14  Measurement of alkaline phosphatase activity 
Alkaline phosphatase activity was evaluated in hESCs and hEryPs using alkaline 
phosphatase detection kit.  Cells were fixed with 4% paraformaldehyde for no more 
than 2 mins and washed with rinsing buffer provided. Freshly prepared Naphthol/Fast 
Red Violet solution was added to the cells and incubated for 15 mins at room 
temperature in the dark. Cells were washed with rinsing buffer. Staining results were 
viewed under inverted light microscope (Nikon Eclipse Ti-400, Japan). Red staining 
on the cells was considered positive for alkaline phosphatase activity.  
3.2.15  Immunocytochemistry 
Fluorescent immunocytochemistry: Cells grown on coverslips (hESCs, CCD1112sk) 
or cytospun onto slides (hEryPs) were fixed with 4% paraformaldehyde for 10 mins. 
For nuclear antigens (Oct4, Sox2, Nanog and acetyl-histone 3, acetyl-histone 4 and 
lysine9 trimethyl-histone 3), cells were permeabilized with 0.1% Triton X-100 for 3 
mins. 10% normal goat serum (diluted with 1x PBS) was added to block non-specific 
binding for 30 mins. Diluted primary antibody (in 10% normal goat serum, final 
concentration: 10 µg/ml except histone antibodies 2 µg/ml) was added to the cells and 
incubated for one hour. Cells were washed with 1x PBST (1x PBS + 0.1% Tween-20) 
twice and then incubated with fluorescent secondary antibody (in 10% normal goat 
serum, final concentration: 10 µg/ml) for 30 mins in the dark. After washing twice 
with 1x PBST, cell nuclei were counter stained with DAPI (1:1000 dilutions in 1x 
PBS). Cells were mounted with Vectashield before viewing under fluorescent 
microscope (Olympus IX70, Japan) or confocal microscope (Olympus FV1000, 
Japan).  All procedures were performed at room temperature. 
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Alkaline phosphatase immunocytochemistry: Cytospun slides (hEryPs) were fixed 
with methanol/acetone (v/v, 1:1) for 2 mins and rinsed with 1x PBS. Cells were 
blocked with 10% normal goat serum for 2 hours, and then incubated with primary 
antibody (1:100 dilutions in 10% normal goat serum except epsilon-haemoglobin 
antibody, 1:1000 dilutions) for one hour at room temperature or overnight at 4oC. 
Biotinylated secondary antibody (1:100 dilutions in 1x PBS) was incubated for 30 
mins, and streptavidin alkaline phosphatase (1:100 dilutions in 1x PBS) was added for 
30 mins. Vector Blue substrate was added to the cells and incubated for 10 to 20 mins 
in the dark. Between each step of antibody incubations, cells were washed with 1x 
PBST for 5 mins for 2 to 3 times. Cells were finally washed with distilled water and 
stained with Nuclear Fast Red for 20 mins. All procedures were done at room 
temperature. Slides were viewed under up-right microscope (Olympus BX51, Japan). 
Blue staining on the cells indicated positive expression of the antigens. 
3.2.16  Fluorescence-activated cell sorting (FACS) analysis 
Live hEryPs were blocked with 10% normal goat serum for 20 mins and then 
incubated with primary antibodies against CD29, CD34, CD35, CD36, CD44, CD45, 
CD47, CD59, CD71, CD73, CD90, CD105, CD117 and Glycophorin A (1:100 
dilutions in 10% normal goat serum) for one hour at room temperature. After washing 
with 1x PBS, secondary antibody conjugated with Alexa Fluor 488 (1:500 dilutions in 
10% normal goat serum) was added for 30 mins in the dark. SYTO red nuclear dye 59 
was used to stain the cell nuclei for 20 mins in the dark. After washing with 1x PBS, 
cells were immediately analysed with flow cytometry by Cyan ADP Analyzer 
(Beckman Coulter, USA). For each antigen, five biological samples were analysed.  
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3.2.17  H & E staining of chorionic villi paraffin sections 
Chorionic villi samples were fixed with 10% Formalin for 24 hours at room 
temperature. Tissue paraffin block preparation, sectioning and H & E staining were 
performed by staff in the histology service at Institute of Molecular and Cell Biology, 
Singapore. For H & E staining, slides were first deparaffined with Xylene for 10 mins 
twice and then rehydrated with 100%, 100%, 95% and 70% ethanol for 3 mins each.  
Ethanol was rinsed off with water twice. Slides were stained with Harris Hematoxylin 
for 5 mins and rinsed with water and then quickly dipped in accumulated 
differentiation solution for 1 – 2 secs and rinsed with water twice. Slides were dipped 
in 0.2% ammonia water for 1 – 2 secs and rinsed with water, then 95% ethanol for 2 
mins twice. Slides were stained with Eosin for 3 mins and rinsed with 95% ethanol 
and then dehydrated with 95%, 95%, 100%, 100% ethanol for 1 min each. Finally, the 
Slides were cleared with Xylene for 3 mins 3 times and mounted with Depex 
mounting medium and coverslip.  
3.2.18  Histological analysis of hEryP maturation 
Hematoxylin and eosin stained tissue sections were examined by upright microscope 
(Olympus BX51, camera DP50, Japan) and inverted microscope (Nikon Eclipse Ti, 
camera DS-U3, Japan). To calculate the proportions of polychromatic hEryPs, 
orthochromatic hEryPs and anucleated RBCs in the fetal circulation, five areas 
containing blood vessels were randomly chosen from each tissue section and their 
respective numbers were counted. The diameter and cross-sectional area of hEryPs 
and their nuclei were measured using Nikon NIS elements software. For each 
gestational week (7 to 11 weeks), three biological samples of chorionic villi were 
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analysed. Only one sample obtained at 6 weeks was suitable for cell counting. 15 
areas (3 times of 5 areas) were chosen and the cells were counted.  
3.2.19  Cell cycle analysis  
Cells were harvested from culture dish and spun down at 3000 rpm for 5 mins. Cell 
pellets were resuspended in 100 µl of 1x PBS. 900 µl of 70% ethanol was added drop-
wise to the cell suspension with low speed vortexing (MS1 Minishaker, IKA, USA). 
Cells were fixed at -20oC for 15 mins, then spun down and resuspended in 1x PBS. 
Propidium iodide (final concentration: 20 µg/ml) and RNase A (final concentration: 
0.2 mg/ml) were added to the cell suspension and incubated at 37oC for 20 mins in the 
water bath. Stained cells were kept at 4oC until cell cycle analysis by flow cytometry. 
Percentages of cells at G0/G1, S and G2/M phase of the cell cycle were analysed 
respectively. For orthochromatic hEryPs, five biological samples were evaluated for 
each gestational week (7 to 10 weeks). For polychromatic hEryPs, three biological 
samples were evaluated.  
3.2.20  BrdU cell proliferation assay 
BrdU (final concentration: 50 µM) was added to the culture medium for one hour at 
37oC with 5% CO2. Treated cells were cytospun onto glass slides and fixed with 100% 
ethanol for 30 mins at room temperature. Incubation with anti-BrdU antibody (1:4 
dilutions) was one hour at room temperature. After washing with 1x PBST, cells were 
incubated with secondary antibody conjugated with Alexa Fluor 488 for 30 mins at 
room temperature. Cells were then counter stained with DAPI (1:1000 dilutions) and 
examined under confocal microscope (Olympus FV1000, Japan).  Green staining in 
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the cell nucleus was considered BrdU positive, which indicated mitotic activity in the 
cell.  
3.2.21  Phalloidin cell cytoskeleton staining 
Alexa Fluor 488 phalloidin was used for staining the actin of hEryPs and hEryDs to 
track their nuclear movement. Cytospun Slides were fixed using 4% 
paraformaldehyde for 10 mins at room temperature. 0.1% Triton X-100 was used to 
permeabilize the cells. For blocking of non-specific binding, 1x PBS with 1% BSA 
was incubated for 20 mins. Diluted phalloidin was added and incubated for 20 mins at 
room temperature in the dark. DAPI (1:1000 dilutions) was used to counter stain the 
cell nuclei. Cells were washed twice with 1x PBS and covered with Vectashield 
mounting media before viewing under confocal microscope (Olympus FV1000, 
Japan). 
3.2.22  Time-lapse live cell imaging 
Live Cell Array slide (20 µm microwell, NUNC, USA) was used for the time lapse 
imaging of hEryPs. Cell nucleus was stained with SYTO red nuclear dye 59. 2 µl of 
cell suspension (cell density: 3 – 5 x 106 cells/ml) in culture medium was loaded onto 
the central well of the slide. Slide was filled fully with culture medium to prevent 
dehydration and placed in a humidified chamber at 37oC with 5% CO2.  Images were 
taken every 10 mins using confocal microscope (Olympus FV300, Japan) under 20x 
magnification with 4x zoom (Figure 3-2).  
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Figure 3-2 Time-lapse live imaging of hEryPs  
Scale bar, 20 µm. 
 
3.2.23  Co-culture of hEryPs with macrophages 
Macrophages were seeded one day before the co-culture experiment in RPMI1640 
medium in a 6-well plate. hEryPs were added at number of 1 to 3 x 105 on top of the 
macrophages (cell number ratio of 1:1) directly or contained within a NUNC 
Transwell (Thermo Scientific, USA) to prevent physical contacts between the two cell 
population. hEryP culture medium was used to culture the mixed cells. Control wells 
were hEryPs cultured alone and macrophages cultured alone. Cytospun slides were 
made from each well for Wright’s staining on day 1, day 3 and day 5 of co-culture.   
3.2.24  TUNEL assay 
Promega DeadEnd Fluorometric TUNEL system was used to detect DNA 
fragmentation in the nuclei of hEryPs. Briefly, cytospun slides were fixed with 4% 
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paraformaldehyde for 10 mins at room temperature. hEryPs treated with DNase I (10 
U/ml) for 10 mins were used as positive control. Cells were permeabilized with 0.1% 
Triton X-100 for 5 mins and washed with 1x PBS for 5 mins. Equilibration buffer was 
added for 5 mins and then 45 µl of incubation buffer including nucleotide mix and 
rTdT enzyme was added to each slide for one hour at 37oC in the dark. To stop the 
reaction, 2x SSC was added and incubated for 15 mins at room temperature. Cells 
were washed with 1x PBS twice and counter stained with DAPI (1:1000 dilutions). 
Slides were viewed under inverted fluorescent microscope (Olympus IX70, Japan). 
Green fluorescence in the cell nucleus indicated DNA fragmentation.  
3.2.25  Annexin V assay 
Annexin V binds to the phosphatidylserine exposed on the plasma membrane of 
apoptotic cells. This assay was used to detect early sign of apoptosis. Live hEryPs 
were washed once with 1x PBS, once with 1x Annexin V buffer at 3000 rpm for 5 
mins and then resuspended in 1x Annexin V buffer. 2 µl of AnnexinV-FITC and 5 µl 
of PI stain (stock concentration 10 mg/ml) were added to 1 ml of cell suspension. 
Sample was analysed immediately by flow cytometry. FITC positive cells were 
considered Annexin V positive.  
3.2.26  Statistics 
Standard deviations or standard errors were calculated for experiments with more than 
two biological/experimental replicates performed.  Standard error was used in some 
studies where the trend of the population of interest needs to be estimated. For 
comparing two populations (the same sample size), student t-test was used to 
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calculate the p value (for paired experiment, paired t-test was used). For comparing 
more than two populations (the same sample size), one-way ANOVA test was used to 
calculate the p value.   
  




3.3.1 Isolation of hEryPs from chorionic villi 
Aim: To validate the consistency and efficiency in obtaining adequate numbers of 
hEryPs from first trimester chorionic villi samples for downstream experiments.  
3.3.1.1 Number and purity of hEryPs  
hEryPs are rare in the maternal blood. Hence, hEryPs for all the experiments were 
obtained from placental chorionic villi unless otherwise stated (from maternal blood). 
The protocol used for isolation of hEryPs from chorionic villi has been established by 
our group (Ponnusamy et al., 2008). The detailed procedures were described in 
section 3.2.4. For each tissue sample processed, after the density gradient 
centrifugation (DGC) step, the total number of hEryPs obtained from the bottom red 
pellet was counted and their purity among the anucleated RBCs were calculated 
(hEryP purity = Number of hEryPs / Total number of cells (hEryPs + RBCs)).  
Table 3-2 shows the average number and purity of hEryPs obtained from chorionic 
villi at different gestational weeks (7 to 11 weeks). The standard deviation of cell 
number and purity were high because they depended primarily on the amount and 
condition of placental tissues collected. On average, larger numbers of hEryPs were 
obtained from samples at 9 to 10 weeks of gestation due to the bigger size of tissues 
and higher frequency of these cells in the fetal blood during that period. For samples 
at 11 weeks of gestation, the hEryP number decreased significantly. The purity of 
hEryPs was relatively high between 7 to 9 weeks of gestation. However, from 10 
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weeks onwards, it was reduced drastically because more anucleated RBCs were 
circulating in the fetal blood at that gestation. The pattern of decreasing purity of 
hEryPs as the gestation increased is consistent to the previous observation in the pure 
fetal blood that frequency of hEryPs peaked around 9 weeks of gestation and became 
negligible at 14 weeks of gestation (Choolani et al., 2001). 
Table 3-2 Number and purity of hEryPs obtained from chorionic villi samples 
Cell number and purity are presented as average ± standard deviation. Samples at 6 
weeks of gestation were not included here because very few samples were collected, 
and the number of hEryPs extracted was very few. 
 
3.3.1.2 Enrichment of hEryPs by MACS 
To further improve the purity of hEryPs for downstream experiments such as DNA 
and RNA extraction, an additional enrichment step using magnetic-activated cell 
sorting (MACS) was performed with magnetic antibodies against CD71 or 
Glycophorin A (GPA). Overall, CD71 antibody was found to be more specific than 
GPA antibody in MACS positive selection of hEryPs, as shown by the much higher 
cell purity obtained after the sorting with CD71 (Figure 3-3, *p<0.05). The recovery 
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rates (hEryP recovery rate = Number of hEryPs post enrichment / Number of hEryPs 
pre enrichment) between the two antibodies were comparable to each other. The 
Wright’s staining in Figure 3-4 shows the cell population before and after CD71-
MACS.  The purity of hEryPs was tremendously improved after the MACS process.  
Figure 3-3 Recovery and purity of hEryPs after CD71-MACS and GPA –MACS 
The recovery and purity of hEryPs obtained after MACS with CD71 and GPA 
antibodies were calculated respectively in percentage (Y-axis). The recovery rates 
were comparable in the two methods. Purity of hEryPs after CD71-MACS was 
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Figure 3-4 Wright’s staining of cell population before and after CD71-MACS 
Top picture shows the low purity of hEryPs in the mixed cell population before 
CD71-MACS. Bottom picture shows the much improved purity of hEryPs in the 
CD71+ fraction after CD71-MACS. Scale bar, 20 µm.  
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3.3.2 Morphological features of hEryPs 
Aim: To describe the morphology and size of viable hEryPs isolated from chorionic 
villi samples.   
3.3.2.1 Cell morphology and size  
hEryPs are also called primitive nucleated red blood cells. Most of the hEryPs 
observed under the microscope presented the same bi-concave circular shape as that 
of anucleated RBCs (Figure 3-5, a-e), but part of their plasma membrane was 
protruded due to the presence of a nucleus (a-b, arrows). Small portion of the hEryPs 
presented folded and irregular shapes (Figure 3-5, f-j). According to the 
measurements from 11 biological samples (6 to 11 weeks of gestation), the 
cytoplasmic diameter of hEryPs was on average 15 µm (± 1.39 µm), with a minimum 
of 12 µm and a maximum of 21 µm. Therefore, the cytoplasmic size of a hEryP was 
about twice of an anucleated RBC which has a diameter of 6 to 8 µm. 
Figure 3-5 Cell morphology of hEryPs  
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3.3.2.2 Nuclear to cytoplasmic ratio  
hEryPs observed had small nuclear to cytoplasmic ratio due to the highly condensed 
nucleus and the big cytoplasm which was filled with large amount of haemoglobins, 
as shown in Figure 3-6. Similar to definitive erythroblasts (section 2.4.1 Figure 2-1), 
as the hEryPs matured from the polychromatic to orthochromatic stage, their nuclei 
condensed further. This made the nuclear to cytoplasmic ratio even smaller. To 
estimate the nuclear to cytoplasmic ratio which is normally expressed in volume, the 
diameters of hEryP cytoplasm and nucleus were measured from 11 biological samples 
(100 hEryPs per sample). The average nuclear to cytoplasmic ratio in diameter was 
about 0.34 (Table 3-3).  
Figure 3-6 Wright’s staining of hEryPs 
The cytoplasm of hEryPs was pink (stained by eosin) because of haemoglobins and 
the pyknotic nuclei were dark purple (stained by thiazine). Chromatin structure was 
very condensed and chromatin aggregations were visible from the nucleus staining. 
Scale bar, 20 µm. 
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Table 3-3 Nuclear and cytoplasmic diameters of hEryPs 
 Minimum (µm) Maximum (µm) Average ± SD (µm)  
Nuclear diameter 4.08 6.75 5.11 ± 0.30 
Cytoplasmic 




-- --  0.34 
 
 
3.3.3 Stemness and erythroid marker evaluation 
Aim: To examine whether hEryPs possess any stemness and erythroid markers for the 
potential of proliferation in vitro.  
Stem cells are known to be able to self-renew and also to differentiate to daughter cell 
type. Stemness refers to the characteristics that stem cells possess, and can be 
evaluated through certain markers. It is of interest to check if any of the stemness 
markers are present on the hEryPs as the name “erythroblast” given and the fact that 
they are produced during early embryogenesis. It may also give clues to the in vitro 
culture and expansion of small number of hEryPs in the maternal blood for NIPD. 
Hence, characteristic markers of human embryonic stem cells (hESCs), mesenchymal 
stem cells (MSCs) and hematopoietic stem cells (HSCs) were evaluated respectively 
on the hEryPs. 
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3.3.3.1 hESC markers 
hESCs are pluripotent cells, in other words, they can differentiate into all types of 
tissues in the human body. Six genes are highly expressed in hESCs, namely Oct4, 
Sox2, Nanog, Lin28, c-Myc and Klf4. All of them play important roles in maintaining 
the undifferentiated status and self-renewal capacity of hESCs. Characteristic surface 
antigens expressed on hESCs are SSEA-3, SSEA4, Tra-1-60 and Tra-1-81. Two 
enzymes are very active in hESCs viz. alkaline phosphatase and telomerase. The 
telomerase is responsible for keeping the self-renewal ability of cells by preventing 
shortening of the telomere ends on the chromosomes during cell division.  
Real-time RT PCR was performed to measure the relative expression levels of the six 
pluripotent genes in hEryPs, FMSCs (fetal mesenchymal stem cells) and CCD1112sk 
(Figure 3-7). hESCs were used as the standard with which the other cell types were 
compared. Thus, its log RQ (relative quantity) value was zero for all the six genes. A 
negative log RQ value indicated a down regulation in the gene expression compared 
with hESCs and vice versa. Results showed significant down regulations in the 
expressions of Oct4, Sox2, Nanog and Lin28 in all the cell types including hEryPs. 
However, the down regulations for Oct4, Sox2 and Lin28 expression were less in 
hEryPs than CCD1112sk. Interestingly, for c-Myc and Klf4, none of the three cell 
types presented down regulated expressions. The expression levels were comparable 
to those of hESCs. It is probably because these two genes play essential roles in the 
cellular activities of many cell types.  
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Figure 3-7 Relative expression levels of pluripotent genes  
hESCs were used as the calibrator for the relative quantification of gene expression 
levels in hEryPs, FMSCs and CCD1112sk. Hence, Log RQ value of hESCs is zero 
(leftmost bar) for all the gene expressions. A negative RQ value indicated down 
regulation of the gene and vice versa. RNA from three biological samples of hEryPs 
were evaluated. *, p<0.05; **, p<0.01; §, p>0.05. Error bars represent standard 
deviations. 
 
Telomerase activity was measured quantitatively in hEryPs using hESCs as positive 
control. As shown in Figure 3-8, hEryPs had significantly lower expression level of 
telomerase than hESCs, indicating their limited self-renewal ability. When hEryPs 
were stained for detecting alkaline phosphatase activity, no red staining was observed, 
while hESC colony was stained red (Figure 3-9). It indicated no or very low level of 
alkaline phosphatase was expressed in the hEryPs.  
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Figure 3-8 Telomerase activity of hEryPs and hESCs 
hESCs were used as positive control. hEryPs had significantly lower telomerase 
activity than hESCs (p<0.005). Three biological samples of hEryPs were measured. 
Error bars represent standard deviations.  
 
Figure 3-9 Alkaline phosphatase activity of hEryPs and hESCs  
Colonies of hESCs were used as positive control, which were stained red (left).  
hEryPs were not stained red (right). Three biological samples of hEryPs were tested.  
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Immunocytochemistry of hESC surface antigens including Tra-1-60, Tra-1-81, 
SSEA3 and SSEA4, and nuclear antigens including Oct4, Sox2 and Nanog was 
performed on hEryPs on cytospun slides. All these hESC markers were not expressed 
in the hEryPs (Figure 3-10). 
Figure 3-10 Immunocytochemistry of hESC markers  
Cell nuclei were stained with DAPI (blue). Secondary antibodies for the seven hESC 
markers were either conjugated with Alexa Fluor 488 (green) or Alexa Fluor 568 
(red).  hESCs were used as positive control. Five biological samples of hEryPs were 
evaluated for each marker. None of the markers was expressed in the hEryPs. Scale 
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3.3.3.2 MSC CD markers 
It was suggested that primitive erythropoiesis originates from the mesoderm layer of 
the yolk sac wall (Pereda and Niimi, 2008). Thus, MSC markers including CD10, 
CD13, CD73, CD90 and CD105 were also examined on hEryPs by FACS analysis 
(Figure 3-11). The nuclei of hEryPs were stained by SYTO red nuclear dye in order 
to distinguish them from anucleated RBCs. Cells positive for the CD marker should 
be Alexa Fluor 488 (green) positive. In the FACS dot plot, the green positive hEryPs 
were located in the right upper quadrant. Results showed that all these CD markers 
were hardly expressed in the hEryPs as the percentages of positive cells were very 
low, which were smaller than 5%.  
Figure 3-11 FACS analysis of MSC CD markers  
The population of hEryPs were SYTO red positive cells, as indicated on Y axis. 
Average percentages of hEryPs positive (AF488, X axis) for the CD markers were 
calculated from five biological samples with standard deviations. 
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3.3.3.3 HSC CD markers 
Hematopoietic stem cells (HSC) give rise to all the blood lineages during 
hematopoiesis in the bone marrow at both fetal and postnatal life. CD34, CD45 and 
CD117 are the three characteristic markers highly expressed in these multipotent stem 
cells. CD45 is also expressed in white blood cells. FACS results indicated that hEryPs 
hardly expressed the HSC CD markers (Figure 3-12). This result was expected 
because hEryPs are differentiated blood cells from the primitive erythropoiesis in the 
yolk sac which has different origin from the definitive erythropoiesis in the bone 
marrow.   
Figure 3-12 FACS analysis of HSC CD markers  
hEryPs were SYTO red positive cells, as indicated on Y axis. Average percentages of 
hEryPs positive (Alexa Fluor 488, X axis) for the CD markers were calculated from 
five biological samples with standard deviations.  
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3.3.3.4 Erythroid markers 
Previous results showed that hEryPs do not have any of the stem cell markers that are 
typical to hESCs, MSCs and HSCs. This is consistent with their differentiated status 
in the primitive erythropoiesis. They do not hold pluripotency or multipotency that 
can give rise to other cell lineages.  Erythroid and erythrocyte (RBC) CD markers 
were further examined on hEryPs to characterize their surface antigen profile. These 
included CD35, CD36, CD71, CD47, CD59 and Glycophorin A (GPA). FACS 
analysis was performed to measure the percentages of hEryPs positive for these 
markers (Figure 3-13 A and B). hEryPs were found to be highly positive  for CD36, 
CD71, CD47, CD59 and GPA (80.77% - 95.61%), but not for CD35. 
Immunocytochemistry using fluorescent and enzymatic methods both confirmed the 
FACS results by showing positive staining of the CD markers on the hEryPs (Figure 
3-14 A and B).  
Figure 3-13 FACS analysis of Erythroid CD markers  
A. FACS analysis dot plots for the erythroid CD markers. SYTO red positive cells (Y 
axis) were the hEryPs. Average percentages of positive cells (Alexa Fluor 488, X axis) 
were presented. B. Percentages of hEryPs positive for the CD markers analysed by 
FACS. Data were calculated from five biological samples with standard deviations.  
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Figure 3-14 Immunocytochemistry of erythroid CD markers 
A. Immunocytochemistry with secondary antibodies conjugated with Alexa Fluor 488 
(green). DAPI (blue) was used to stain cell nuclei. Only CD35 was negative. Scale bar, 
20 µm. B. Immunocytochemistry by alkaline phosphatase method. Positive cells were 
stained blue. Nuclear fast red was used to stain cell nuclei. Staining results were 
consistent to A. Scale bar, 20 µm. 
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A distinct feature of primitive erythroid cells is that they produce mainly the 
embryonic type of haemoglobins i.e. epsilon haemoglobin (ε-Hb) and zeta 
haemoglobin (ζ-Hb), encoded by the alpha and beta chains of the haemoglobin gene.  
They are only expressed during primitive erythropoiesis. Immunocytochemistry result 
(Figure 3-15) showed that 100% of hEryPs expressed epsilon haemoglobins strongly 
in their cytoplasm. This intracellular marker could be used to distinguish hEryPs from 
hEryDs and adult anucleated RBCs which do not normally express embryonic 
haemoglobins.  
Figure 3-15 Immunocytochemistry of epsilon haemoglobins 
hEryPs on cytospun slides were immunostained with anti-ɛ haemoglobin antibody by 
alkaline phosphatase method. Blue staining on hEryPs indicates positive expression of 
this haemoglobin. Anucleated RBCs were not stained. Scale bar, 20 µm. 
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3.3.4 Maturation of hEryPs 
Aim: To describe the morphological changes associated with hEryP maturation and 
understand the spatial-temporal distribution pattern of primitive blood cells in the 
fetal circulation during the first trimester of gestation.  
3.3.4.1 Cytological changes during maturation in vivo 
Paraffin sections of chorionic villi from 6 to 11 weeks of gestation were made and 
stained by H & E (Figure 3-16). Three types of cells were mainly observed within the 
blood vessel lumens: polychromatic hEryPs, orthochromatic hEryPs and anucleated 
RBCs.  In the 6 week villi, majority of the blood cells were polychromatic hEryPs 
whose nuclei were big with more spread-out chromatin structure and cytoplasm 
stained bluish (6 weeks inset). As the gestation increased, the number of 
polychromatic hEryPs decreased, and number of orthochromatic hEryPs increased. 
Orthochromatic hEryPs had more condensed and smaller nuclei and pinkish 
cytoplasm due to haemoglobin accumulation. At 9 weeks, majority of the hEryPs had 
matured into the orthochromatic type (9 weeks inset). By 11 weeks, the total number 
of hEryPs dropped drastically. They were less frequently observed in the blood 
vessels. Anucleated RBCs (11 weeks inset) became the prominent cell type in the 
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Figure 3-16  H & E staining of chorionic villi paraffin sections  
Chorionic villi sections (6 to 11 gestational weeks) were stained with H & E. Both 
polychromatic and orthochromatic hEryPs were observed in the blood vessels. From 6 
to 8 weeks, polychromatic hEryPs (6 weeks arrow and inset) were more prevalent. 
From 9 weeks onwards, numbers of orthochromatic hEryPs (9 weeks arrow and inset) 
and anucleated RBCs (11 weeks arrow and inset) increased significantly. Original 
magnification, 1000X. 
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From the villi H & E staining, it could be seen that the composition of blood cells in 
the fetal circulation is constantly changing with the gestational age. To quantify these 
changes, the proportions of polychromatic hEryPs, orthochromatic hEryPs and 
anucleated RBCs were calculated from representative areas in the villi sections at 
different gestational weeks (Figure 3-17). Consistent to the cell distributions seen in 
the villi sections, from 6 to 8 weeks of gestation, majority of cells in the fetal blood 
were polychromatic hEryPs (86% at 6 weeks, 83% at 7 weeks and 76% at 8 weeks). 
From 9 week onwards, the number of orthochromatic hEryPs and anucleated RBCs 
overtook that of polychromatic hEryPs (32% at 9 weeks). At 11 weeks, the proportion 
of polychromatic and orthochromatic hEryPs was very small (together about 8%) in 
the fetal blood.  
The diameter and cross-sectional area of hEryP cytoplasm and nucleus were measured 
accordingly to track the morphological changes during maturation. The diameter of 
cytoplasm presented an increasing trend while the diameter of nucleus decreased as 
the gestational age increased (Figure 3-18A). This is consistent to the nucleus 
condensation observed in the maturing hEryPs in the villi (Figure 3-16). Similarly, 
the nuclear to cytoplasmic cross-sectional area ratio decreased as the nucleus became 
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Figure 3-17  Proportions of hEryPs and anucleated RBCs in the fetal blood 
Numbers of polychromatic and orthochromatic hEryPs and anucleated RBCs were 
counted from the chorionic villi sections at 6 to 11 weeks of gestation. Proportions of 
the three types of cells in the fetal blood were presented. Three biological samples of 
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Figure 3-18  Nuclear and cytoplasmic diameters and area ratio of hEryPs 
Diameters (A) and cross-sectional area (B) of the hEryP nucleus and cytoplasm were 
measured in the chorionic villi sections at different gestational weeks (6 to 11 weeks).  
Three biological samples of villi were analysed for each gestational week, except for 
6 weeks (one sample). Error bars represent standard deviations.  
 
 
                                                                         Chapter 3: Biology of hEryPs – Results 
89 
 
3.3.4.2 Spontaneous maturation in vitro 
From the observations made on chorionic villi sections, it is known that hEryPs 
mature while circulating in the fetal blood during first trimester. It is not clear whether 
they also differentiate when cultured in vitro. When polychromatic hEryPs obtained 
from early gestation villi samples (7 to 8 weeks) were cultured, interestingly, they 
underwent spontaneous differentiation to orthochromatic hEryPs within one week’s 
time (Figure 3-19). In the beginning of the culture, the polychromatic hEryPs had less 
condensed nuclei and a more alkaline cytoplasm that turned blue with Wright’s 
staining (Figure 3-19 arrows). Some of them were undergoing mitosis (Figure 3-19 
arrow heads). After a few days’ culture in the IMDM medium without addition of any 
growth factor or differentiation factor, they differentiated spontaneously into 
orthochromatic hEryPs. On day 3 and 5 of culture, the nuclei of hEryPs decreased in 
size and their cytoplasm turned pink which indicated the loss of RNAs and 
accumulation of haemoglobins in the cytoplasm. On day 7 of culture, most of the cells 
had matured to orthochromatic hEryPs which had highly condensed nuclei and 
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Figure 3-19 In vitro maturation of polychromatic hEryPs  
Polychromatic hEryPs were cultured and cytospun onto slides for Wright’s staining 
on day 1, 3, 5 and 7. Spontaneous hEryP maturation was observed as culture time was 
prolonged. Day 1: arrow heads, polychromatic hEryPs undergoing mitosis; arrows, 
polychroamtic hEryPs, cytoplasm stained blue. Day 3 and Day 5: cell nuclei 
condensed and cytoplasm turned pinkish due to haemoglobin accumulation. Day 7: 
hollow arrows, orthochroamtic hEryPs, matured from polychroamtic hEryPs, 
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3.3.5 Proliferative potential of hEryPs 
Aim: To investigate the proliferative potential of hEryPs for in vitro expansion of 
them for NIPD.  
3.3.5.1 Cell cycle analysis 
In the cascade of mammalian primitive erythropoiesis, as the progenitor and precursor 
cells become more and more differentiated, their ability to produce daughter cells is 
gradually lost (Baron et al., 2012). The proliferative potential of hEryPs was explored 
with the hope that they could be expanded in culture for NIPD. The cell cycle profiles 
of hEryPs at 7 to 10 gestational weeks were analysed by flow cytometry. As shown in 
Figure 3-20, there were no significant differences in each of the three phases of cell 
cycle between the hEryPs from different gestational weeks. On average, the majority 
of the hEryPs (82.9% ± 1.1%) were at the non-dividing G0/G1 phase, very small 
percentage (2.0% ± 0.3% ) were at DNA replication S phase and a small percentage 
(11.3% ± 2.2%) at mitotic G2/M phase.  This result demonstrated that hEryPs isolated 
from villi samples have limited proliferative activity during this period of gestation. 
Additionally, when only polychromatic hEryPs were isolated from one sample at 
early gestation, their cell cycle profile was quite different from the overall profile of 
hEryPs (Figure 3-21). About 30% of the polychromatic hEryPs were at mitotic phase 
and 9% of them were at S phase. It suggested that unless the majority of hEryPs are 
the polychromatic type, their proliferative potential will be limited.  
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Figure 3-20 Cell cycle profiles of hEryPs at different gestational weeks  
For each gestational week (7 to 10 weeks), percentages of hEryPs at G0/G1, S and 
G2/M phase were analysed respectively, from five biological samples. The average 
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Figure 3-21 Cell cycle profiles of polychromatic hEryPs 
Cells at mitotic phase (G2/M) was 30%, DNA replication phase (S) was 9% and non-
dividing phase (G0/G1) was 59%. 
 
3.3.5.2 BrdU assay 
The cell cycle analysis result showed that only a small portion of hEryPs were under 
mitosis. To further detect these dividing cells among the population, BrdU assay was 
carried out. When a cell is at the DNA replication phase (S phase) of the cell cycle, it 
takes up the thymidine analogue BrdU when added to the culture medium. Addition 
of anti-BrdU antibody and immunostaining will enable detection of positively stained 
cells at S phase. As expected, after the staining, most of the hEryPs did not take up 
BrdU for DNA replication (Figure 3-22). Occasional positive cells were indicative of 
few hEryPs undergoing cell division. This assay further confirmed that hEryPs were 
not active in cell proliferation.  
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Figure 3-22 Anti-BrdU immunostaining of hEryPs 
The nuclei of hEryPs were stained with DAPI and anti-BrdU conjugated with Alexa 
Fluor 488. Green positive nucleus (arrow) indicated the cell had taken up the BrdU 
for DNA synthesis during the S phase of cell cycle. Cells with non-stained nuclei 
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3.3.5.3 Immunocytochemistry of proliferating cell nuclear antigen 
Proliferating cell nuclear antigen (PCNA) is expressed on mitotic cells as its name 
suggests. It was used to evaluate the proliferation status of hEryPs as well. 
CCD1112sk was used as a positive control for the immunocytochemistry of this 
antigen. The nuclei of CCD1112sk were mostly positive, while the nuclei of hEryPs 
were all negative (Figure 3-23). This result further supported the previous 
experimental results and clearly indicated that hEryPs had limited proliferative 
potential. 
Figure 3-23 Immunocytochemistry of PCNA on CCD1112sk and hEryPs 
Secondary antibody of PCNA was conjugated with Alexa Fluor 488 (green). Cell 
nuclei were counter stained with DAPI (blue). Left panel: CCD1112sk nuclei were 
PCNA positive. Scale bar, 50 µm. Right panel: hEryP nuclei were PCNA negative. 
Scale bar, 20 µm.  
 
                                                                         Chapter 3: Biology of hEryPs – Results 
96 
 
3.3.6 Do hEryPs enucleate in vitro? 
Aim: To find out if hEryPs enucleate spontaneously (without and with the presence of 
erythropoietin) or require the presence of macrophages for their enucleation in vitro. 
The enucleation phenomenon in mammalian primitive erythropoiesis has been of 
interest for long time, but many of the studies were carried out using murine models 
(Isern et al., 2008; McGrath et al., 2008). In humans, a recent study suggested that 
hEryPs enucleated and got eliminated in the chorionic villous stroma of placenta, and 
the enucleation process was mediated by macrophages that resided in the same stroma 
site (Van Handel et al., 2010). However, some groups reported that hEryPs 
differentiated from hESCs did not enucleate in culture (Olivier et al., 2006; Lu et al., 
2008). Hence, cultures of hEryPs alone and with macrophages were both studied here. 
The effect of erythropoietin was also evaluated to see it could induce the enucleation 
of hEryPs.  
For the enucleation study, hEryPs were not purified with CD71 MACS prior to the 
culture to avoid external forces which might create artifacts of enucleation. Therefore, 
both hEryPs and anucleated RBCs were present from the beginning of culture. 
Nuclear extrusion from the cytoplasm and presence of free floating naked nuclei in 
the culture were considered as signs of ‘enucleation’.  
3.3.6.1 Culture of hEryPs and hEryDs 
Definitive erythroblasts (hEryDs) isolated from human cord blood were used as the 
positive control cells. Both hEryPs and hEryDs were cultured in the IMDM medium 
(IMDM basal medium, 30% FBS, 1% BSA, 10-4 mol/l β-mercaptoethanol, 100 µg/ml 
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iron-saturated transferrin and 1% AA) for 7 days. Cultured cells were cytospun onto 
slides. Wright’s staining was performed to check the cell morphology over the time.  
When hEryPs were cultured alone, their morphology did not change (Figure 3-24, 
upper panel) over the 7 days. Their nuclei remained within the cytoplasm all the time.  
There were no extruded nuclei observed in the culture. However, some degenerating 
hEryPs were found on day 7. Their cytoplasm was weakly stained by eosin indicative 
of permeabilized plasma membrane (Figure 3-24, arrow head). In contrast, hEryDs 
started enucleating within 3 days of culture (Figure 3-24, lower panel, arrows). The 
morphology of hEryD before enucleation was shown on day 1 (Figure 3-24, inset i, 
see enlarged picture). On day 3, many of their nuclei moved to the periphery of the 
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Figure 3-24 Wright’s staining of hEryPs and hEryDs in culture 
Upper panel shows the staining of hEryPs cultured on day 1, 3 and 7. Lower panel 
shows the staining of hEryDs cultured on day 1 and 3. Arrow head: hEryP undergoing 
cell death, cytoplasm was weakly stained indicative of loss of plasma membrane 
integrity. Arrows: hEryDs undergoing enucleation. i: hEryD before enucleation. ii: 
hEryD undergoing enucleation. Nucleus is being extruded from the cytoplasm. 
Enlarged pictures of i and ii are shown at the right. Scale bar, 20 µm.  
 
 
Cytoskeleton of hEryPs and hEryDs was also stained by phalloidin-FITC (green 
fluorescence) to track the nuclear movement during the culture period. The nucleus 
was counter stained by DAPI (blue fluorescence). The cytoskeleton staining 
demonstrated no evidence of nuclear extrusion in the hEryPs from day 1 to day 7 of 
culture (Figure 3-25, upper panel). The cell nuclei retained within the cytoplasm. 
However, the cytoskeleton staining of hEryD showed enucleation on day 3 of culture 
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where the cell nucleus moved outside the cytoplasm (Figure 3-25, lower panel, day 3 
inset). These results were consistent to the Wright’s staining results.  
Figure 3-25 Cytoskeleton staining of hEryPs and hEryDs in culture 
Upper panel shows the cytoskeleton staining (green fluorescence) of hEryPs cultured 
for 7 days. Lower panel shows the staining of hEryDs cultured for 3 days. Cell nuclei 
were strained by DAPI. hEryD day 1 (D1) arrow: hEryD before enucleation; day 3 
(D3) arrow: hEryD undergoing enucleation. Enlarged pictures of arrowed cells are 
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Time-lapse live imaging was further performed to capture the behaviour of hEryPs in 
culture. On day 3 of culture, hEryPs were loaded onto the Live Cell Array (section 
3.2.22) for time-lapse imaging continuously for 24 hours under standard culture 
conditions. Images were taken every 10 mins. From the images taken over the time 
course, only shrinking of cell size and subsequent cell degeneration were observed in 
some of the hEryPs (Figure 3-26). No enucleation of hEryPs was seen.  
Figure 3-26 Time-lapse live imaging of hEryPs in culture 
Pictures were captured during the 24 hours’ live imaging of hEryPs using confocal 
microscopy under 20x magnification with 4x zoom. The hEryP nucleus was initially 
stained with SYTO red nuclear dye. Representative pictures from one selected hEryP 
are shown. At the time of 10 hour 10 min, the cell has shrunken to a smaller size, at 
the time of 11 hour 30min, the plasma membrane became permeabilized and the 
nucleus became visible due to the loss of plasma membrane integrity. No nucleus 
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3.3.6.2 Effect of erythropoietin 
Erythropoietin (EPO) was found to play important roles in the definitive 
erythropoiesis, but not in the primitive erythropoiesis (Lee et al., 2001). To evaluate 
the effect of erythropoietin on the culture of hEryPs, erythropoietin (2 U/ml) was 
added to the IMDM culture medium. Wright’s staining of the cultured cells was 
performed on day 1, day 3 and day 7 (Figure 3-27). No significant difference in the 
morphologies of hEryPs was observed between the control cells (no EPO added) and 
cells cultured with EPO. The hEryP nuclei were within the cytoplasm under both 
conditions over the 7 days’ culture. Hence, no enucleation of hEryPs was induced 
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Figure 3-27 Culture of hEryPs with Erythropoietin (EPO) 
hEryPs were cultured in IMDM medium (left panel) and the same medium 
supplemented with EPO (2 U/ml) (right panel). Wright’s staining was done on day 1, 
day 3 and day 7 of culture. hEryP morphology appeared the same and no enucleation 
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3.3.6.3 Co-culture of hEryPs with macrophages 
hEryPs and macrophages were co-cultured to check if macrophages could mediate the 
enucleation of hEryPs. Two co-cultured methods were used. One method was that 
hEryPs were added directly on top of macrophages, so the two cell types had physical 
contact to each other. The other method was that hEryPs were contained in a transwell 
which was then placed on top of the macrophage layer. The transwell physically 
separated the hEryPs from macrophages, but they were in the same culture well and 
the same medium. The purpose of using two methods was to study if physical contact 
with macrophages was needed for hEryP enucleation. Surprisingly, in both of the 
culture methods, enucleation of hEryPs was not observed in the Wright’s staining 
results (Figure 3-28, arrows). Degenerated hEryPs were seen however, which had the 
same morphology as the degenerated hEryPs captured in the live imaging (Figure 
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Figure 3-28 Wright’s staining of hEryPs co-cultured with macrophages 
Upper panel shows the Wright’s staining of hEryPs cultured with direct contact to 
macrophages. Lower panel shows the staining of hEryPs cultured in the transwell 
which separated hEryPs from macrophages at the bottom. Arrows, healthy hEryPs 
with no enucleation. Arrow heads, degenerating hEryPs with weakly stained 
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3.3.7 Degeneration of hEryPs 
Aim: To study whether hEryPs undergo apoptosis or other means of cell death in the 
fetal circulation and after entering the maternal circulation.  
3.3.7.1 hEryPs in the fetal circulation 
It was found that after 12 weeks of gestation, the number of hEryPs in the fetal 
circulation decreased dramatically (Choolani et al., 2001).  It is still unclear how 
hEryPs are eliminated in the fetal circulation after first trimester. In this experiment, 
TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling ) assay was 
performed on hEryPs at 7 to 11 weeks of gestation to check whether they were 
undergoing apoptosis in the fetal blood. TUNEL assay detects the fragmented DNA in 
the nucleus of apoptotic cells by adding fluorescent tag to the end of DNA fragments. 
My results showed that hEryPs freshly isolated from villi samples during this 
gestational period were all TUNEL negative (Figure 3-29, green negative), which 
suggested that they were alive and healthy while circulating in the fetal blood until 11 
weeks of gestation. Interestingly, when culturing these isolated cells for one to two 
weeks, the number of TUNEL positive hEryPs increased accordingly (Figure 3-30). 
It indicated that within the native in vivo environment, hEryPs did not undergo 
apoptosis up to 11 weeks of gestation, while in vitro culture environment might 
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Figure 3-29 TUNEL staining of hEryPs from villi at different gestational weeks 
TUNEL staining was performed on cytospun slides of hEryPs at 7 to 11 weeks of 
gestation. hEryPs treated with DNase were used as positive control. DAPI was used to 
stain cell nuclei. Green fluorescence in the cell nucleus was considered TUNEL 
positive, which indicated the presence of DNA fragmentation. Scale bar, 20 µm.  
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Figure 3-30 TUNEL staining of hEryPs cultured in vitro  
TUNEL staining was performed on cytospun slides of hEryPs cultured for one week 
and two weeks respectively. The number of TUNEL positive hEryPs (apoptotic) 
increased as the culture time was prolonged. Scale bar, 20 µm.  
 
hEryPs isolated from villi were also evaluated for Annexin V staining by flow 
cytometry. Annexin V binds to the phosphatidylserine which becomes externalized to 
the outer leaflet of the plasma membrane on cells at early stage of apoptosis. Freshly 
isolated hEryPs had very small percentage of Annexin V positive cells (Figure 3-31), 
indicating very few of them showed early sign of apoptosis. This was consistent to the 
TUNEL assay results. Similarly, when hEryPs were cultured for one to two weeks, 
more of the hEryPs became positive for Annexin V staining. PI (propidium iodide) 
staining was also positive because degenerating hEryPs lost their membrane integrity 
and their nuclei were stained by PI.  hEryPs cultured for one week had about 5% 
Annexin V positive cells, and after one more week of culture, the percentage of 
positive cells increased to 95%. Therefore, when hEryPs were cultured in vitro, it was 
difficult to maintain their viability as the culture conditions were not as optimal as the 
in vivo environment. 
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Figure 3-31 Annexin V and PI staining of hEryPs 
Annexin V- FITC and PI were used to stain hEryPs freshly isolated from villi and 
hEryPs cultured for one week and two weeks respectively. Cells positive for both 
Annexin V and PI were considered as undergoing cell death.  
 
3.3.7.2 hEryPs in the maternal circulation 
The fate of the fetal cells that enter the maternal circulation is still not clear. Whether 
they undergo any changes that predispose them to death and degradation or perhaps 
they develop immunological tolerance in the maternal circulation is not known. From 
the previous results, it is understood that hEryPs were not undergoing apoptosis in the 
fetal circulation by 11 weeks of gestation. Herein, the hEryPs isolated from maternal 
blood samples (8 to 11 weeks of gestation) were examined for TUNEL staining to see 
if any sign of cell death i.e. DNA fragmentation was observed. From the maternal 
blood, both live and dead hEryPs could be identified and isolated. Figure 3-32 shows 
that dead hEryPs were 100% positive for TUNEL. However, for live hEryPs, the 
TUNEL staining result varied from sample to sample. In some samples, hEryPs were 
all TUNEL negative while in other few they were positively stained.  It is difficult to 
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conclude whether the DNA fragmentation in the TUNEL positive live hEryPs was 
caused by maternal effects, because the enrichment of these cells from maternal blood 
was quite a long process, and the resultant stress to the cells could be a contributing 
factor to their unhealthy status.    
Figure 3-32 TUNEL staining of hEryPs from maternal blood 
hEryPs isolated from maternal blood on cytospun slides were stained with TUNEL. 
Cell nuclei were stained with DAPI. Green fluorescence in the nuclei indicated 
TUNEL positive i.e. presence of DNA fragmentation. Dear hEryPs were all TUNEL 
positive (right panel). Some live hEryPs were TUNEL positive (middle panel), while 










An in-depth study on the biological properties of hEryPs was performed in this 
chapter with two aims: to understand the nature of this primitive blood cell type and 
to make use of its properties for NIPD. 
The morphology and size of hEryPs were described and measured. This offered 
important information for identification of these cells among other cell types. Their 
morphological characteristics will be used for their isolation from maternal blood, as 
described in the following chapter (section 4.3.1). 
The surface antigens of hEryPs have been studied previously using 
immunocytochemistry (Choolani et al., 2003). In this chapter, more antigens were 
evaluated in a quantitative manner by flow cytometry. Compared to the previous 
study, CD47 and GPA were both found to be highly expressed on hEryPs, and CD35 
was not expressed. However, my flow cytometry results showed a higher percentage 
of CD71 positive hEryPs. It could be due to the more sensitive detection by this 
technique. hEryPs did not present any of the stem cell markers (hESCs, MSCs, HSCs) 
examined. This result was expected because they are at the terminal stage of primitive 
erythropoiesis. The intracellular marker, epsilon haemoglobin, was highly expressed 
in hEryPs, but not other blood cells. Hence, it is a specific marker for confirming the 
identity of these cells.  
hEryPs in the chorionic villi presented a similar maturation process as mEryPs and 
hEryDs. During their maturation, the precursor cells polychromatic hEryPs decreased 
in size, their nuclei underwent condensation to form orthochromatic hEryPs and 
haemoglobin was accumulated in the cytoplasm (De la Chapelle et al., 1969). 
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Interestingly, when the polychromatic hEryPs isolated from chorionic villi were 
cultured, they underwent the same maturational process spontaneously as what 
happened in vivo. This probably suggested that the differentiation of hEryPs from 
polychromatic to orthochromatic stage can occur independently without external 
signals from the surrounding environment or cells.  
Cell proliferation and enucleation are of most interest when studying the cultural 
behaviours of hEryPs, as the number of these cells isolated from maternal blood is 
very small. The cell cycle profiles and BrdU assay results both indicated that majority 
of the hEryPs were at the non-dividing phase. Although the earlier stage 
polychromatic hEryPs had a higher proliferative potential, they were less frequent 
than the orthochromatic hEryPs in the fetal circulation especially after 9 weeks of 
gestation, as shown by the H & E staining of villi sections. Therefore, it would be 
difficult to expand the number of hEryPs in culture due to their limited proliferative 
potential.   
Whether enucleation occurs in the maturation of hEryPs has been a myth. It was 
recently suggested  by one study that they might enucleate in the placental stroma via 
interactions with macrophages in vivo (Van Handel et al., 2010). However, my results 
demonstrated that hEryPs did not extrude their nuclei when cultured alone, or with 
addition of erythropoietin or in the presence of macrophages. No phagocytosis of 
extruded nuclei was observed in the co-culture of hEryPs with macrophages. Instead, 
some of the hEryPs underwent degeneration after long period of culture, but none of 
them appeared to be engulfed by macrophages.  Another two findings in my study 
may explain the lack of interactions between hEryPs and macrophages. Firstly, 
hEryPs expressed high levels of CD47 on the membrane surface as shown by FACS 
analysis and immunocytochemistry. CD47 has been identified as a ‘marker of self’ 
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expressed on the anucleated RBCs for them to escape from macrophage clearance 
(Oldenborg et al., 2000). Secondly, the negative annexin V staining on the freshly 
isolated hEryPs from villi indicated that they did not expose phosphatidylserine on the 
outer leaflet of their plasma membrane. The phosphatidylserine exposure on cell 
membrane is an early sign of apoptosis (Fadok et al., 1998) and a required signal for 
macrophage phagocytosis during the enucleation of definitive erythroblasts (Yoshida 
et al., 2005). These properties of hEryPs seemed not support their interactions with 
macrophages both in vitro and in vivo. Therefore, it is likely that hEryPs did not 
require enucleation at the end of their maturation. Moreover, for the application of 
NIPD, absence of enucleation in the cultured hEryPs is practically beneficial because 
the cell nucleus is kept intact within the cytoplasm before the subsequent molecular 
analysis on the cell DNA. 
In the fetal blood, hEryPs did not show any signs of apoptosis or degeneration by 11 
weeks of gestation, as suggested by TUNEL staining results. This observation is 
consistent to the previous finding by others that hEryPs located in the villous stroma 
were not apoptotic (Van Handel et al., 2010). However, after entering the maternal 
circulation, some of them underwent degeneration as shown by the positive TUNEL 
staining (Figure 3-32). It could be due to the physiological effects of maternal 
environment on the fetal cells which triggered cell death pathways in these cells 
(Sekizawa et al., 2000; Babochkina et al., 2005a). It was also possible that the long 
process of cell enrichment posed stress on these cells.   
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Chapter 4: Isolation and Culture of hEryPs 
4.1 Introduction 
The fact that fetal cells are extremely rare in the maternal blood is the biggest 
challenge faced by cell-based method in NIPD. In order to obtain pure fetal genetic 
materials for downstream diagnosis, the fetal cell enrichment must be robust enough 
to separate as many maternal cells as possible from the target fetal cells. At present, 
antibody-based enrichment methods are considered efficient, but antibodies that are 
specific to the fetal cells or maternal cells are still being explored for a good 
separation of the two cell populations. In vitro culture of cells enriched from maternal 
blood has been attempted with the hope of expanding the number of fetal cells among 
the mixed population. However, in most of the cases, the number of maternal cells 
was expanded as well, which lead to confounding results of molecular tests (Chen et 
al., 1998; Han et al., 1999; Bohmer et al., 2002).   
One possible way of removing maternal cells completely is to isolate the fetal cells 
individually from the mixed pool of cells. This approach requires distinguishable 
morphological features or markers of the fetal cells for separating them from maternal 
cells. Use of laser microdissection to capture fetal cells on microscopic slides has 
been done before (Kolialexi et al., 2007). Prior to the microdissection, all cells had to 
be fixed and immunostained. Only cells carrying the fetal markers were captured. The 
whole process was very labour intensive and time consuming because large number of 
slides needed to be prepared and processed accordingly. The DNA quality of the 
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captured fetal cells could also be compromised due to the chemical fixation and 
multiple staining steps.  
In this chapter, a novel technique of isolating and culturing pure hEryPs from 
enriched maternal blood was developed. The cell isolation step utilized a hand-
controlled micromanipulator to manually pick up hEryPs identified according to 
specific criteria. The fetal origin of picked cells was confirmed using several 
molecular tests including quantitative PCR, immunocytochemistry and fluorescent in 
situ hybridization (FISH).  At the same time, a microdroplet culture system was 
designed for maintaining the viability of picked cells for an extended period of time. 
The culture system was first optimized using hEryPs from chorionic villi by 
evaluating different gaseous conditions and effect of mitogen on the cell viability. It 
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4.2 Materials and Methods 
4.2.1 Reagents, culture media, antibodies and kits 
Chemical reagents: 
Hoechst 33342 nuclear dye (Invitrogen, USA); Mineral Oil (Sigma Aldrich, USA); 
10x PBS (Vivantis, USA); Ethanol, Methanol (Quality Reagent Chemical, New 
Zealand); Glacial Acetic Acid (BDH Prolabo, VWR International, USA).  
Biological reagents:  
Fetal bovine serum (FBS) (Biochrome AG, Germany); bovine serum albumin (BSA), 
β-mercaptoethanol, antibiotic-antimycotics (AA) (Invitrogen Gibco, USA); Pokeweed 
mitogen, human iron-saturated transferrin (Sigma Aldrich, USA); human male 
genomic DNA (Promega, USA); TaqMan real-time PCR probes for SRY and HBB 
(Applied Biosystems, USA). 
Culture media: 
Iscove’s modified Dulbecco’s medium (IMDM) (Invitrogen Gibco, USA).  
Antibodies: 
Primary antibody against human antigen (host in mouse): epsilon haemoglobin 
(Fitzgerald, USA). 
Secondary antibody (host in goat): Anti-mouse IgG (H+L) biotinylated (Vector 
Laboratories, USA). 
Antibody conjugated with fluorescein: CD45 Alexa Fluor 488 (Invitrogen, USA) 




PicoPlex Whole Genome Amplification kit (Rubicon Genomics, USA); TaqMan 
Universal PCR Master Mix (Applied Biosystems, USA); Vysis CEP X Spectrum 
Orange/Y Spectrum Green Direct Labeled Fluorescent DNA Probe kit (Abbott 
Molecular, USA); Vector Blue Alkaline Phosphatase substrate kit (Vector 
Laboratories, USA).  
4.2.2 Manual isolation of hEryPs from maternal blood  
Maternal blood samples from pre or post termination of pregnancy (TOP) and on-
going pregnancies were collected (10 to 23 ml per sample). Sample was first 
centrifuged with Percoll density gradient (DGC). After the DGC, cells collected from 
the interface layer were then subjected to CD45 depletion and CD147 selection using 
MACS. DGC and MACS were performed by Dr Aniza and Jaspal Singh. MACS 
enriched cells (CD45-/CD147+) were used as the starting material for manual cell 
isolation. Cells were resuspended in IMDM culture medium and stained with CD45 
antibody conjugated with Alexa Fluor 488 and nuclear dye Hoechst 33342. 5 µl of 
CD45 antibody and 1 µl of Hoechst dye (stock conc.10 mg/ml) was added to 1 ml of 
cell suspension and incubated for 30 mins at 37oC.  Cells were then centrifuged at 
3000 rpm for 5 min and resuspended in 100 µl of medium for every 1 to 3 x 106 cells. 
One arm of micromanipulator (Narishige, Japan) and inverted fluorescent microscope 
(Olympus IX70, USA) were set up prior to the cell isolation. A glass micropipette 
(Origio, USA) with internal diameter of 22 -25 µm and flat-cut end was attached to 
the micromanipulator and aligned properly. 100 - 200 µl of the cell suspension was 
loaded onto a 60 mm culture dish. 50 µl of culture medium and 50 µl of 1x PBS were 
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loaded onto the same dish in two separate droplets. The cell picking process was 
carried out in the droplet containing cells. The medium droplet was for keeping the 
picked cells, and the PBS droplet was for washing the picked cells before they were 
transferred to other vessels.  
During the isolation, hEryPs were identified according to specific criteria under the 
fluorescent microscope. After picking by the micropipette, cells were immediately 
transferred to the culture medium droplet. Depending on the downstream experiment, 
cells picked were cultured or transferred to PCR tubes (size 200 µl, Axygen, USA) or 
glass slides.  
4.2.3 Whole genome amplification of hEryPs  
PicoPlex WGA (whole genome amplification) kit was used to extract and amplify the 
DNA of picked cells (1 to 10 cells per reaction) from maternal blood samples. 
Manufacturer’s instructions were followed. Briefly, the picked cells were transferred 
into PCR tubes and frozen at -20oC before WGA. Cell DNA was first extracted by 
adding extraction enzyme and buffer to the PCR tube and incubating it on a thermal 
cycler according to the required setting. Pre-amplification cocktail was then added 
and the sample underwent another round of incubation. Amplification cocktail was 
added lastly and the final round of incubation was performed. All the incubation steps 
required the use of thermal cycler and the settings of temperature, time and cycle 
number were indicated in the manual. After completing all the steps, samples were 
stored at -20oC until further use.  
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4.2.4 Real-time PCR of SRY and β-globin  
Real-time or quantitative PCR was carried out to confirm the origin of cells picked 
from maternal blood samples, especially for those carrying male fetus. SRY (sex-
determining region Y) was used to indicate the male signature of the fetal cells. Beta-
globin (HBB) was a house-keeping gene present on both male and female cells. 
Standards were first prepared from commercial male genomic DNA with different 
concentrations. PCR mix was then prepared which consisted of Taqman PCR master 
mix, forward and reverse primers for the gene of interest, Taqman probe for the gene 
of interest, DNA sample and water. Samples were added to the PCR plate and run on 
ABI Prism 7000 Sequence Detection System (Applied Biosystems, USA) using the 
following setting: 50oC for 2 mins, one cycle; 95oC for 10 mins, one cycle; 95oC for 
15 secs, 55 cycles; 60oC for 1 min, 55 cycles. Real-time PCR results were analysed 
using ABI Prism 7000 SDS software.  
4.2.5 Fluorescence in situ hybridization (FISH) 
Picked cells from maternal blood or chorionic villi were cytospun onto glass slides at 
700 rpm for 5 mins. Cells were first fixed with Carnoy’s fixative (methanol:acetic 
acid (volume) = 3:1) added drop wise for 10 mins on a heat block at 60oC. 2 µl of 
CEP X/Y probe was mixed with 3 µl of hybridization buffer and added to cover the 
cells. Slide was then incubated in a humidified hybridization chamber (PTC-200 
Peltier Thermal Cycler DNA Engine, from MJ Research, USA) with a coverslip on 
top according to the following setting: 75oC for 8 mins, 37oC for 16 hours (this step 
was usually performed overnight). After the hybridization, slide was washed with 0.4% 
SSC at 73oC for 2 mins with gentle shaking and 2x SSC at room temperature for 2 
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mins. 70%, 80% and 100% ethanol was used to serially dehydrate the cells. Finally, 
air dried slides were covered by mounting medium containing DAPI and cover slip 
was sealed with nail polish. FISH results were viewed under fluorescent microscope 
(Olympus BX61, Japan).  
4.2.6 Microdroplet culture of hEryPs 
60 mm tissue culture dish (BD Biosciences, USA) was used as the culture vessel. One 
day before the culture, droplets (10 – 20 µl per small droplet, 50 µl per big droplet) of 
culture medium were added to the 60 mm dish, covered with equilibrated mineral oil 
and incubated in the incubator (37oC, 5% CO2) overnight. On the day of culture, cells 
enriched from chorionic villi or maternal blood samples were transferred to the big 
droplet of medium using a micropipette. With a customized micropipette (Origio, 
USA, internal diameter of 22 - 25 µm and flat-cut end) attached to a 
micromanipulator (Narishige, Japan), hEryPs were picked up from the big droplet and 
transferred to the small droplets.   
For the optimization of microdroplet culture, 50 hEryPs were picked from chorionic 
villi samples and cultured in 5 small droplets of medium (10 cells per droplet, 5 
replicates) in one 60 mm dish. Normoxic condition was air with 5% CO2. Hypoxic 
culture was carried out in a modular incubator chamber (Billups-Rothenberg, 
Germany) purged with gas composing 2% O2, 5% CO2 and 93% N2.  Culture dishes 
were taken out from the incubator and observed every 6 or 12 hours to count the 
number of viable cells in the small droplets.  Average number of viable cells from the 
five droplets in each dish was calculated. For each culture condition, data were 
generated from three biological samples.   
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For the microdroplet culture of hEryPs picked from maternal blood, total number of 
picked cells was first counted. If the cell number was less than 10, they were all 
cultured in one droplet of medium. If the cell number was larger than 10, they were 
divided to several droplets of medium. Cells were observed daily and number of 
viable cells was counted.  




4.3.1 Manual isolation of hEryPs from maternal blood 
Aim: To isolate pure hEryPs from enriched maternal blood with the aid of a 
micromanipulator.  
4.3.1.1 hEryP identification criteria 
According to the characteristics of hEryPs isolated from chorionic villi, three criteria 
were established for identifying hEryPs from enriched maternal blood cells (CD45-
/CD147+ cells, enrichment protocol refer to section 4.2.2). The target cells should 
fulfil: 1) be positive for Hoechst nuclear stain which was blue fluorescent under UV 
filter; 2) be negative for CD45 staining which was green fluorescent; 3) have a twice 
bigger size than normal anucleated RBCs and a low nuclear to cytoplasmic ratio i.e. 
small nucleus and big cytoplasm. Figure 4-1 shows the merged pictures of a hEryP 
(left) and a WBC (right) from maternal blood after staining by Hoechst dye and 
CD45-AF488. hEryP was Hoechst positive and CD45 negative, while WBC was 
Hoechst positive and CD45 positive. Other than the different fluorescent staining on 
the two types of cells, their morphologies were also distinguishable from each other. 
hEryP had circular shape with smooth membrane surface. Its size was much bigger 
than the anucleated RBC, and its nucleus was pyknotic. WBC had an irregular shape 
due to the rough membrane surface, and its nuclear to cytoplasmic ratio was high due 
to the small cytoplasm and big nucleus.  
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Figure 4-1 Hoechst and anti-CD45 staining of hEryP and WBC 
Left, hEryP stained positive by Hoechst nuclear dye (blue) and negative for CD45.  Its 
nucleus was highly condensed and size was about twice of RBC. Right, WBC stained 
positive by both Hoechst nuclear dye and CD45 antibody (green). Its nucleus was 
bigger than hEryP and the cytoplasm was scant. Scale bar, 10 µm. 
 
 
Figure 4-2 shows the manual picking of an identified hEryP from the maternal blood 
with a glass micropipette attached to a micromanipulator. The nucleus of the cell was 
stained by Hoechst dye, thus fluorescent. The cell was negative for CD45 staining. 
The morphology and staining of this cell fulfilled the identification criteria. The 
contaminating cells in the view were anucleated RBCs which were negative for 
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Figure 4-2 Manual isolation of hEryP from enriched maternal blood  
 
4.3.1.2 Physical properties of hEryPs 
A few physical properties of hEryPs were observed during the manual picking process. 
hEryPs did not form cell clumps with surrounding cells such as RBCs and WBCs. 
Due to their rare number in the maternal blood, they were normally found as single 
cells. They had smooth plasma membrane which was not sticky to the culture dish nor 
to the glass micropipette. They were very deformable, thus could easily pass through 
the micropipette during aspiration.  Although these cells could be picked up quickly 
once they were identified, care should be taken to avoid breaking or poking their 
fragile membrane. Once the cell membrane was damaged, the cell disintegrated and 
would be stuck to the culture dish.  
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4.3.1.3 Confirmation of fetal origin  
The identification criteria were used as guidelines when isolating hEryPs from the 
enriched maternal blood. To prove that the picked cells were genuinely fetal, 
downstream molecular tests were carried out. Different tests were applied for a 
sample carrying a male fetus (called ‘male sample’) and a sample carrying a female 
fetus (called ‘female sample’). For a male sample, because of the presence of Y sex 
chromosome in the fetal cells but not the maternal cells, real-time PCR of SRY (sex-
determining region Y) gene or FISH using X/Y probe was used to confirm the origin 
of the picked cells. For a female sample, however, options were less because the fetal 
cell had the same sex as the maternal cells. One simple method used was 
immunostaining of epsilon haemoglobin which was exclusively expressed in the 
hEryPs. Other more complex methods could include Short Tandem Repeat (STR) 
analysis, array-comparative genomic hybridization (aCGH) and DNA sequencing, 
which can also be applied to male samples.  
Figure 4-3 presents the results of three basic molecular tests used to confirm the fetal 
origin of the picked cells from maternal blood. For cells that fulfilled all the 
identification criteria (Figure 4-3A), they were proven to be fetal after the 
confirmation tests. Figure 4-3B shows the successful amplification of SRY and HBB 
gene from the DNA of picked cells from a male sample after real-time PCR. Figure 
4-3C shows the positive expression of epsilon haemoglobin in the picked cells from a 
female sample after immunocytochemistry. Figure 4-3D presents the XY signal in the 
picked cells from a male sample after FISH.  These confirmation tests were performed 
with the assistance of Dr Priya Kadam and Dr Sherry Ho.   
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Figure 4-3 Confirmation of fetal origin of the picked cells from maternal blood 
A. Ten cells picked from maternal blood. Cell nuclei were stained with DAPI. These 
cells fulfilled the identification criteria for hEryPs. B. Real-time PCR of SRY and 
HBB genes on the picked cells from a sample carrying a male fetus. Both SRY and 
HBB were amplified successfully. C. Immunocytochemistry of epsilon haemoglobin 
on the picked cells from a sample carrying a female fetus. Blue staining in the 
cytoplasm indicates positive expression. D. FISH of the picked cells from a sample 
carrying a male fetus (Left panel). Villi hEryPs were used as positive control (Right 
panel). All the four picked cells from maternal blood showed signals of X 
chromosome (red) and Y chromosome (green).   
 
 
                                                  Chapter 4: Isolation and Culture of hEryPs – Results 
126 
 






                                                  Chapter 4: Isolation and Culture of hEryPs – Results 
127 
 
4.3.1.4 Number of hEryP-like cells picked from maternal blood  
Manual isolation of hEryPs via micromanipulation was performed for 81 maternal 
blood samples (8 to 13 weeks of gestation) after prior enrichment with Percoll DGC 
and CD45/CD147 MACS.  Fetal origin of the picked cells was confirmed via the 
methods mentioned above (section 4.3.1.3) in some of the samples, but not all due to 
the optimization process of those confirmatory tests. To evaluate the efficiency of this 
isolation method, the number of cells that met the identification criteria, called 
‘hEryP-like cells’, was counted for each blood sample.  Table 4-1 summarizes the 
manual isolation of hEryP-like cells from pre-TOP, post-TOP and on-going 
pregnancy maternal blood samples. The number of cells obtained after prior 
enrichment with DGC and MACS varied sample by sample. On average, post-TOP 
maternal blood samples had the highest number of CD45-/CD147+ cells after 
enrichment, and also the highest number of hEryP-like cells obtained after manual 
isolation. The isolated cell number was about three times of the cell number from pre-
TOP maternal blood samples. Interestingly, the blood samples obtained from on-
going pregnancy had the lowest numbers in both CD45-/CD147+ cells enriched and 
the hEryP-like cells isolated, probably due to the older gestational ages (10 to 13 
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4.3.2 Development of microdroplet culture for hEryPs 
Aim: To develop a culture system that is suitable for culturing small number of fetal 
cells and is able to maintain their viability or stimulate cell proliferation.     
Fetal cells are rare events among the billions of cells in the maternal circulation.  
Assuming the cell enrichment step can produce only fetal cells without any maternal 
contamination in the end, the sparse number of cells isolated may still not be 
sufficient to perform all kinds of diagnostic tests or to use for other applications. If a 
culture system could be developed to allow the maintenance and expansion of these 
rare fetal cells, it might solve the cell number problem. For cell types that can divide 
easily, their expansion in culture will provide sufficient cell numbers for downstream 
application. However, for cell types having limited proliferative potential, it is more 
important that they could be kept viable after the enrichment and to also explore 
methods to induce their division.     
4.3.2.1 Design of culture system 
The concept of microdroplet culture comes from the embryo culture method used in 
the in vitro fertilization work, where individual embryos were cultured in droplets of 
culture medium covered by mineral oil for long period of time.  In this case, small 
number of fetal cells are cultured inside the droplets of culture medium with volume 
of microliters, hence called ‘microdroplet culture’. hEryPs obtained from chorionic 
villus samples were used for optimization of this culture system.  
In the microdroplet culture system (Huang et al., 2011), individual hEryPs were 
identified and picked up from the original mixed cell population and transferred using 
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a micromanipulator to a small droplet of culture medium covered by mineral oil 
(Figure 4-4). In this small droplet of medium, pure population of hEryPs can be 
monitored over time and different culture conditions could be applied in order to find 
the optimal conditions for the survival of these cells.  
Figure 4-4 Microdroplet culture system for hEryPs 
A: Heterogeneous population of cells lying in the centre large droplet (arrow). Ai: 
Magnified phase contrast image of the heterogeneous cell population before 
micromanipulation. B, C: hEryPs in the large centre droplet are individually picked up 
using a 22 - 25 µm bore micropipette and micromanipulator under the microscope and 
transferred to 10 – 20 µl microdroplets of media in the periphery to obtain 
homogenous populations of hEryPs. Ci: Magnified phase contrast image of hEryPs in 
the peripheral microdroplets. D: Cross-sectional view showing the microdroplets of 
media in a 60 mm culture dish covered by a thin layer of equilibrated mineral oil.  
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4.3.2.2 Culture medium 
The culture medium used for hEryPs in this study has the composition of IMDM basal 
medium, 30% FBS, 1% BSA, 10-4 mol/l β-mercaptoethanol, 100 µg/ml iron-saturated 
transferrin and 1% AA. It was based on formula developed by previous studies on 
culture of human erythroid cells from maternal blood and cord blood (Han et al., 1999; 
Zhang et al., 2007). Ion-saturated transferrin was included in the medium because it is 
required for synthesis of haemoglobins. EPO was not included in the medium because 
it did not have effects on the cultured hEryPs as shown in section 3.3.6.2.  
4.3.2.3 Optimal gaseous environment 
In vivo, fetal cells at early embryonic stage were found to be subjected to low oxygen 
tension (Rodesch et al., 1992) due to lack of oxygen-enriched blood from the mother. 
Since hEryPs are produced in the first trimester, it is likely that they live in a hypoxic 
environment in the fetus. Hence, it would be important to know whether hEryPs 
survive better under the hypoxic condition or normoxic condition when they are 
cultured in vitro. Figure 4-5 shows the morphological features of live hEryPs and 
dead hEryPs under phase-contrast microscopy. Life hEryPs had glowing plasma 
membrane due to light reflection on the spherical surface. The central part of the cell 
appeared darker due to their bi-concave shape. It was hard to see their nucleus 
because it is covered by the intact plasma membrane.  However, dead hEryPs showed 
permeabilized plasma membrane which did not glow. They had dark cytoplasm and 
visible nuclei (Figure 4-5 arrows). With these distinguishable features, live and dead 
hEryPs could be counted accurately for the microdroplet culture study. 
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Figure 4-5 Phase contrast microscopy of live and dead hEryPs 
 
 
By using the microdroplet culture system, small numbers of hEryPs were cultured 
under either normoxic (21% O2) or hypoxic (2% O2) gaseous environment. Number 
of viable cells was counted every 6 hours for 48 hours. Surprisingly, from 18 hours 
onwards, there were significantly more viable cells under the normoxic condition than 
the hypoxic condition, as shown in Figure 4-6. The possible explanation for the better 
survival under normoxic condition could be that hEryPs isolated from the chorionic 
villi are located at the fetal-maternal interface where cells are more exposed to 
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Figure 4-6 Microdroplet culture of hEryPs under normoxic or hypoxic condition 
Starting hEryP number was 10 cells per microdroplet. Five microdroplets were 
cultured under each gaseous condition. Number of viable cells was counted every 6 
hours for 48 hours. hEryPs isolated from three biological samples were examined. 
Error bars represent standard errors. *, p<0.05.   
 
4.3.2.4 Effect of mitogen 
It has been shown previously that hEryPs had limited proliferative activity (section 
3.3.5). To check if mitogen could stimulate the proliferation of hEryPs in a similar 
way as it stimulates lymphocyte proliferation, hEryPs were cultured under normoxic 
culture for 48 hours with Pokeweed mitogen (PW) at three concentrations (0.5, 1 and 
5 µg/ml) which were used to stimulate human lymphocyte growth (Zempleni and 
Mock, 1999). Results from three individual experiments showed that this mitogen was 
not able to induce the proliferation of hEryPs at these concentrations (Figure 4-7). 
Additionally, the cell viability between control and PW treated cells were similar to 
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each other over the 48 hours. It suggested that PW used at these concentrations had 
little effect on the survival of hEryPs in vitro. 
Figure 4-7 Microdroplet culture of hEryPs with Pokeweed mitogen 
Poke weed mitogen concentrations tested were 0.5, 1 and 5 µg/ml. Starting hEryP 
number was 10 cells per microdroplet. Five microdroplets were cultured under each 
condition. Number of viable cells was counted every 6 hours for 48 hours. hEryPs 
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4.3.3 Culture of hEryPs from maternal blood  
Aim: To validate the microdroplet culture system on hEryPs picked from maternal 
blood samples.  
Having optimized the microdroplet culture conditions for hEryPs obtained from 
chorionic villi, hEryPs picked from maternal blood samples were cultured in the 
microdroplets under normoxic condition. Their viability was evaluated over time. Due 
to the different numbers of cells picked from different blood samples, the percentage 
of viable cells at each time point was calculated. Morphological change was observed 
during the culture period. Many of the cells shrunk in size after 2 to 3 days of culture, 
but their plasma membrane remained intact with glowing membrane surface under 
phase-contrast microscope, which indicated that they were still viable. At the day 7 of 
microdroplet culture, hEryPs isolated from four blood samples with different 
gestational ages had a viability of 88% to 100% (Figure 4-8A). This result was 
surprisingly good. Figure 4-8B shows the phase contrast pictures of cultured cells 
from one of the maternal blood samples (MB3) on day 1, 3, 5 and 7. All of the 9 cells 
remained viable on day 7 of culture.  
Figure 4-8 Microdroplet culture of hEryPs from maternal blood 
A. Four maternal blood samples at different gestational weeks were evaluated. 
Percentage of viable cells was calculated for each day of the 7 days’ culture. Cell 
viability at day 7 for MB1, MB2, MB3 and MB4 was 97%, 100%, 100% and 88% 
respectively. B. Phase contrast pictures of hEryPs (MB3) cultured in the microdroplet 
on day 1, 3, 5 and 7. Starting cell number was 9 for one microdroplet. All cells looked 
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healthy during the culture. Day 7 inset shows the rest two cells located in another 
view. Scale bar, 50µm.  
 
 




The approach of isolating pure live fetal cells from enriched maternal blood with 
micromanipulation and then culturing them in the microdroplet culture system is 
novel and applicable for NIPD. The distinct cell morphology as well as the CD45 and 
Hoechst staining made it feasible to distinguish hEryPs from the contaminating cells 
including WBCs and anucleated RBCs. hEryP-like cells identified and picked from 
maternal blood samples were confirmed to be fetal in origin with quantitative PCR, 
immunocytochemistry of epsilon haemoglobin and FISH, which are the common 
methods used for verifying fetal identity. The result that post-TOP maternal blood 
yielded the highest number of hEryP-like cells is consistent with the previous 
observation that post-TOP samples had more fetal cells than pre-TOP samples due to 
significant fetal-maternal haemorrhage post operation (Bianchi et al., 2001). This 
manual isolation approach is particularly useful because the current fetal cell 
enrichment cannot achieve high efficiency and specificity. It could be further 
developed into an automated process in addition to the existing enrichment protocol 
for isolating pure fetal cells from maternal blood.    
The microdroplet culture system developed serves as a good platform for culture of 
small and pure population of fetal cells isolated from maternal blood. The gaseous 
environment for culturing hEryPs has been optimized through this system. hEryPs 
survived better under normoxic condition probably due to the fact that they came 
from the placenta which is more exposed to the oxygen tension in the maternal blood. 
Normoxic culture also makes the in vitro maintenance of these cells easier for 
application. hEryPs isolated from the maternal blood were maintained well in the 
microdroplet culture with high cell viability at the end of one week’s culture. This 
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culture system could also be applied to other types of fetal cells from maternal blood 
for culture or expansion purposes.  
Adding Pokeweed mitogen to the microdroplet culture of hEryPs seemed not effective 
in stimulating their proliferation. The primary reason could be their pyknotic nuclei 
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Chapter 5: Nuclear Reprogramming of hEryPs 
5.1 Introduction 
Nuclear reprogramming of somatic cells is a process of dedifferentiating or 
transdifferentiating the cells to a different cell stage or cell type by altering their 
original gene expression profiles. For example, by introducing the four pluripotent 
factors Oct4, Sox2, c-Myc and Klf4 into human somatic cells, cells that behave like 
human embryonic stem cells (hESCs), namely ‘human induced pluripotent stem cells 
(hiPSCs)’, can be generated (Takahashi et al., 2007).  hiPSCs have indefinite self-
renewal ability and hold pluripotency like hESCs. Hence, they have potentials for 
cell-based therapy. In addition, cell-free extracts from mouse embryonic stem cells 
have also been used to reprogram human differentiated cells to acquire stem cell 
properties (Taranger et al., 2005; Bru et al., 2008).  
Human blood has been recently used to generate hiPSCs (Loh et al., 2009; Brown et 
al., 2010; Chang et al., 2012) as a more feasible cell source than skin biopsies. As 
hEryPs are present in the maternal blood, it is of interest to know whether these fetal 
cells could be nuclearly reprogrammed to generate fetal hiPSCs. It would also be 
useful for NIPD if the small number of hEryPs in the maternal blood can be 
reprogrammed to dividing cells which can generate larger numbers for diagnostic 
purposes. There are some successful examples of generating hiPSCs from terminally 
differentiated cell types such as neurons (Kim et al., 2011) and T lymphocytes (Loh et 
al., 2009). Theoretically, regardless of the original cell state, as long as the 
reprogramming factors can be expressed to functional proteins in the target cells, 
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there is a probability that these cells can be reprogramed into hiPSCs. Nevertheless, 
the overall reprogramming efficiency for generating hiPSC is up to 1% even with 
viral methods (Yamanaka, 2012).  
In this chapter, the nuclear reprogramming efficiency of hEryPs obtained from 
chorionic villi was evaluated using both viral and non-viral reprogramming 
approaches. Firstly, epigenetic factors including histone deacetylase (HDAC) 
inhibitor and DNA methyltransferase (DNMT) inhibitor were used to remodel the 
chromatin structure of hEryPs. Their effects on the condensed hEryP nuclei were 
evaluated. Secondly, lentiviral transductions of hEryPs were attempted with a vector 
encoding the GFP gene and a vector containing the four factors for hiPSC generation. 
Thirdly, hEryPs were co-cultured with cell-free extracts from hESCs to test the 
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5.2 Materials and Methods 
5.2.1 Cell line 
Use of commercial human cell lines was approved by Institutional Research Board of 
National University of Singapore. Human new-born foreskin fibroblast CCD1112sk 
(ATCC, USA) was used as a positive control cell line. Culture and passaging protocol 
of CCD1112sk can be referred to section 3.2.7. Human embryonic kidney cells 293T 
(ATCC, USA) were used for lentivirus production. They were cultured in DMEM 
high glucose basal medium supplemented with 10% FBS and 1% AA. Passaging 
protocol of 293T cells was the same as that of CCD1112sk.  hESCs were cultured on 
mitomycin-C treated mouse feeder cells as detailed in section 3.2.7. 
5.2.2 Reagents, culture media, antibodies and kits 
Chemical reagents: 
Tricostatin A, Sodium butyrate, 5-azacytidine, Ampicillin, Polybrene, Sodium 
chloride, Magnesium chloride, Calcium chloride, Dithiothreitol, Streptolysine-O 
(Sigma Aldrich, USA); SYBR Green I nucleic acid gel stain, Glycerol, HEPES buffer, 
HBSS (Hank’s buffered salt solution) (Invitrogen, USA); TAE buffer (1st BASE, 
Singapore); Agarose (Cambrex, USA).  
Biological reagents:  
Fetal bovine serum (FBS) (Biochrome AG, Germany); bovine serum albumin (BSA), 
β-mercaptoethanol, antibiotic-antimycotics (AA), normal goat serum (Invitrogen 
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Gibco, USA); 10x Trypsin (PAA, Austria); LB powder, human iron-saturated 
transferrin, Type I collagen, Protease inhibitor cocktail, ATP (adenosine triphosphate), 
GTP (guanosine triphosphate), creatine phosphate, creatine kinase (Sigma Aldrich, 
USA); NTP (ribonucleotide) (Roche Applied Science, USA); 100 bp DNA ladder,  
DNA gel loading dye (New England BioLabs, UK).  
Culture media: 
Dulbecco’s Modified Eagle Medium with High Glucose (DMEM High Glucose), 
Iscove’s modified Dulbecco’s medium (IMDM), Dulbecco’s Modified Eagle 
Medium/Nutrient Mixture F-12 (DMEM/F-12) (Invitrogen Gibco, USA). 
Antibodies: 
Primary antibodies against human antigens (host in rabbit): Acetyl-Histone 3, Acetyl-
Histone 4, K9-trimethyl-Histone 3 (Merck Millipore, USA). 
Secondary antibody (host in goat): Anti-rabbit IgG (H+L) Alexa Fluor 568 (Merck 
Millipore, USA).  
Commercial kits: 
QIAmp DNA Mini kit, Plasmid Plus Maxi kit (Qiagen, USA); TransIT-293 
transfection kit (Mirus Bio, USA); Lenti-X p24 Rapid Titer kit (Clontech, USA); PCR 
SuperMix (Invitrogen, USA); Human STEMCCA Constitutive Polycistronic (OKSM) 
Lentivirus Reprogramming kit (Merck Millipore, USA).  
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5.2.3 Epigenetic factor treatment 
Epigenetic factors including Trichostatin A (TSA), sodium butyrate (NaB) and 5-
azacytidine were added individually or together (TSA and NaB) to the IMDM culture 
medium. hEryPs were cultured in the supplemented medium for 24 hours or 48 hours 
before being cytospun onto glass slides for immunocytochemistry 
(immunocytochemistry protocol detailed in section 3.2.15). hEryPs without any 
treatment of epigenetic factors were used as control. Histone acetylation and 
trimethylation levels were examined in the nuclei of the control hEryPs and the 
treated hEryPs. The intensity of fluorescence stained after immunocytochemistry was 
quantified using Image J software (USA).  
5.2.4 Plasmid propagation and extraction 
Plasmids were propagated from E.coli glycerol stocks (stored at -80oC). LB agar 
plates and LB broth were prepared from LB powder for E.coli culture. Tip of glycerol 
stock was streaked onto LB agar plates containing ampicillin (100 µg/ml). The agar 
plates were incubated at 37oC overnight. On the next day, single white colony was 
picked with a micropipette tip and inoculated into 5 ml of LB broth containing 
ampicillin (100 µg/ml) as a starter culture. Starter culture was incubated for 8 hours at 
37oC with vigorous shaking at 250 rpm. 500 µl of starter culture was added to 500 ml 
of LB broth containing ampicillin (100 µg/ml) in a 1L conical culture flask and grown 
for 12 to 16 hours at 37oC with vigorous shaking at 250 rpm. On the following day, 
LB culture turned cloudy. E. coli in the LB culture were pelleted down in 50 ml 
Falcon tubes at 6000 g for 15 mins at 4oC using centrifuge (Beckman Allegra X-15R, 
Beckman Coulter, USA).  Plasmid was extracted from the cell pellets using Plasmid 
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Plus Maxi kit according to the manufacturer’s instructions. Plasmid DNA 
concentration was measured using Nanodrop. Plasmids were stored at -20oC before 
use. 
5.2.5  Production and concentration of lentiviral vectors 
Lentiviruses (2nd generation) were produced from 293T cells by transfecting the cells 
with a mixture of packaging plasmids encoding viral core, envelop and the vector of 
interest. 293T cells were seeded on Type I collagen (final concentration: 1 mg/ml) 
coated T-75 flasks (6 – 8 x 106 cells per flask) with culture medium containing heat-
inactivated FBS. Cells were ready for transfection when reaching the confluency of 
80% to 90%.  On the day of transfection, for each flask, three types of plasmids (Core: 
6.5 µg, Envelop: 3.5 µg, Vector of interest: 10 µg) were mixed with 40 µl of TransIT-
293 transfection reagent diluted in 200 µl of DMEM basal medium and incubated for 
15 mins at room temperature. The transfection mixture was added to the cells drop-
wise and gently rocked to distribute evenly. 24 hours post transfection, culture 
medium was changed to normal culture medium. Supernatant was collected at 48 
hours and 72 hours post transfection, pooled and filtered with 0.22 µm nitrocellulose 
filter (Merck Millipore, USA) to remove cell debris.  To further concentrate the 
lentiviruses produced, the supernatant was ultracentrifuged in ultracentrifuge tubes 
(30 ml per tube) (Beckman Coulter, USA) at 26,000 rpm with SW 28 rotor (Beckman 
Coulter, USA) in ultracentrifuge (Model L-80, Beckman Coulter, USA) for 140 mins 
at 4oC.Concentrated lentiviruses were resuspended in 1x PBS with 1% BSA and 
directly used or stored at -80oC in 1.5 ml Cryovials (10 - 20 µl per vial) (NUNC, 
USA).   
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5.2.6  Lentiviral transductions of cells 
Cell culture medium was changed to medium containing 10% heat-inactivated fetal 
bovine serum before the transduction. Polybrene (final concentration: 4 µg/ml) was 
added to the medium and mixed well with the cells. Lentiviral vectors were added to 
the cells (hEryPs, CCD1112sk) at multiplicity of infection (MOI) as required. The 
volume of lentiviral vector needed is calculated as below: 
Volume of lentiviral vector (µl)  =  Cell number  MOI 1000
Lentiviral titer (TU/ml)
   
Cells were transduced for 24 hours and then replaced with fresh normal culture 
medium.  
For transduction with UCOE-GFP vector, MOI of 10 was used. Cells were observed 
at 72 hours post transduction for GFP expression under fluorescent microscope 
(Nikon Eclipse Ti-400, Japan). To evaluate the lentiviral transduction efficiency, 
transduced cells were detached (for adherent cells) by 1x Trypsin for 5 mins and 
washed with 1x PBS 2 to 3 times.  GFP positive cells were analysed by flow 
cytometry.  
For lentiviral transduction with STEMCCA OKSM (Oct4, Klf4, Sox2, c-Myc) 
reprogramming kit, the protocol provided by the kit was followed. CCD1112sk was 
used as a positive control cell. Briefly, target cells were plated (on day 0) and 
transduced with the lentiviruses provided by the kit at MOI of 75 twice (each 24 hours) 
continuously for two days (day 1 and 2) and then replaced with fresh culture medium. 
Cells were cultured until day 6 and then plated onto mouse embryonic fibroblast 
feeder cells. Between day 10 and 15, small colonies of hiPSCs should appear in the 
culture. When colony size reached about 200 cells or larger, they were cut into 2 to 3 
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pieces by 21 gauge needle and transferred using a micropipette into new culture 
dishes or plates for further expansion on the mouse feeder cells.  
5.2.7  Genomic DNA extraction 
Genomic DNA of non-transduced and transduced cells (hEryPs and CCD1112sk) was 
extracted (up to 5x106 cells per sample) post 72 hours of lentiviral transduction using 
QIAamp DNA Mini kit. The DNA extraction followed manufacturer’s instructions. 
DNA concentration was measured using Nanodrop. DNA samples were stored at -
20oC before further analysis.  
5.2.8  Conventional PCR and DNA gel electrophoresis 
Conventional PCR was performed on genomic DNA extracted from non-transduced 
cells (hEryPs, CCD1112sk) and UCOE-GFP transduced cells, with primers (final 
concentration: 200 nM) specific to the UCOE promoter, GFP gene and GAPDH gene 
(house-keeping gene). Primer sequences are shown in Table 5-1. 45 µl of PCR 
SuperMix was mixed with 5 µl of primers and DNA template for each reaction. PCR 
reactions were run on PTC-200 Peltier Thermal Cycler (GMI, USA). PCR setting was: 
94oC for 45 secs, 55oC for 30 secs, 72oC for 1 min 30 secs, 30 cycles.  
Table 5-1 Conventional PCR primers 
Gene Forward (5’ to 3’) Reverse (5’ to 3’) 
GAPDH GAGTCAACGGATTTGGTCGT  TTGATTTTGGAGGGATCTCG 
UCOE CACACGACCTGGATGGAGTGGGAC GGTTGGGAGGTGGGTCTGAAACG
GFP GCTACGTCCAGGAGCGCACC GCTGGTAGTGGTCGGCGAGC 
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To analyse the products from conventional PCR, DNA gel electrophoresis was run 
using 1% agarose gel (1 g agarose into 100 ml water) in 1x TAE buffer. 5 µl of SYBR 
Green I nucleic acid gel stain was added to the hot gel and mixed well before the gel 
solidified. After the gel was casted, DNA samples mixed with loading dye and 100 bp 
DNA ladder (1 µl) were added respectively to the gel wells. Gel was run at 100 V for 
30 to 40 mins. Gel results were viewed and pictures were taken (Kodak 1D, Eastman 
Kodak,  USA).  
5.2.9 Preparation of hESC extracts 
Two types of hESC extracts were prepared for the co-culture experiments. One was 
extracted only from the cytoplasm of hESCs (cytoplasmic extracts) and the other was 
from the whole hESCs (whole cell lysate). hESCs were incubated with TrypLETM 
Express for 5 mins, neutralized with culture medium and then harvested with a cell 
scraper. Cells were washed with ice cold 1x PBS and cell number was counted. After 
centrifugation at 1000 rpm for 5 mins, hESC pellet was resuspended in cell lysis 
buffer (100 mM HEPES, 50 mM NaCl, 5 mM MgCl2, 1 mM Dithiothreitol and 
protease inhibitor cocktail) according to every 1 x 105 cells in 1 µl of buffer, and 
incubated for 30 mins on ice. For the preparation of hESC cytoplasmic extracts, after 
the incubation in lysis buffer, cells were vortexed for 2 mins, and centrifuged at 1000 
g for 10 mins. Only the supernatant (contain hESC cytoplasmic extracts) was 
collected, snap frozen in liquid nitrogen and stored at – 80oC until use.  For the 
preparation of hESC whole cell lysate, cells in the lysis buffer were sonicated for 1 
min on ice at amplitude of 30. The sonicated product was centrifuged at 15, 000 g for 
15 mins at 4oC. The supernatant was collected (contains whole cell lysate), snap 
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frozen and stored at – 80oC until use. A schematic diagram of the preparation of the 
two types of hESC extracts is shown in Figure 5-1. 
Figure 5-1 Preparation of hESC cytoplasmic extracts and whole cell lysate 
 
5.2.10  Co-culture of hESC extracts with hEryPs 
For co-culture of hEryPs with the hESC cytoplasmic extracts and whole cell lysate 
respectively, hEryPs were pre-treated with Streptolysin-O (200 ng/ml in HBSS) for 50 
mins at 37oC for plasma membrane permeabilization. After the treatment, cells were 
washed with HBSS and centrifuged at 3000 rpm for 5 mins at 4oC. hEryPs were then 
suspended in the hESC extracts (100% extracts) or diluted extracts (1:1 dilution with 
culture medium, 50% extracts) (50 µl for a maximum of 5 x 105 hEryPs) containing 
an ATP-generating system (1 mM ATP, 100 µM GTP, 10 mM creatine phosphate, 25 
µg/ml creatine kinase and 1 mM NTP). The incubation was 1 hour at 37oC with 
occasional agitation. After the incubation, cells in the extracts were diluted with 
IMDM culture medium containing 2 mM CaCl2 (for sealing the permeabilized cell 
membrane) and cultured at 37oC for 2 hours. At last cells were centrifuged and 
cultured in normal culture medium in the incubator until observation. The cell number 
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of hEryPs was counted on day 1, day 2 and day 3 after the co-culture with hESC 
extracts.  




5.3.1 Chromatin remodelling of hEryPs  
Aim: To evaluate the effects of epigenetic factors such as HDAC (histone deacetylase) 
inhibitor and DNMT (DNA methyltransferase) inhibitor on the condensed chromatin 
of hEryPs.  
In the mammalian cell nucleus, DNA wraps around histone proteins to form units 
called nucleosomes which make up the chromatin. The chromatin structure is closely 
related to the compactness of nucleosomes determined by the post-translational 
modifications on the histone tails. Changes in the chromatin structure can regulate 
gene expressions in the cells. A loose chromatin structure is usually associated with 
active gene transcriptions because genes are more exposed to transcription factors and 
enzymes; vice versa, a condensed chromatin structure is associated with gene 
repressions or silencing. Acetylation and methylation of histones affect the chromatin 
structure by altering the space between the nucleosomes. Genes are more active in 
transcriptions when the histones around them are more acetylated and less 
trimethylated. Epigenetic factors are molecules that can change the modifications on 
the histones or directly on the DNA. The nuclei of hEryPs are highly condensed. 
Hence, epigenetic factors were used to treat hEryPs and their effects on the hEryP 
chromatin structure were evaluated.   
                                            Chapter 5: Nuclear Reprogramming of hEryPs – Results 
151 
 
5.3.1.1 Condensed nuclei of hEryPs 
To confirm that hEryPs have very condensed nuclei at both genetic and epigenetic 
levels, DAPI staining and immunocytochemistry of histone acetylation were 
performed on hEryPs and control cells CCD1112sk.  DAPI binds to nucleic acids in 
the cells. The DAPI staining (blue fluorescence under UV filter) can indicate the 
location and compactness of DNA inside the cell nucleus. Under the same 
magnification, the nuclei of hEryPs (Figure 5-2, left top) were much more condensed 
than those of CCD1112sk (Figure 5-2, left bottom). There were many chromatin 
aggregations, called ‘heterochromatin’ found in the hEryP nuclei. These 
heterochromatins are indicative of gene repressions within those regions.  In contrast, 
the chromatin in the nuclei of CCD1112sk was loosely spread out. Their nuclei were 
more active in gene transcriptions.  
Histone 3 acetylation level (red fluorescence) was high in the nuclei of CCD1112sk 
(Figure 5-2, right bottom), but very low in the hEryP nuclei (Figure 5-2, right top). 
High histone acetylation accounts for an open chromatin structure. It was expected 
that hEryPs had minimal level of histone acetylation in their nuclei, because they had 
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Figure 5-2 Nuclear and acetylated histone staining of hEryPs and CCD1112sk 
The nuclei of hEryPs and CCD1112sk were stained with DAPI (blue, left panel) and 
anti-acetylated histone 3 conjugated with Alexa Fluor 568 (H3Ace, red, right panel). 
hEryPs had much smaller nuclei and much lower level of histone 3 acetylation than 
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5.3.1.2 Effects of epigenetic factors on chromatin structure 
The highly condensed nuclei of hEryPs may be the main reason for their limited 
proliferative activity. It could also pose a challenge for their nuclear reprogramming 
because the nuclei are not active in gene transcriptions and translations. It would be 
useful if their nuclei could be decondensed first. Histone deacetylase (HDAC) 
inhibitors such as Trichostatin A and sodium butyrate can effectively prevent histone 
deacetylation in the cell nucleus. Thus, they can increase histone acetylation level and 
help loosen up the chromatin. DNA methyltransferase (DNMT) inhibitors such as 5-
azacytidine can inhibit DNA and histone methylation which attribute to gene 
silencing. The effects of Trichostatin A, sodium butyrate and 5-azacytidine on the 
hEryP chromatin were evaluated respectively.  
hEryPs were treated with Trichostatin A (TSA, 500 nM), sodium butyrate (NaB, 4 
mM) or a combination of the two factors for 24 hours. The immunocytochemistry 
results of histone 3 and 4 acetylation in the non-treated and treated hEryPs are shown 
in Figure 5-3. The first rows in both panel A and B showed that compared with the 
non-treated hEryPs, significant increase in the acetylation levels of histone 3 and 
histone 4 (red fluorescence) was observed in the hEryPs treated with TSA, NaB or a 
combination of the two. The red fluorescence intensity was also measured in all the 
groups to quantify the histone acetylation levels (Panel C). Results showed that for 
both histone 3 and histone 4, there was significant increase in the acetylation levels 
(p<0.01) in the hEryP nuclei after the treatment with TSA, NaB or a combination of 
TSA and NaB.  
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Figure 5-3 Immunocytochemistry of histone 3 & 4 acetylation on hEryPs treated 
with Tricostatin A (TSA) and sodium butyrate (NaB)  
A and B. hEryPs were stained with DAPI (blue, nuclear stain), anti-H3Ace (A, red) or 
anti-H4Ace (B, red) and anti-GPA (green, to identify hEryPs). There was significant 
increase in the histone acetylation levels in the hEryPs treated with TSA, NaB or 
TSA+NaB, compared with non-treated cells (top panels). The bottom panels present 
the merged pictures from the three types of staining. Scale bar, 10 µm. C. 
Fluorescence intensity (represent histone acetylation level) measurements of control 
and treated hEryPs. The increase in the histone acetylation levels (histone 3 and 4) 
was significant (p<0.01) in the treated hEryPs compared with non-treated cells. Error 
bars represent standard deviations. 
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hEryPs were treated with 5-azacytidine (5-aza) for 48 hours and immunostained with 
anti-H3TriMe (Trimethylated histone 3). The staining results were shown in Figure 
5-4A. The red fluorescence represented the histone 3 trimethylation. There was a 
reduction in the level of histone 3 trimethylation in the treated hEryPs (right panel), 
compared with the non-treated hEryPs (left panel). When the red fluorescence was 
quantified, the reduction in histone 3 trimethylation after treatment with 5-azacytidine 
was significant (Figure 5-4B, p<0.01).  
Figure 5-4 Immunocytochemistry of histone 3 trimethylation on hEryPs treated 
with 5-azacytidine  
A. hEryPs were stained with DAPI (blue, nuclear stain), anti-H3TriMe (red) and anti-
GPA (green, to identify hEryPs). The 5-azacytidine (5-aza) treated hEryPs had 
reduced histone 3 trimethylation compared with non-treated hEryPs (top panel). The 
bottom panel of pictures are merged pictures from the three types of staining. Scale 
bar, 10 µm. B. Red fluorescence intensity was measured for control and 5-aza treated 
hEryPs. The reduction in the histone 3 trimethylation in the treated hEryPs was 
significant (p<0.01), compared with the control cells. Error bars represent standard 
deviations. 
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5.3.1.3 Microdroplet culture of hEryPs with Tricostatin A 
The previous results showed that epigenetic factors could remodel the chromatin 
structure of hEryPs. However, it was not known whether the viability or proliferative 
potential of hEryPs could be enhanced after the treatment. Microdroplet culture 
(developed in section 4.3.2) was performed to evaluate the effect of Tricostatin A 
(TSA) on the culture of hEryPs. Pokeweed mitogen (PW) was also added to the 
culture medium to test if cell proliferation could be stimulated under synergistic effect 
with TSA. The culture was maintained for 72 hours. Compared to the control hEryPs 
without any addition of factors, hEryPs treated with TSA, PW, and a combination of 
TSA and PW all presented similar trends in their survival curves (Figure 5-5). Using 
the combination of TSA and PW, the hEryPs survived better on average than the other 
three conditions. However, the improvement in the viability was not statistically 
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Figure 5-5 Microdroplet-culture of hEryPs with TSA and Pokeweed mitogen 
hEryPs were cultured with TSA (2 µM), Pokeweed mitogen (PW, 5 µg/ml) or a 
combination of the two. Non-treated hEryPs were used as control. Each condition had 
five microdroplets with 10 cells per microdroplet in the beginning. Numbers of viable 
hEryPs were counted every 12 hours for 72 hours’ culture. Three biological samples 
of hEryPs were tested. There was no statistically significant difference in the cell 
viability in the three treated conditions compared to control (p>0.05). Error bars 
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5.3.2 Lentiviral transductions of hEryPs (viral reprogramming) 
Aim: To evaluate the transduction efficiency of lentiviral vectors including a GFP 
encoding vector and an iPSC (induced pluripotent stem cells) vector on hEryPs. 
Lentiviral vectors can be used to transduce both dividing and non-dividing 
mammalian cells. The gene of interest contained in the vector can integrate into the 
host cell genome upon successful transduction, thus result in permanent gene 
expression in the transduced cells. Human iPSC (hiPSC) has been generated from 
keratinocytes with a single lentiviral vector encoding the four reprogramming factors 
viz. Oct4, Sox2, Klf4 and c-Myc (Carey et al., 2009).  
5.3.2.1 Transduction with GFP lentiviral vector 
A lentiviral vector with a strong promoter UCOE (ubiquitous chromatin opening 
element) and EGFP gene (encoding GFP) was used to transduce hEryPs to examine 
the lentiviral transduction efficiency in this cell type.  CCD1112sk was used as a 
positive control cell. Five biological samples of hEryPs were transduced with UCOE-
GFP at MOI of 10 for 24 hours. GFP expression was analysed 72 hours post 
transduction. The UCOE-GFP transduction results are shown in Figure 5-6. At 72 
hours post transduction, CCD1112sk showed high GFP expressions (top panel, bright 
green fluorescence). However, there was no GFP expression observed in the 
transduced hEryPs.  FACS analysis was further performed to measure the percentage 
of GFP positive cells in the transduced hEryPs (Figure 5-7). The GFP positive cell 
percentage was equivalent to that of non-transduced hEryPs, which indicated that 
there was no true GFP positive cell in the transduced population but background noise.  
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Figure 5-6 Transduction of CCD1112sk and hEryPs with UCOE-GFP lentiviral 
vector  
CCD1112sk and hEryPs were transduced with UCOE-GFP lentiviral vector for 24 
hours at MOI of 10. Images were taken using fluorescent microscope at 72 hours post 
transduction. CCD1112sk cells strongly expressed GFP (top panel), while none of the 
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Figure 5-7 FACS analysis of hEryPs transduced with UCOE-GFP lentiviral 
vector 
The transduced hEryPs had comparable percentage of GFP+ cells (2.8% ± 0.1%) to 
the non-transduced cells (2.9% ± 0.3%). This suggested that there was no genuinely 
GFP positive cell in the transduced hEryPs but background noise.  
 
To investigate the reason for hEryPs not expressing the GFP gene after lentiviral 
transduction with UCOE-GFP, genomic DNA of transduced hEryPs and CCD1112sk 
were extracted.  Conventional PCR was performed to check the integration of UCOE-
GFP vector in the host cell genome. Primers targeting the UCOE promoter and EGFP 
gene were used. PCR products were analysed by DNA gel electrophoresis. Results 
showed that in the transduced CCD1112sk cells (positive control), there were two 
bright bands indicating amplified PCR products with UCOE and EGFP primers. This 
indicated the integration of UCOE promoter and EGFP gene in the genome of 
CCD1112sk (Figure 5-8, lane 2 and 3). However, in the transduced hEryPs, the DNA 
bands were not so visible, which meant no integration of UCOE promoter and EGFP 
gene in the genome of hEryPs (Figure 5-8, lane 9 and 10). Interestingly, in the 
hEryPs treated with Tricostatin A (TSA) before the lentiviral transduction, the bands 
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were much brighter than the non-treated hEryPs (Figure 5-8 lane 12, 13). This 
suggested an enhanced integration of UCOE and EGFP in the hEryP genome after the 
treatment with TSA which has been shown previously to be able to decondense the 
hEryP chromatin structure (section 5.3.1.2).  
Figure 5-8 DNA gel electrophoresis of UCOE promoter and EGFP gene 
Conventional PCR products from genomic DNA of CCD1112sk and hEryPs using 
primers specific for UCOE promoter, GFP and GAPDH (house-keeping gene) were 
analysed on DNA gel electrophoresis respectively. Middle lane is the 100 bp DNA 
ladder. Lane 1-3: CCD1112sk transduced with lentiviral vector; lane 4-6: hEryPs 
control (non-transduced); lane 8-10: hEryPs transduced with lentiviral vector; lane 11-
13: TSA-treated hEryPs transduced with lentiviral vector. CCD stands for 
CCD1112sk. FE106 stands for hEryP sample no. 106.  
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5.3.2.2 Transduction with iPSC lentiviral vector 
Lentiviral transduction with STEMCCA OKSM (Oct4, Klf4, Sox2, c-Myc) iPSC 
vector was carried out in the hEryPs and CCD1112sk following the protocol provided 
by the kit. In the transduced CCD1112sk cells (positive control), between day 8 to day 
10 post transduction, small colonies of cells having hESC-like morphology i.e. hiPSC 
appeared in the culture on top of mouse feeder cells (Figure 5-9A). The colonies 
grew bigger as the culture continued. Large colonies of hESC-like cells could be 
observed at day 13 post transduction (Figure 5-9B).  
Three biological samples of hEryPs were transduced with the same iPSC vector. 
However, no colony of hESC-like cells was observed up to 30 days of culture. As 
shown in Figure 5-9C, many hEryPs underwent degeneration after long time of 
culture. Their plasma membrane became permeabilized and nuclei were visible.  
Figure 5-9 Lentiviral transduction of hEryPs and CCD1112sk with iPSC vector 
A. A small colony of hESC-like cells (hiPSC) formed on top of mouse feeder cells on 
day 9 post transduction of CCD1112sk. Scale bar, 100 µm. B. Three bigger colonies 
formed on day 13 post transduction of CCD1112sk. Scale bar, 200 µm. C. Transduced 
hEryPs cultured on top of mouse feeder cells on day 11. Cells looked degenerated 
with visible nuclei and degraded plasma membrane. No hESC-like colony was 
observed in the culture. Scale bar, 30 µm.  
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5.3.3 Co-culture with hESC extracts (non-viral reprogramming) 
Aim: To examine the reprogramming efficiency of hESC extracts on hEryPs by co-
culture of these cells with hESC cytoplasmic extracts or whole cell lysate.  
Cell-free extracts from embryonic stem cells were believed to contain active 
components that are able to reprogram the genome of differentiated cells (Taranger et 
al., 2005; Bru et al., 2008). In this study, cytoplasmic extracts and whole cell lysate 
prepared from hESCs were applied to the hEryPs via a co-culture method. The plasma 
membrane of hEryPs was first permeabilized by Streptolysine-O in order to take up 
the active components from the hESC extracts. hEryPs cultured in normal medium 
without any treatment were used as control cells. There were two extract 
concentrations used under each type, namely 100% extracts and 50% extracts (diluted 
with equal volume of culture medium). The endpoint studied here was the number of 
viable hEryPs at day 1, day 2 and day 3 post extract treatment or without treatment 
(control).  
As shown in Figure 5-10, the numbers of hEryPs in the hESC extract treated 
conditions (cytoplasm 50%, cytoplasm 100%, whole cell 50%, whole cell 100%) were 
comparable to the control on day 1, 2 and 3. In all the conditions, the cell numbers 
were decreasing from day 1 to day 3. No cell proliferation was induced after the hESC 
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Figure 5-10 Number of hEryPs after co-culture with hESC extracts 
Control: hEryPs without any treatment, cultured in normal medium. Cytoplasm 50%: 
hEryPs co-cultured with 50% hESC cytoplasmic extracts. Cytoplasm 100%: hEryPs 
co-cultured with 100% hESC cytoplasmic extracts. Whole cell 50%: hEryPs co-
cultured with 50% hESC whole cell lysate. Whole cell 100%: hEryPs co-cultured 
with 100% hESC whole cell lysate. The starting cell number on day 0 was taken as 
100%. Relative cell number was calculated as percentage (Y axis). Three biological 
samples of hEryPs were evaluated. Error bars represent standard deviations.  




The reprogramming efficiencies of epigenetic factors, lentiviral transduction and 
hESC extracts on hEryPs were studied respectively. The treatment of hEryPs with 
HDAC inhibitors (Tricostatin A and sodium butyrate) and DNMT inhibitor (5-
azacytidine) increased histone acetylation and decreased histone trimethylation in 
their nuclei significantly. These changes on the histone modifications led to a less 
condensed chromatin structure which may be more accessible to transcription factors 
for gene expressions. Although these structural changes alone in the nucleus were not 
sufficient to induce proliferation in the hEryPs, they may enhance the efficiency of 
subsequent reprogramming procedures.  
Lentiviral transduction is considered efficient in delivering foreign genes into somatic 
cells. In the case of hEryPs, the lentiviral transduction efficiency was very low with 
UCOE-GFP vector, and there was poor integration of the target genes to the cell 
genome. Transduction of hEryPs with iPSC vector also did not produce any hESC-
like colonies after one month of culture. The following reasons may account for their 
poor transduability: 1) the chromatin of hEryPs was too condensed to allow access by 
the lentiviruses, hence the poor vector integration in the genome; 2) gene transcription 
and translation machinery is absent or not functional in these terminally differentiated 
cells; 3) the promoters used in the lentiviral vectors were silenced after entering the 
cells, as a result, the genes could not be transcribed. The first two reasons more likely 
led to the unsuccessful viral transductions because the last reason still requires 
promoter integration in the host cell genome while the absence of amplified PCR 
product of the UCOE promoter in the transduced hEryPs suggested no integration of 
this promoter in the hEryP genome.  After the treatment with Tricostatin A which 
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opened up the chromatin structure of hEryPs, the UCOE-GFP vector integration to the 
cell genome was better than the non-treated cells, although there was still no GFP 
expression on the phenotype.  
Similarly, when hEryPs were treated with hESC extracts and cultured, no cell 
proliferation was observed. Most treated cells underwent degeneration as in the 
control as the culture was prolonged. It could be the same reasons that cause the poor 
reprogramming efficiency in these cells as in the lentiviral transductions. The highly 
condensed nuclei of hEryPs did pose a structural block for the reprogramming factors 
to access the cell genome. What’s more, the epigenetic status in the hEryP genome 
may not favour gene transcriptions and translations as these cells are terminally 
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Chapter 6: General Discussion 
6.1 Hypotheses 
Human fetal primitive erythroblasts (hEryPs) have been identified as ideal target cells 
in the maternal blood for first trimester non-invasive prenatal diagnosis (NIPD). 
However, the enrichment and culture of hEryPs pose major challenges for their use in 
NIPD due to their rare numbers in the maternal circulation. The biological properties 
of these cells are poorly understood as they are produced in the yolk sac only during 
first trimester of gestation. It is unclear whether hEryPs undergo enucleation like the 
definitive erythroblasts produced in the bone marrow. My thesis work aimed to better 
understand the properties of this cell type and develop techniques for their application 
in NIPD. The main hypotheses involved in the thesis are: (1) hEryPs do not enucleate 
in vitro; (2) Pure hEryPs can be isolated from maternal blood and cultured for an 
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6.2 Findings and Implications 
6.2.1 Understanding the biology of human primitive erythroblasts  
Even though the existence of primitive erythropoiesis in the yolk sac of mammalian 
embryos was discovered more than hundred years ago (Maximov, 1909), the final 
differentiation product, named ‘primitive erythroblast’, remains poorly understood in 
the humans. The name ‘erythroblast’ was given because these cells are nucleated and 
contain haemoglobins, which resemble the late stages (polychromatic and 
orthochromatic erythroblasts) of definitive erythropoiesis in the bone marrow. 
However, unlike the definitive erythroblasts which further extrude their nuclei 
(process of enucleation) to form erythrocytes before entering the circulation, primitive 
erythroblasts are nucleated while circulating in the fetal blood. This is probably why 
some researchers prefer to call them ‘primitive erythrocytes’ or ‘embryonic red blood 
cells’.   
The study on the biology of human primitive erythroblasts (hEryPs) performed in my 
thesis work provides additional insights to the properties of these cells. The 
morphology of hEryP is unique in that it is twice big of a normal erythrocyte and 
contains a highly condensed nucleus. It has the same bi-concave disk shape as 
erythrocyte, which differs from the globular shape of a definitive erythroblast. CD 
marker profile analysis showed that hEryPs were highly positive for CD36, CD71, 
CD47, CD59 and GPA, all of which are also expressed on the surface of erythrocytes 
except CD71 which is expressed on the definitive erythroblasts. The cell cycle profile 
of hEryPs indicated that majority of them were at non-dividing state. Only a small 
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percentage of the cells at a less matured stage (polychromatic hEryPs) were 
undergoing mitosis.  
Whether mammalian primitive erythroblasts enucleate has been controversial. In the 
mouse, some evidences suggested that mEryPs (mouse primitive erythroblasts) 
enucleate in the fetal liver (Kingsley et al., 2004). However, no direct proof has been 
given for hEryP enucleation. Instead, a few studies reported that embryonic red blood 
cells produced from hESCs did not enucleate in vitro (Olivier et al., 2006; Lu et al., 
2008). In my study, hEryPs isolated from chorionic villi did not show any nuclear 
extrusion in culture, even in the presence of erythropoietin. When they were co-
cultured with macrophages, no phagocytosis of the nuclei of hEryPs was observed. 
Hence, hEryPs did not enucleate in vitro.  
It is possible that hEryPs do not enucleate even in vivo during their maturation if 
considering another two findings in my study. hEryPs expressed high levels of CD47, 
which is also expressed on the erythrocytes as ‘marker of self’ for them to escape 
from clearance by macrophages (Oldenborg et al., 2000). My annexin V staining 
results showed no exposure of phosphatidylserine on the plasma membrane of fresh 
hEryPs isolated from chorionic villi. However, phosphatidylserine exposure is present 
on the enucleating definitive erythroblasts to facilitate the engulfment of the extruded 
nuclei by macrophages. Therefore, these two properties of hEryPs do not support their 
enucleation through interaction with macrophages. 
There is a school of thought to explain why the nucleus of primitive erythroblast 
remains and the cell is not enucleated (Tavassoli, 1991). Definitive erythropoiesis 
occurs extravascularly, the terminal nucleated stage i.e. orthochromatic erythroblasts 
enucleate to form reticulocytes which are able to squeeze through the blood vessels to 
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reach the circulation (differentiation pathway shown in Figure 2-1). The removal of 
the nucleus also provides more room in the cytoplasm for haemoglobin synthesis in 
the final product, erythrocyte. In contrast, primitive erythroid cells differentiate within 
the blood vessels accompanied with nucleus condensation and haemoglobin 
accumulation in the cytoplasm. Before the definitive erythropoietic organs form in the 
embryo, the primitive erythroblasts circulate in the fetal blood and serve the same 
function as the anucleated erythrocytes, which is to supply oxygen to the tissues and 
organs. Hence, enucleation may not be a necessary step in their maturation pathway. 
If this theory is correct, it could also explain the large size, pyknotic nucleus and rich 
haemoglobin content of these cells. On the other hand, if hEryPs do enucleate in vivo, 
it could be a rare event with unknown mechanisms, because in my study, the paraffin 
sections prepared from first trimester chorionic villi rarely showed anucleated hEryPs 
in the blood vessels.  
The number of hEryPs in the fetal blood decreased dramatically after first trimester 
(Choolani et al., 2001; Choolani et al., 2003). The same trend was observed in my 
chorionic villi sections at 6 to 11 gestational weeks. It is likely that they started 
degenerating after certain gestational age. Interestingly, TUNEL staining results 
indicated that hEryPs were not undergoing apoptosis in the fetal circulation until 11 
weeks of gestation. It is unclear through what kind of mechanism these cells are 
cleared from the fetal blood stream.  
From the perspective of NIPD, the better understanding of the properties of hEryPs 
builds foundations for the development of relevant techniques such as cell enrichment 
and culture. The absence of enucleation in these cells provides additional advantage 
for their use in NIPD, as the fetal genetic materials will be contained within the cell 
cytoplasm before analysis. Based on their biological properties, my thesis further 
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developed cell isolation, culture techniques and examined the reprogramming 
efficiency of hEryPs for their applications in NIPD.  
6.2.2 Isolation and culture of pure hEryPs from maternal blood 
Two new techniques were developed in the present work for the use of hEryPs for 
NIPD. One is the isolation of pure live hEryPs from maternal blood with a 
micromanipulator. Cells picked according to the identification criteria were proven to 
be fetal in origin by quantitative PCR, FISH and immunocytochemistry. Isolation of 
pure fetal cells solves the problem of massive maternal cell contamination in the 
enriched blood samples.  Compared to previously reported isolation methods of single 
fetal cells (Takabayashi et al., 1995; Sekizawa et al., 1998), the current technique has 
the following advantages: 1) fetal cells were isolated when they were still alive. They 
could offer DNA with better quality than chemically fixed cells for downstream 
analysis. 2) specific identification criteria were established, which can be 
computerized for automation of the isolation process.  The isolated pure fetal cells can 
be used for a range of diagnostic tests such as FISH, array CGH and DNA sequencing. 
Importantly, DNA from pure fetal cells can be potentially used to diagnose any kind 
of chromosomal and genetic diseases, which is more advantageous than the cell-free 
fetal DNA fragments present in the maternal blood.  
The other technique, microdroplet culture, is designed for culturing small number of 
cells in a confined and optimal environment. Fetal cells are normally rare in the 
maternal blood. After their isolation, this culture system can be applied for 
maintaining their viability or expanding their numbers to generate sufficient genetic 
materials for prenatal diagnosis. The culture conditions such as gaseous environment 
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and addition of growth factors can be optimized based on the cell type of interest. The 
microdroplet culture of hEryPs was optimized here. Although they had limited 
proliferative potential, the viability of hEryPs isolated from maternal blood could be 
maintained in vitro for at least one week.  
6.2.3 Reprogramming efficiency of hEryPs  
To date, no other study has been reported on the nuclear reprogramming efficiency of 
hEryPs, probably because these cells are only produced during early embryogenesis. 
As first trimester maternal blood contains hEryPs, it opens a new cell source for in 
vitro manipulations of these cells such as nuclear reprogramming after their isolation.  
The nuclear reprogramming efficiency of hEryPs was evaluated in my study. 
Epigenetic factors Tricostatin A, sodium butyrate and 5-azacytidine were able to 
remodel the histone modifications on the condensed chromatin of hEryPs. As a result, 
their nuclei became less condensed. This structural change made their genome more 
accessible thus may enhance their reprogramming efficiency. It was found that 
hEryPs could not be transduced efficiently by lentiviral vectors. It is probably due to 
their pyknotic nuclei which limited access of the viral vectors to integrate to the 
genome. However, after treatment with Tricostatin A, the vector integration in the 
hEryP genome was improved.  
The terminally differentiated status and the condensed nuclei of hEryPs were the 
primary causes for their poor reprogramming efficiency with lentiviral transduction 
and hESC extract treatment. However, the chromatin structure of these cells could be 
remodelled by epigenetic factors. This may facilitate their reprogramming with more 
developed methods in the future.  




Human fetal primitive erythroblasts (hEryPs) isolated from chorionic villi were used 
as the source material for most of the experiments because large numbers of them 
could be obtained from tissues. Their number in the maternal blood was too small to 
be used for performing the biology study, optimization of culture conditions and 
testing their reprogramming efficiency. Ultimately, hEryPs isolated from maternal 
blood need to be tested with all the developed techniques. There might be some 
differences in the properties between hEryPs from villi and those from maternal blood. 
For the microdroplet culture of hEryPs from maternal blood, only four samples were 
validated. As the number of hEryPs isolated from maternal blood varied from sample 
to sample, more maternal blood samples could be collected to evaluate the usefulness 
of this culture system, particularly blood samples from on-going pregnancy.  The 
culture time could be prolonged to more than one week to find out the maximum 
length of period for keeping hEryPs viable in vitro.  
In the nuclear reprogramming study with viral methods, only a limited number of 
viral vectors (UCOE-GFP and EF1α-KOSM) were attempted for hEryPs. Other viral 
vectors with different promoters could be tested to check whether these cells require 
specific promoters in order to be transduced successfully.  The molecular mechanisms 
behind their poor transduability were not fully studied due to time constraint.  
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6.4 Future Directions 
The technique developed for isolating pure hEryPs from maternal blood are of value 
for NIPD. The manual isolation technique has been incorporated to the standard 
enrichment protocol as the final step (after DGC and MACS) for getting pure hEryPs 
from maternal blood samples in our group. The cells isolated have been sent for FISH 
and array CGH analysis, and will be used for DNA sequencing as well in the future. 
Despite the small number of hEryPs isolated from 20 ml of maternal blood, current 
molecular technologies are capable of analysing DNA from even one single cell 
(Zong et al., 2012). The automation of this isolation process is currently being 
developed by our collaborators from SMART (Singapore-MIT Alliance for Research 
and Technology) and IME (Institute of Microelectronics), Singapore.   
The microdroplet culture system can be further applied to other fetal cell types found 
the maternal blood or rare cells present in the human peripheral blood such as cancer 
stem cells. This culture method offers the convenience of confining the culture 
environment for as few as one single cell and the ease of monitoring. Cells that are 
proliferative can be expanded in the culture to a larger number for subsequent 
applications such as molecular diagnosis and cell nuclear reprogramming.   
Human blood has become a popular source for generating human induced pluripotent 
stem cells (hiPSCs) because blood is readily available and the collection procedure is 
not as invasive as tissue biopsies. As fetal cells are present in the maternal blood 
during pregnancy, it will be beneficial in the field of fetal medicine if fetal hiPSCs can 
be generated from maternal blood. Fetal cells from amniotic fluid and chorionic villi 
have been reprogrammed to iPSCs successfully (Ye et al., 2009) which in turn can be 
differentiated into desirable tissues for intra-uterine fetal therapy. Current protocols of 
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generating hiPSCs require large numbers of cells to begin with due to the low 
reprogramming efficiency. If the fetal cells can be first expanded in the microdroplet 
culture to sufficient numbers, they can then be used for hiPSC generation. 
Furthermore, as the hiPSC technique becomes more efficient and requires less number 
of cells, direct reprogramming on the small numbers of fetal cells from maternal 
blood may become a reality in the future.  Besides the application in fetal cell-based 
therapy, the fetal hiPSCs generated from maternal blood will also be useful for NIPD 
as these cells can self-renew indefinitely and produce large cell numbers for 
performing diagnostic tests.  
The following schematic diagram (Figure 6-1) shows the potential use of fetal cells 
from maternal blood for non-invasive prenatal diagnosis and fetal cell-based therapy 
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Figure 6-1 Potential applications of fetal cells from maternal blood in non-
invasive prenatal diagnosis and fetal cell-based therapy 
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